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Eosinophilic granuloma (EG) and mast cell tumour (MCT) are skin diseases that 
affect horses as well as other animal species. In equine species they exhibit similar 
and potentially overlapping morphological features, and it is not clear if they are 
two different entities or represent a continuum of the same disease. Equine 
eosinophilic granuloma is the most common inflammatory nodular skin disease in 
horses and represents a chronic inflammation characterised by intense infiltrates of 
eosinophils associated with macrophages. The cause of this change is not fully 
clear. However, different factors are reported to potentially cause it and in turn lead 
to a hyper sensitivity reactions, dominated by eosinophils. In contrast, equine mast 
cell tumour is an uncommon neoplastic disease characterised by aggregates of mast 
cells, admixed with variable numbers of eosinophils and scattered areas presenting 
with lesions morphologically identical to those observed in equine eosinophilic 
granuloma. The aim of this study is to investigate the morphological and molecular 
features of equine eosinophilic granuloma and mast cell tumour in order to better 
understand their pathogenesis.  
One hundred and ninety one lesions from 153 horses which had previously been 
diagnosed with equine eosinophilic granuloma or mast cell tumour were retrieved 
form the archive of the Department of Veterinary Pathology and Public Health, 
University of Liverpool. Clinical data were recorded and histomorphological 
features were investigated. The present study showed that Thoroughbreds with 
Thoroughbreds cross, and Arabian with Arabian cross are the most affected breeds 
with EG and MCT. In addition, however, a large number of different breeds were 
affected which had no sex predilection. With regard to MCT, the Arab breed was 
significantly predominant and males were overrepresented. The age range was 
wide, with older horses more affected by MCT than by EG, as expected. The most 
common location of the lesions was the trunk for eosinophilic granuloma and the 
head for MCT.  
The morphological examination for 191 lesions was performed regardless (blind) 
of initial diagnosis. This analysis revealed variable histological features among 
cases. Criteria examined were: location of lesions within the skin, lesion size, area 
and number of eosinophilic granuloma component (EGC) and mast cell aggregates 
(MCA), presence of individual mast cells infiltrating the lesions, association 
between EGC and hair follicle structures, presence of embedded collagen in EGC, 
evidence of mineralisation, evidence of ulceration, density of infiltrating viable 
eosinophils within the MCA, mitotic activity of the mast cell population, and 
presence and number of lymphocyte aggregates. Using these criteria, four lesions 
exhibiting unique morphological features were identified. These cases were 
characterised by marked eosinophil infiltration and embedded mast cell population 
with very large pleomorphic mast cells. These four cases were excluded from the 




From all 191 examined cases, 95 lesions were selected for further analysis. Five 
morphological categories were created based on the presence and relationship 
between the EGC and MCA components as following: category I (EGC only), 
category II (EGC > MCA), category III (EGC= MCA), category IV (EGC < MCA), 
and category V (MCA only). Based on these categories, three major groups were 
created: Group1 (Category I), Group2 (Categories II, III, and IV), and Group3 
(Category V). The newly classified eosinophilic granuloma (EG) corresponded to 
roup 1 (Category I), while mast cell tumour (MCT) was identified through gGroups 
2+3 (Categories II, III, IV, and V). EG lesions exhibited more variable histological 
features among cases within group 1, while MCT lesions were more similar among 
other groups. There were differences in lesion size and number between the 
categories with EG being smaller than MCT with size among different categories 
of MCT being highly variable. Deep dermis was the most common location for 
MCT, while EG was the lesion found most superficially. However, both EG and 
MCT stretched to different layers and when a “depth score” was evaluated, there 
was no difference between categories. Interestingly, a strong association between 
Category I lesions (EG) and hair follicle structures involvement was identified 
(52% of cases). Individual mast cells scattered throughout the lesions were evident 
in 13 lesions (42%) of Category I (EGC only) while they were present in all lesions 
of Category II (EG > MCT), and absent in the other categories. The analysis of Von 
Kossa stained sections indicated that EG exhibited significantly more 
mineralisation than MCT (P˂0.001). Ulceration was present in both EG and MCT 
with no difference and was probably a secondary change not linked with the 
pathogenesis of either lesions. Collagen fibres or their fragments were visualised in 
almost all EG lesions (93%) within EGC, using the Masson Trichrome Stain. EG 
showed significantly more fragments of collagen within the EGC cores than MCT. 
The presence of lymphocytes aggregates was mainly a feature of EG (61% cases) 
rather than MCT, where only rare lymphocytes aggregates were detected in a few 
cases. The density of viable eosinophils infiltrating in MCA had an increasing trend 
among categories. The number of mitotic figures was different among Categories 
(II to V) with significantly higher numbers in Category V (P˂0.01). Morphological 
evaluation identified macrophages actively phagocytosing eosinophils; this was 
only detected in MCT lesions, while no evidence of such phenomenon was noted 
in EG. Lendrum’s stain, used to identify eosinophils within the sections, 
successfully highlighted the eosinophils granules, but also demonstrated that 
eosinophils in EGC cores exhibited different staining colours (purple, intense red, 
pale red) or were colourless. The presence of this colour pattern demonstrated that 
the EGC core did not have a regular centrifugal development as expected, but an 
“irregular onion ring” like arrangement, with different orders of colours change, 
overlapping each other. Purple Lendrum’s stain overlapped perfectly with von 
Kossa stained areas suggesting that this chromatic affinity indicates mineralisation.  
In the present study infiltration of immune cells was investigated using 




infiltrating in large numbers in EG and MCT, but higher CD3 density was detected 
in EG lesions compared to MCT. CD79a-postive lymphocytes, indicative for B 
lymphocytes, which though rare in both MCT and EG lesions were, when present, 
forming lymphocyte aggregates. These cells were significantly more present in EG 
lesions compared to MCT (P˂0.05). Histiocytes (Iba1- positive) were more 
numerous in EG compared to MCT; in both categories they were highly 
represented. Their observation was associated with EGC but also infiltrating in 
between mast cells in MCT, possibly representing tumour-associated macrophages 
(TAMs).  
Analysis of cytokine expression was performed using in-situ hybridisation on 
formalin fixed paraffin embedded tissue (Eotaxin, MIP1-alpha, IL-4, IL-5, IL-13, 
TGF-beta, SCF) or immunohistochemistry (RANTES) in a sub group of lesions 
(n=10) belonging to EG (n=5) and MCT (n=5). In EG the predominant cytokine 
expressed by macrophages and lymphocytes including epithelioid macrophages 
was IL-13, which was significantly more expressed in EG compared to MCT. In 
MCT the most represented cytokine was IL-5 which was transcribed by mast cells 
and lymphocytes and was significantly higher in MCT than EG (P˂0.05). Among 
other cytokines RANTES was expressed in lymphocytes and histiocytes in higher 
number in EG compared to MCT. Other cytokines investigated such as IL-4, MIP-
1a, TGF beta, and SCF showed weaker differences amongst groups, and their role 
in the two lesions was less clear.  
Summarising, according to the results of this study:  
EG were predominantly lesions characterised by EGC with mineralised cores and 
the presence of collagen fragments. EGC were associated in some cases with 
lymphocytes aggregates composed of B cells, and often extended to the most 
superficial layers of the skin with hair follicle involvement. T cells were 
predominant, and IL-13 transcribed by lymphocytes and macrophages is likely to 
be predominantly involved in eosinophils recruitment in these lesions.  
MCT were lesions predominantly located in deep dermis, exhibiting a variable 
number and variable sizes of EGC or, in some cases, none. MCT exhibited large 
numbers of infiltrating macrophages consistent with TAMs. Within the MCA, 
scattered macrophages phagocytosing eosinophils were detected, a unique feature 
of MCT. EGC associated with MCT were less often mineralised than those of EG, 
and only very rarely associated with B cells. IL-5 was the most abundant cytokine 
transcribed in these lesions by mast cells and lymphocytes, and it is believed that it 
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CHAPTER 1: INTRODUCTION  
1. Introduction  
Eosinophilic granuloma (EG) is a chronic inflammatory condition observed in 
horses, cats and, though less frequently, dogs. It is characterised by intensive 
infiltrates of eosinophils, macrophages as well as lymphocytes and plasma cells 
(Ackermann, 2017, Mauldin and Peters-Kennedy, 2016). Despite its frequency, the 
aetiology and pathogenesis of EG is still unknown and possibly multifactorial 
(Mauldin and Peters-Kennedy, 2016, Scott and Miller, 2011b). In contrast, mast 
cell tumours (MCT) are neoplastic processes that involve the presence of neoplastic 
mast cell accumulations in a tissue. MCT are commonly reported in domestic 
animals, particularly in dogs and cats, but also occur in horses. The aetiology is 
unknown (Clarke et al., 2014, Kiupel, 2017, Mair and Krudewig, 2008, Mauldin 
and Peters-Kennedy, 2016, Ressel et al., 2015, Scott and Miller, 2011c).  
However, different factors have been suggested to be associated with EMCT 
(equine mast cell tumour), such as parasitic infection, chronic inflammatory and 
autoimmune responses (Cole et al., 2007, Malikides et al., 1996). Interestingly, 
MCT and EG in horses share similar histological features, which often lead to 
misdiagnosis and confusion (Kiupel, 2017, Scott and Miller, 2011b, 2011c).  
At present, it is not clear whether a “continuum” exists between the two processes 
(EG and MCT) in horses, or whether they are two different entities with an 
unrelated pathogenesis.  
The association between inflammation and cancer as well as tumorigenesis has been 
discussed (Korniluk et al., 2017, Landskron et al., 2014, Porta et al., 2009, Prete et 
al., 2011, Taniguchi and Karin, 2018). In addition, the associated mechanisms and 
malignant transformation have been explored in laboratory animals (Erdman and 
Poutahidis, 2010, Maeda and Omata, 2008, Mantovani et al., 2008). However, it is 
likely that a relation between chronic inflammation with or without infection and 
cancer exist and is similar in both humans and laboratory animals (Morrison, 2012). 
In fact, the number of reports documenting similarities in genetic expression, 
inflammatory cell infiltrates, cytokine and chemokine expression, and other 
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biomarkers in humans and domestic animals is continuously increasing (Morrison, 
2012, Fürdös et al., 2015, Carvalho et al., 2016). So far, however, there is 
insufficient data to document the proportion of malignant tumours in domestic 
animals that result from inflammation (Morrison, 2012). In veterinary medicine, 
available information on inflammation and infection associated with cancer 
formation is scarce and predominantly limited to short and case reports (Ewald and 
Swain Ewald, 2015, Morrison, 2012). During active inflammation, the cell 
microenvironment is highly unstable with combined abundance of reactive oxygen 
and nitrogen species, cytokines, chemokines, and growth factors (Brenner et al., 
2014, Yang and Zhang, 2017). Any disturbance in normal tissues will trigger 
immune cells which results in an inflammatory response and unleashes various 
mediators such as cytokines, chemokines, matrix-remodelling proteases, reactive 
oxygen, and nitrogen species (Gabriele and Bruno, 2009, Roca et al., 2009).  
Ultimately, the relationship and link between inflammation and cancer 
development is well accepted (Crusz and Balkwill, 2015, Elinav et al., 2013, 
Fernandes et al., 2015, Korniluk et al., 2017, Landskron et al., 2014, Multhoff et 
al., 2011), though many questions remain unanswered (Morrison, 2012).  
1.2 Chronic inflammation, granulomatous inflammation, granuloma and 
eosinophilic granuloma: Concepts and cellular components  
1.2.1 Chronic inflammation  
Chronic inflammation is an inflammation of prolonged duration (Ackermann, 2017, 
Kumar et al., 2017). It occurs when an acute inflammatory response has failed to 
eradicate the causative agent or following a repeated acute inflammation process 
leading to severe tissue injury and necrosis, or due to exposure to several factors 
(biochemical or virulence) in response to the inciting stimulus or microorganism 
(Ackerman, 2017). Chronic inflammation is the simultaneous occurrence of active 
inflammation, tissue destruction and attempts at repair (Kumar et al., 2017). 
Chronic inflammation is defined morphologically by the presence of macrophages, 
lymphocytes and plasma cells in tissues (Ward, 2010). When inflammation 
becomes chronic, the adaptive immune response is activated with involvement of 
the cellular and non-cellular mechanisms of acquired immunity (Kumar et al., 2017, 
Ward, 2010). Immune mechanisms play further roles in the resolution of 
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inflammation and in the healing process, including the repair and regeneration of 
lost and damaged tissues (Cekici et al., 2014, Gilroy and De Maeyer, 2015, 
Headland and Norling, 2015, Sugimoto et al., 2016).  
In chronic inflammation, the response is predominantly regulated by cytokines, 
chemokines, and inflammatory mediators released by inflammatory cells at the 
inflammation site (such as macrophages, lymphocytes and plasma cells), leading to 
severe tissue damage, proliferation of fibroblasts, and the deposition of collagen 
(Ackermann, 2017, Headland and Norling, 2015, Kumar et al., 2017).  
1.2.2 Granulomatous inflammation  
Granulomatous inflammation is a distinctive type of chronic inflammation, and it 
is characterised by infiltration dominance of macrophages including epithelioid 
macrophages (i.e. activated macrophages) and multinucleated giant cells 
(Ackermann, 2017, Kumar et al., 2017, Shah et al., 2017). The immune cells are 
arranged either in a random fashion or as organised nodules, i.e. granulomas 
(Ackermann, 2017). Different causative agents are responsible for granulomatous 
inflammation and include exogenous agents (infectious e.g. bacteria, viruses, fungi, 
protozoa, helminths and environmental substances - such pollens, dust mites, 
foodstuff) or endogenous antigens (e.g. autoantigens, tumour antigens, and viral 
antigens) and/or idiopathic factors (Ackermann, 2017, Kumar et al., 2017). Several 
factors are required to develop and regulate granulomatous inflammation. These 
factors can be categorised as inciting agents, the host immune response (T cells and 
macrophages), interactions between and reaction of the infiltrating cells via 
cytokines, chemokines, and inflammatory mediators at the site of chronic 
inflammation (Ackermann, 2017, Kumar et al., 2017).  
1.2.3 Granuloma  
A granuloma is a focus of chronic inflammation consisting of aggregations of 
macrophages that (including epithelioid macrophages and multinucleated gain 
cells) are surrounded by layers of lymphocytes and plasma cells (Kumar et al., 
2017).  
A current definition of the term “granuloma” is provided by Pagán and 
Ramakrishnan (2018, p 639)  
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“Granulomas are organised aggregates of macrophages, often with characteristic 
morphological changes, and other immune cells. These evolutionarily ancient 
structures form in response to persistent particulate stimuli—infectious or non-
infectious—that individual macrophages cannot eradicate”. 
1.2.4 Eosinophilic granuloma (EG)  
Eosinophilic granuloma (EG) is a specific type of chronic inflammation 
characterised by intense infiltrates of eosinophils with macrophages, and variable 
amounts of lymphocytes and plasma cells (Ackermann, 2017). EG exhibits flame 
figures (dense eosinophilic area around collagens due to accumulation of Major 
Basic Protein (MBP) from degranulated and degenerated eosinophils) as noted by 
Ackermann, (2017), and Fondati et al., (2001). EG sometimes do not form distinct 
nodules and the inflammatory cells (eosinophils and macrophages) are distributed 
in variable numbers randomly within the lesions (Ackermann, 2017). A definite 
cause has so far not been determined in any of the affected species (Ackermann, 
2017, Mauldin and Peters-Kennedy, 2016).  
1.3 Eosinophilic dermatitis in animals  
Eosinophilic dermatitis is a frequent skin condition in several animal species and, 
in particular, in cats and horses (Bloom, 2006, Gross et al., 2005, Mauldin and 
Peters-Kennedy, 2016). Eosinophilic inflammation is a common reaction in both 
cats and horses (Bloom, 2006, Gross et al., 2005, Mauldin and Peters-Kennedy, 
2016). It is also thought to be associated with those chemotactic stimuli that recruit 
neutrophils in other species, but eosinophils and neutrophils in cats and horses 
(Mauldin and Peters-Kennedy, 2016). Among eosinophilic skin inflammatory 
conditions in horses, EG represents a particular morphological entity (Scott and 
Miller, 2011b).  
Several factors can induce eosinophilic dermatitis. These include environmental 
allergens, food, parasites, insects, drugs, endogenous (free keratin in dermis) and 
exogenous factors (for example, embedded insect parts), foreign material, and viral 
infections (feline herpesvirus 1 in cats) (Buckley and Nuttall, 2012, Mauldin and 
Peters-Kennedy, 2016).  
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Eosinophilic granuloma in cats, eosinophilic stomatitis in dogs and eosinophilic 
granuloma dermatitis in horses are possibly caused by antigen in T helper cells, 
however so far no specific antigen has been detected (Ackermann, 2017, Wobeser, 
2015) .  
1.3.1 Eosinophilic granuloma complex in cats  
Feline eosinophilic granuloma complex encompasses a number of distinct clinical 
entities with overlapping histopathologic features (Buckley and Nuttall, 2012, 
Mauldin and Peters-Kennedy, 2016). These primary entities (namely feline 
eosinophilic granuloma, eosinophilic plaque and indolent ulcer) can occur 
separately or in combination, without breed or sex predilection (Bloom, 2006, 
Buckley and Nuttall, 2012). In addition, some studies such as that by Bonello et al., 
2012, have reported that eosinophilic granuloma complex is more common in 
young cats (2-4 years) and amongst  females; but this possible predisposition is not 
well documented (Buckley and Nuttall, 2012).  
 It has been suggested that the above terms are used for clinical dermatology, 
whereas “Eosinophilic dermatosis” should be used in diagnostic dermatopathology 
(Bloom, 2006, Fondati et al., 2001). The causative agent of feline eosinophilic 
granuloma complex is unknown, however, many causes have been suggested which 
assume that eosinophilic granuloma complex is the consequence of a 
hypersensitivity reaction to, amongst other things, insect bites wuch as fleas and 
mosquitos, atopy, and food allergies) (Bonello et al., 2012, Mauldin and Peters-
Kennedy, 2016). Other proposed causes are eosinophil dysfunction, embedded 
insects parts or foreign bodies, and the release of major basic protein (MBP) 
(Buckley and Nuttall, 2012). Studies in cats indicate that flame figures result from 
the deposition of eosinophilic MBP on collagen bundles and widespread 
degranulation of eosinophils and eosinophilic debris surrounding the collagens 
bundles (Fondati et al., 2001, Bardagí et al., 2003). In addition, the flies’ domestic 
allergen I (FELD I) can be an auto-allergen responsible for chronic inflammation 
in felines with eosinophilic granuloma complex as noted by Hnilica, (2017), and 
Wisselink et al., (2002).  
Typically, indolent ulcer occurs as solitary, unilateral, alopecic, ulcerated, firm 
lesions on the upper lip adjacent to the philtrum, with possible associated regional 
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lymphadenopathy. These lesions are non-pruritic, non-painful, and rarely 
associated with peripheral eosinophilia (Bloom, 2006, Bonello et al., 2012, Gross 
et al., 2005, Mauldin and Peters-Kennedy, 2016). Eosinophilic plaques are typically 
raised, round, oozing, and erythematous and occur at the abdomen, thighs, inguinal 
and axillary areas with associated regional lymphadenopathy. They are severely 
pruritic with associated peripheral eosinophilia (Bloom, 2006, Gross et al., 2005, 
Mauldin and Peters-Kennedy, 2016). In contrast, EG lesions of young cats show 
variable pruritus and possible eosinophilia and are either cutaneous or oral, papular, 
nodular or linear lesions. Cutaneous lesions are linear and appear at the caudal or 
medial thighs, as well as on footpads, the pinnae, and the lower lip. Oral lesions 
occur as nodules on the tongue, frenulum, or soft plate, and are more severe and 
aggressive than their cutaneous counterpart (Bloom, 2006, Bonello et al., 2012, 
Forsythe, 2011, Gross et al., 2005, Hnilica, 2017, Miller et al., 2013).  
Histologically, feline eosinophilic granuloma complex comprises dermal infiltrates 
dominated by eosinophils and is organised in various patterns (superficial, deep 
perivascular, interstitial, or diffuse), with or without flame figures, and may exhibit 
small foci of collagen fibres expanded by oedema and surrounded by degranulated 
eosinophils. In addition, a granulomatous reaction may be present around the flame 
figures (Fondati et al., 2001, Bardagí et al., 2003). The most common histological 
features of indolent ulcer are eosinophilic infiltration with fewer neutrophils and 
variable fibrosis, with rare eosinophilic degranulation around collagen fibres (flame 
figures). In eosinophilic plaque, severe epithelial hyperplasia with acanthosis, 
spongiosis and eosinophilic exocytosis, as well as epidermal and follicular 
mucinosis are common findings; eosinophils may infiltrate the panniculus, and 
ulceration is often observed (Bloom, 2006, Gross et al., 2005, Mauldin and Peters-
Kennedy, 2016).  
Feline EG is seen as diffuse dermal granulomatous inflammation, with numerous 
eosinophils, fewer mast cells and macrophages, and sometimes lymphocytes. In the 
inflamed areas, there are large irregular foci of eosinophilic degranulation and 
degeneration around collagen bundles (flame figures). These large foci can be 
surrounded by macrophages and multinucleated giant cells. Focal infiltrative to 
necrotising mural eosinophilic folliculitis or furunculosis, and focal eosinophilic 
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panniculitis may be seen in cutaneous lesions. In addition, the overlying epithelium 
is often hyperplastic and ulcerated, and mucinosis of the epidermis and hair 
follicle’s outer root sheath may be present. Older lesions often have palisading 
macrophages around flame figures, with fewer eosinophils (Buckley and Nuttall, 
2012, Mauldin and Peters-Kennedy, 2016). The differential diagnosis for 
eosinophilic granuloma complex in cats includes neoplasia (squamous cell 
carcinoma, lymphoma, mast cell tumour), dermatophytosis, feline cowpox 
infection, cutaneous viral disease, mycobacterial infection, deep fungal infection, 
bacterial folliculitis and furunculosis or abscess, foreign body reaction, sterile 
granulomatous disease, and trauma-induced changes (Bloom, 2006, Buckley and 
Nuttall, 2012, Gross et al., 2005).  
1.3.2 Canine eosinophilic granuloma  
Canine eosinophilic granuloma is a rare condition and shares many histological 
features with feline eosinophilic granuloma (Bloom, 2006, Bonello et al., 2012, 
Gross et al., 2005, Hnilica, 2017, Kim et al., 2011, Mauldin and Peters-Kennedy, 
2016). An age or sex predisposition is not reported (Vercelli et al., 2005). 
Nevertheless, EG has been reported as more common in young male Siberian 
Huskies and Cavalier King Charles (Bredal et al., 1996). The cause of canine 
eosinophilic granuloma is unknown. However, genetic factors and a 
hypersensitivity reaction are suggested, along with multiple allergen factors are 
proposed (Bredal et al., 1996, Kim et al., 2011, Mauldin and Peters-Kennedy, 
2016).  
Clinically, EG lesions in dogs are mainly nodules or plaques in the oral passage, 
associated with blood eosinophilia (Bonello et al., 2012, Kim et al., 2011, Mauldin 
and Peters-Kennedy, 2016). Cutaneous lesions are less common and present as non-
pruritic lesions at different body sites such as the muzzle, neck, flank and prepuce 
(Vercelli et al., 2005). The typical histological finding is diffuse dermal 
eosinophilic inflammation, commonly found as foci of bright eosinophilic collagen 
surrounded by degranulating eosinophils and occasionally surrounded by 
epithelioid macrophages and possibly ulcerated or acanthotic epithelium/epidermis 
(Bloom, 2006, Gross et al., 2005, Mauldin and Peters-Kennedy, 2016). Differential 
diagnosis for canine eosinophilic granuloma are an infectious and foreign body 
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granuloma, neoplasms and eosinophilic furunculosis (Bloom, 2006, Gross et al., 
2005).  
 1.4 Equine eosinophilic nodular diseases  
Eosinophilic inflammation is a common reaction pattern in horses. There are three 
nodular conditions of unknown aetiology and pathogenesis, including equine 
eosinophilic granuloma (EEG), axillary nodular necrosis and unilateral papular 
necrosis (Mauldin and Peters-Kennedy, 2016, Scott and Miller, 2011b). 
Hypersensitivity reaction, insect bites, silicone-coated needles are suspected causes 
of such inflammatory reactions (Scott and Miller, 2011b, Slovis et al., 1999). In 
addition, there are other nodular diseases in horses, with a defined aetiological 
cause, which share histological features with EEG, i.e. are characterised by massive 
eosinophilic infiltration and areas of necrosis; for example, cutaneous 
habronemiasis. Furthermore, cutaneous mast cell tumours can share both clinical 
and histological features with equine eosinophilic granuloma (EEG) and are also of 
unknown aetiology (Mauldin and Peters-Kennedy, 2016, Scott and Miller, 2011c).  
1.4.1 Equine eosinophilic granuloma (EEG)  
Equine eosinophilic granuloma (EEG) is the most frequent inflammatory nodular 
skin disease and cutaneous eosinophilic nodular condition in horses (Pilsworth and 
Knottenbelt, 2005, Scott and Miller, 2011b, White, 2015, Wobeser, 2015). It is 
reported worldwide and without breed, sex, or age association (Mauldin and Peters-
Kennedy, 2016, Pilsworth and Knottenbelt, 2005, Scott and Miller, 2011b, 
Wobeser, 2015). Previously, these conditions were termed “collagenolytic 
granuloma” which turned out to be inaccurate because several studies demonstrated 
that the areas of brightly eosinophilic collagen surrounded by eosinophils do not 
represent areas of collagen degradation but are “flame figures” as described above 
(Ackermann, 2017, Mauldin and Peters-Kennedy, 2016, Scott and Miller, 2011a).  
 1.4.1.1 Pathogenesis and causes of equine eosinophilic granuloma (EEG)  
 Despite the frequency of EEG, its aetiology and pathogenic mechanisms are still 
unknown. EEG is likely multifactorial, and several factors have been thought to 
cause and trigger such an inflammatory reaction, including traumatic injury in the 
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saddle region and atopy (Mauldin and Peters-Kennedy, 2016, Scott and Miller, 
2011b, Wobeser, 2015).  
1.4.1.2 Clinical findings  
EEG generally presents as single or multiple nodular lesions from 0.5-10 cm in 
diameter and are most frequently found on the withers and back, in the girth area, 
the mane, the rump, and the face (Mauldin and Peters-Kennedy, 2016, Scott and 
Miller, 2011b, Wobeser, 2015). The lesions are often round, firm and well 
circumscribed, without ulceration, alopecia, pain or pruritus. Some lesions, 
however, can be cystic or plaque-like, with a central caseous core (Mauldin and 
Peters-Kennedy, 2016, Scott and Miller, 2011b, Wobeser, 2015). The key 
histopathologic feature of EEG is the collagen degeneration/collagenolysis or 
necrobiotic collagen. However, it is currently known as flame figures, due to the 
presence of eosinophilic degranulation products released from degranulated 
eosinophils coating the collagen but there is no collagen degeneration (Fernandez 
et al., 2000, Scott and Miller, 2011b).  
1.4.1.3 Diagnosis and histopathological findings  
History and clinical signs as well as skin biopsy are used to diagnose EEG (Scott 
and Miller, 2011). In addition, the cytological examination shows infiltration of 
different immune cells (such as eosinophils, histiocytes, and lymphocytes) and the 
absence of microorganism (Mathison, 1995, Scott and Miller, 2011b). The typical 
histological finding of EEG is a nodular to diffuse eosinophilic granulomatous 
inflammation of the dermis, occasionally also the panniculus.  
Multifocal areas of “flame figures” are a key feature, as well as occasional small 
foci of folliculitis or furunculosis and the presence of scattered lymphoid nodules, 
which could, in some cases, predominate in the lesions. In advanced lesions, there 
are areas of dystrophic mineralisation, which can lead to misdiagnosis as calcinosis 
circumscripta (Mauldin and Peters-Kennedy, 2016, Scott and Miller, 2011b, 
Wobeser, 2015).  
The differentiation of EEG from unilateral papular necrosis and axillary nodular 
dermatosis is relatively straightforward; however, these two lesions have many 
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features in common with EEG which may lead to diagnostic challenges (Mathison, 
1995, Stannard, 2000).  
EEG needs to be differentiated form other eosinophilic nodular skin diseases 
including parasitic diseases such as habronemiasis (summer sore), fungal diseases 
such as pythiosis and zygomycosis, neoplastic diseases such as mast cell tumours, 
and multisystemic eosinophilic epitheliotropic diseases (MEED) (Scott and Miller, 
2011b).The latter is a rare eosinophilic condition that results in eosinophilic 
infiltration with occasional eosinophilic granuloma formation in many organs, 
including the skin and intestine (Scott and Miller, 2011b).The cause of MEED is 
considered either ato be severe hypersensitivity reaction or a clonal proliferation of 
T cells, resulting in the recruitment of eosinophils due to the secretion of interleukin 
5 (Laisse et al., 2017, Perle et al., 1998).  
1.4.2 Unilateral papular dermatosis  
Unilateral papular dermatosis is an uncommon nodular skin disease in horses and  
reported worldwide especially in spring and summer. Some studies suggest that the 
quarter horse breed is over-represented (Mathison, 1995, Mauldin and Peters-
Kennedy, 2016, Scott and Miller, 2011b, Stannard, 2000). The cause and 
pathogenesis is still unknown. However, due to the eosinophilic nature of the lesion 
and the seasonality, it has been proposed that it could represent an insect bite 
hypersensitivity reaction (Scott and Miller, 2011b, Stannard, 2000). Since the 
lesions occur on one side of the body, a hypersensitivity reaction to an ectoparasite 
inhabiting the bedding would also be a possibility (Scott and Miller, 2011b). 
Clinically, the condition is characterised by multiple unilateral cutaneous papules 
of 2-10 mm in size, preferentially on the trunk but sometimes on the neck, shoulders 
or abdomen, with no signs of pruritus or pain. However, some lesions become 
crusted and alopecic. Histologically, the lesions are characterised by eosinophilic 
folliculitis and furunculosis, and eosinophilic granulomas with flame figures may 
be present in the surrounding dermis (Mathison, 1995, Mauldin and Peters-
Kennedy, 2016, Scott and Miller, 2011b, Stannard, 2000). Some lesions can exhibit 
wedge-shaped areas of necrosis or superficial to mid dermal eosinophilic 
granulomas and necrosis but without clear involvement of hair follicles (Scott and 
Miller, 2011b).  
Chapter 1: Introduction  
11  
  
1.4.3 Axillary nodular necrosis (girth galls)  
Axillary nodular necrosis is a very rare dermatosis of horses that can occur 
throughout the year with no age, breed, or sex predilection (Mauldin and Peters-
Kennedy, 2016, Scott and Miller, 2011b). Cause and pathogenesis is still unclear. 
This dermatosis is also described as a focal nodular eosinophilic granuloma and 
arteritis (Mauldin and Peters-Kennedy, 2016, Scott and Miller, 2011b). The 
condition, also known by owners as “girth galls”, is linked to overworking or ill-
fitting tack. However, it has been reported in both working and nonworking horses 
(Scott and Miller, 2011b, Stannard, 2000). Clinically, it is characterised by 
cutaneous nodules that typically occur in the girth area, or behind the elbow. 
However, it may also appear caudal to the shoulder and on the proximal, medial 
aspect of the forearm (Mauldin and Peters-Kennedy, 2016, Scott and Miller, 2011b, 
Stannard, 2000). The lesions are firm, round, well circumscribed, and 1-10 cm in 
diameter, can be single or multiple and are sometimes arranged in a linear pattern; 
with neither pruritus nor pain. The overlying skin and hair coat are usually 
unaltered. Histologically, the lesions are characterised by coagulative necrosis 
surrounded by eosinophilic granulomatous dermatitis, usually with panniculitis, 
flame figures, dystrophic mineralisation of collagen, lymphoid nodules, 
eosinophilic or necrotising vasculitis with endothelial cell hypotrophy, vessel 
occlusion, and intimal mucinosis (Mauldin and Peters-Kennedy, 2016, Scott and 
Miller, 2011b).  
1.5 Mast cell tumours in animals  
Mast cell tumours (MCT) occur in many animal species such as dogs, cats, horses 
and cows at diverse locations and with variable biological behaviour; similarities 
out-weigh variations (Goldschmidt and Hendrick, 2002). 
MCT in animals frequently affect the dermis and subcutis as focal or multicentric 
nodular masses (Goldschmidt and Hendrick, 2002, Kiupel, 2017, Misdorp, 2004), 
but can in principle occur in many different tissues and organs, such as the 
gastrointestinal tract, respiratory tract, salivary glands, eyes, testes and spleen 
(Head et al., 2002, Kiupel, 2017, Mair and Krudewig, 2008).  
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Among domestic animals, MCT have been most frequently reported and most 
intensely studied in dogs, as well as in cats while they have only been infrequently 
or sporadiclly reported in horses (Kiupel, 2017, Mair and Krudewig, 2008, 
Misdorp, 2004).  
In dogs, MCT are the most common malignant skin cancer and exhibit significant 
variability in their biological behaviour. They develop most frequently in the skin, 
but can also grow in the intestines, liver, spleen, and elsewhere (Kiupel, 2017). 
Cutaneous MCT comprise 7-21% of skin tumours in dogs, with no sex or age 
predilection, however many breeds are predisposed, the boxer being the best known 
example (Blackwood et al., 2012, Kiupel, 2017, Strefezzi et al., 2009). So far, 
knowledge and information on the differences between cutaneous and subcutaneous 
MCT are sparse. Nonetheless, previous studies have shown that subcutaneous MCT 
are generally less aggressive than their cutaneous counterparts (Blackwood et al., 
2012, Kiupel, 2017, Thompson et al., 2011). In addition, extracutaneous MCT or 
mast cell leukaemia are rarely seen (Strefezzi et al., 2009).  
In cats, mast cell tumours are the second most common cutaneous tumours, 
accounting for approximately 20% of skin tumours. Siamese cats appear to be 
predisposed to MCT, but other breeds can also be affected, and there is no sex 
predisposition (Blackwood, 2015). Feline MCT (FMCT) is classified histologically 
into Mastocytic and Atypical.  
Mastocytic tumours can be further classified into 2 subtypes: well differentiated 
MCT and pleomorphic MCT (Blackwood, 2015, Blackwood et al., 2012, 
Goldschmidt and Hendrick, 2002, Sabattini and Bettini, 2010). Well differentiated 
MCT are completely circumscribed encapsulated masses that can extend into the 
subcutis. They are mostly composed of sheets of cells resembling normal mast cells, 
with mild pleomorphism, a low mitotic rate and low numbers of eosinophils and 
lymphocytes (Goldschmidt and Hendrick, 2002, Gross et al., 2005, Sabattini and 
Bettini, 2010).  
Pleomorphic MCT on the other hand exhibit a tendency to infiltrate deep into the 
dermis and subcutis (Gross et al., 2005, Sabattini and Bettini, 2010). They are 
comprised of large cells with eccentric nuclei and prominent 1`nucleoli, and contain 
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variable numbers of giant cells with a multilobulated nucleus. Regarding the mitotic 
rate, there are conflicting results; an older study reported a variable and often low 
mitotic rate (Johnson et al., 2002), whereas a more recent one describes high mitotic 
activity (Sabattini and Bettini, 2010). Pleomorphic MCT are usually infiltrated by 
large numbers of eosinophils (Hendrick et al., 1998, Goldschmidt and Hendrick, 
2002, Gross et al., 2005). Recently, a new subcategory of well differentiated MCT 
with prominent multinucleated cells has been described (Melville et al., 2015).  
Poorly differentiated tumours carry a worse prognosis; but most feline cutaneous 
MCT (50-90%) are well differentiated and show benign behaviour (Blackwood, 
2015). The atypical form of MCT occurs primarily in Siamese cats under 4 years 
of age. Siamese cats are also predisposed to the development of the mastocytic 
form. This type of FMCT previously termed “histiocytic” is characterised by large, 
polygonal to spindle shaped neoplastic cells with abundant amphophilic cytoplasm. 
The nuclei are large and vesicular and may be slightly indented; mitotic figures are 
infrequent. Admixed eosinophils and lymphoid aggregates tend to be more 
numerous than in mastocytic MCT (Blackwood, 2015, Henry and Herrera, 2013, 
Sabattini and Bettini, 2010).  
In cattle, mast cell tumours are infrequent and can affect many organs too. However, 
the skin is the most frequently affected site and usually develops malignant and 
highly metastatic MCT resulting in multicentric cutaneous disease (Kiupel, 2017, 
Pérez et al., 1999, Smith and Phillips, 2001). Young animals can exhibit solitary or 
multiple lesions at various body sites (Hill et al., 1991, Kiupel, 2017, Shaw et al., 
1991, Smith and Phillips, 2001, Welle et al., 1995). Furthermore, congenital 
systemic mast cell tumours have also been reported in a stillborn calf (Smith and 
Phillips, 2001).  
In horses, mast cell tumour is an uncommon neoplastic disease and understanding 
of it is limited (Goldschmidt and Hendrick, 2002, Kiupel, 2017, Mair and 
Krudewig, 2008, Scott and Miller, 2011c). Equine mast cell tumour (EMCT) is 
characterised by aggregate areas of neoplastic mast cells, admixed with variable 
numbers of eosinophils, and areas of eosinophilic granuloma and dystrophic 
mineralisation (Kiupel, 2017, Mair and Krudewig, 2008, Scott and Miller, 2011c). 
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The latter are similar to those seen in EEG, and frequently lead to misdiagnosis of 
EMCT (Kiupel, 2017, Mair and Krudewig, 2008, Scott and Miller, 2011c).  
1.5.1 Histopathology and grading classification systems of MCT in animals  
In all other species, apart from dogs, and to a lesser extent cats, there is limited 
information on their morphological classification (Mair and Krudewig, 2008). 
However, in dogs MCT has been widely studied and described. Several 
classification and grading systems based on the degree of cellular differentiation, 
the nuclear morphology and the overall cellularity have been proposed (Bostock, 
1973, Hottendorf and Nielsen, 1967, Patnaik et al., 1984).  
The Patnaik grading system (Patnaik et al., 1984) is the best known grading scheme 
and is used to predict the clinical behaviour of MCT in dogs; it divides canine MCT 
into three grades. More recently, the Patnaik system was criticised for its inaccuracy 
regarding certain categories (i.e. MCT grade 2) (Kiupel et al., 2004), and due to its 
ambiguity, leading to discordance (50%) among pathologists in grading MCT 
(Northrup et al., 2005, Pinczowski et al., 2008). A recent two-tier system for 
grading MCT in dogs was developed based on the number of mitoses, the presence 
of multinucleated cells or bizarre nuclei, and  karyomegaly (increased nuclear size) 
(Kiupel et al., 2011).  
High-grade MCT tumours have been shown to be significantly associated with a 
shorter time to metastasis, tumour associated mortality, and a shorter overall 
survival time (less than 4 months). Low-grade MCT tumours, on the other hand, 
have a median survival time of more than two years (Kiupel et al., 2011).  
Furthermore, several recent studies have demonstrated that subcutaneous MCT in 
dogs should be distinguished from their cutaneous counterparts, and that the 
existing grading systems are not appropriate for their prognosis (Blackwood et al., 
2012, Garrett, 2014, Thompson et al., 2011). Notably, more than 90% of 
subcutaneous MCT have a benign course and can be controlled surgically (Kiupel, 
2017, Newman et al., 2007, Thompson et al., 2011). In addition, 10% of dogs with 
subcutaneous MCT die from MCT-associated diseases whilst 11% develop a 
second subcutaneous MCT distant from the first one. Moreover, 5-8% recur and 
metastasise, respectively (Garrett, 2014, Kiupel, 2017, Thompson et al., 2011).  
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1.6 Mast cell tumours in horses  
In horses, MCT represent 3-7% of the referred cutaneous neoplasms cases in equine 
hospitals (Scott and Miller, 2011c, Valentine, 2006). So far, they have not been 
fully investigated and most of our knowledge is based on a limited number of 
studies as well as other descriptive reports in individual animals.  
The classification of MCT in horses is also referred to as “mastocytosis” or 
“mastocytoma” (Altera and Clark, 1970, Cheville et al., 1972, Mair and Krudewig, 
2008, Mauldin and Peters-Kennedy, 2016, Moulton, 1990). It is still debated (Altera 
and Clark, 1970, Clarke et al., 2014, Goldschmidt and Hendrick, 2002, Johnson, 
1998, Kiupel, 2017, Mair and Krudewig, 2008, Mauldin and Peters-Kennedy, 2016, 
Millward et al., 2010, Moulton, 1990, Prasse et al., 1975, Ressel et al., 2015, Scott 
and Miller, 2011c). Moreover, an aetiology has not been identified, but parasitic 
infections, chronic inflammation and autoimmune reactions have been reported to 
be associated with equine MCT (Cole et al., 2007, Malikides et al., 1996).  
Equine MCT can be misdiagnosed as an inflammatory skin disease (such as 
eosinophilic granuloma), due to shared common features including: the variable 
sizes of mast cell aggregates, the well -differentiated appearance of neoplastic mast 
cells, the high number of infiltrating eosinophils, the well-circumscribed areas of 
collagen degeneration (flame figures) and focal to multifocal areas of necrosis, and 
the level of mineralisation (Goldschmidt and Hendrick, 2002, Kiupel, 2017, Mair 
and Krudewig, 2008, Mauldin and Peters-Kennedy, 2016, Scott and Miller, 2011c, 
Tan et al., 2007).  
In addition, older (present for a long time) cutaneous MCT usually exhibit a variable 
degree of fibrosis and palisading granuloma formation and can also display 
extensive dystrophic mineralisation similar to that found in eosinophilic 
granulomas (Goldschmidt and Hendrick, 2002, Scott and Miller, 2011c). It follows, 
that MCT may share characteristics with calcinosis criumscripta (Goldschmidt and 
Hendrick, 2002, Mair and Krudewig, 2008, Mauldin and Peters-Kennedy, 2016, 
Scott and Miller, 2011c).  
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1.6.1 Clinical sings of equine mast cell tumour  
Equine MCT are generally benign lesions. They occur in three different clinical 
forms; solitary, congenital, and a malignant form affecting many organs (Mair and 
Krudewig, 2008). Solitary tumours are the most common form, affecting mainly 
the superficial skin (Mauldin and Peters-Kennedy, 2016, Ressel et al., 2015, Scott 
and Miller, 2011c).  
Solitary cutaneous MCT usually show one of two notable patterns; the slowly 
progressive or static growth, where chronic lesion is rarely shows sudden rapid 
growth (Kiupel, 2017, Mair and Krudewig, 2008, McEntee, 1991, Scott and Miller, 
2011c). The cutaneous MCT lesions are most frequently single, but multiple lesions 
widely separated or close to each other may occasionally present in the skin of 
horses (Altera and Clark, 1970, Mair and Krudewig, 2008, McEntee, 1991).  
Solitary MCT affects the dermis or subcutis of the head (i.e. lip, nostril, jaw, and 
periorbital area), trunk, and limbs. It usually presents as a partially encapsulated 
and firm or fluctuant lesion. Other features such as alopecia, hyperpigmentation or 
ulceration can also be found (Mair and Krudewig, 2008, Scott and Miller, 2011c). 
MCT usually present as non-painful and nonpruritic lesions, but may exhibit 
sporadic discharge of caseous material (Mair and Krudewig, 2008). In contrast, 
MCT that affects other areas such as the limbs are predominantly firm and 
immovable, and tend to be found in proximity to joints. In these latter locations, 
portions of the tumour are usually calcified and may be visible radiographically 
(Samii et al., 1997).  
The congenital form of cutaneous mastocytosis is rare in horses and mainly affects 
newborn foals and spontaneously regress. In this way it resembles human cutaneous 
mastocytosis in young children (Mair and Krudewig, 2008, Prasse et al., 1975). 
This form is characterised by multifocal cutaneous nodules of variable size, 
occurring on the trunk, lateral hind limbs and within bone marrow (Prasse et al., 
1975).  
Malignant MCT are the rarest in horses (Malikides et al., 1996, Martin and Leipold, 
1972, Reppas and Canfield, 1996, Riley et al., 1991, Ritmeester et al., 1997). The 
reported cases that exist describe a primary intraosseous tumour, which only 
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affected the phalanx, synovial infiltration and can spread to local lymph nodes. It  
may lead to lameness but without documented involvement of other organs. In 
addition, the malignant form is associated with circulating eosinophilia, 
hyperfibrinogenaemia; furthermore, pruritus associated with the lesion or 
disseminated pruritus have also been reported (Reppas and Canfield, 1996, Riley et 
al., 1991).  
Widespread metastasis appears to be extremely rare (Mair and Krudewig, 2008). 
However, Tan et al., (2007) described a multicentric form of mastocytoma, which 
affected the thoracic and abdominal cavities as well. Furthermore, multicentric 
MCT have been reported in a Rocky Mountain horse which exhibited primary 
clinical signs such as draining tracts and distal limb subcutaneous oedema involving 
multiple limbs (Millward et al., 2010).  
Equine MCT have been also reported in the eye, affecting the conjunctiva, sclera, 
nictitating membrane and globe (Doran and Collins, 1986, Flores et al., 2017, Halse 
et al., 2014, Hum and Bowers, 1989, Lavach, 1992, Malikides et al., 1996, Martin 
and Leipold, 1972, McEntee, 1991, Nyrop, 1992, Ward et al., 1993). They have 
also been described in nasal cavities and the nasopharynx (Malikides et al., 1996, 
McEntee, 1991, Richardson et al., 1994), the trachea (Wenger and Caron, 1988), 
and the tongue (Seeliger et al., 2007).  
To date there is no clear evidence of any risk factors associated with MCT in horses, 
however it has been suggested that the male sex is predisposing (Altera and Clark, 
1970, Doran and Collins, 1986, Mair and Krudewig, 2008, McEntee, 1991, Samii 
et al., 1997, Stannard, 1976). In addition, Arab horses appear to be over-represented 
(Clarke et al., 2014, Cole et al., 2007, Mair and Krudewig, 2008, Samii et al., 1997).  
1.6.2 The prognosis of equine mast cell tumours  
To date there is limited information pertaining to the typing and grading of equine 
cutaneous MCT. Two recent investigations have described recurrent and 
multicentric tumours and investigated the morphological characteristics of 
cutaneous MCT in horses; they obtained contrary results (Clarke et al., 2014, Ressel 
et al., 2015).  
Chapter 1: Introduction  
18  
  
Clarke et al. investigated the histologic features and KIT expression patterns of 72 
equine cutaneous MCT in order to determine any associations with clinical 
outcomes. The study concluded that most tumours were well differentiated with 
low mitotic rates (i.e. 96%), and normal KIT staining patterns. It concluded that 
KIT staining pattern and histologic features are not associated with clinical 
outcome. In contrast, Ressel et al., investigated 45 equine MCT and assessed the 
proliferation (PCNA expression) and KIT expression together with morphological 
features. They identified two types of MCT, well differentiated and poorly 
differentiated. Following the definition of the KIT expression patterns in dogs 
(Webster et al., 2004), most well differentiated MCT were found to exhibit KIT 
pattern I, whereas one third (comprised of poorly differentiated mast cells) showed 
KIT pattern II or III. The authors showed that the aberrant KIT expression 
accompanies a high proliferation rate and that these two features characterise a 
subset of poorly differentiated equine MCT. This confirmed their true neoplastic 
nature (Ressel et al., 2015). This latter study supports the need for further 
investigations to understand the biological process of cutaneous MCT in horses. 
1.7 Diagnostic and prognostic methods of MCT in animals  
Diagnostic and prognostic assessment approaches to cutaneous MCT have been a 
focus of research over a longer period in particular in dogs and on a combination of 
different methods leading to a variety of guidelines (Table 1). Generally, these 
methods are based on history, clinical sings, cytological and/or histological 
examination (Blackwood, 2015, Scott and Miller, 2011c, Strefezzi et al., 2009). 
Furthermore, the behaviour and progression of cutaneous MCT is highly variable, 
leading to treatment failure in a number of cases. However, several methods have 
been developed and used particularly in the treatment of pets (Blackwood et al., 
2012, Strefezzi et al., 2009).  
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1.7.1 Diagnostic approaches to mast cell tumours  
1.7.1.1 Cytological examination 
A rapid diagnosis of cutaneous MCT can be achieved through a cytological 
evaluation of fine needle aspirates (FNA) or the impression smears of excisional 
surgical biopsies (Blackwood et al., 2012, Friedrichs and Young, 2013, London and 
Seguin, 2003). Typical MCT produce a smear with large numbers of mast cells 
associated with eosinophils. However, mast cell granules might not be easy to 
identify with the rapid modified Wright’s staining techniques due to the aqueous 
nature of the granule contents that may not be metachromatic (Friedrichs and 
Young, 2013, Jackson et al., 2013, London and Seguin, 2003, Raskin and Meyer, 
2016).  
These are effective methods for initial diagnosis in some animals and limit the list 
of differential diagnoses (Friedrichs and Young, 2013, Pavel et al., 2016). However, 
it is recommended that there is a need to confirm the cytological assessment though 
histology, using HE and Toluidine Blue-stained sections (Kiupel, 2017, London 
and Seguin, 2003).  
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1.7.2 Prognostic assessment  
1.7.2.1 Histological grading systems  
For canine MCT, a combination of the histological grading systems with additional 
approaches are combined (Amorim et al., 2010, Fonseca-Alves et al., 2015, 
Murphy et al., 2004, Patnaik et al., 1984). This does not exist for MCT within other 
species.  
1.7.2.2 Mitotic index  
The mitotic index (MI) is based on the determination of the number of mitoses /10 
high power fields (Blackwood et al., 2012, Romansik et al., 2007, Strefezzi et al., 
2009). For instance, a median survival estimation for dogs suffering from MCT and 
having a MI of less than 5 was 70 months, whereas for an MI of 5 or more it was 2 
months (Blackwood et al., 2012, Romansik et al., 2007). In addition, dogs with 
MCT showing a MI≤10 had a median survival of approximately 11 weeks only 
(Blackwood et al., 2012, Romansik et al., 2007). The impact of MI on the survival 
index has recently been a topic of discussion (Kiupel, 2017).  
1.7.2.3 Histochemical and immunohistochemical approaches  
1.7.2.3.1 Cell proliferation markers  
Evaluation of the proliferative activity using cell proliferation markers aims to 
complement or substitute the counting of mitoses (Stoimenov and Helleday, 2009). 
Proliferating cell nuclear antigen (PCNA) is a non-histone protein necessary for 
DNA synthesis and repair. It is maximally expressed during the S-phase of the cell 
cycle (Bologna-Molina et al., 2013, Stoimenov and Helleday, 2009); this high 
expression is associated with recurrent and metastatic tumours (Mukaratirwa, 2005, 
Romansik et al., 2007, Scase et al., 2006).  
AgNORS are argyrophilic nucleolar organising region-associated proteins that bind 
silver molecules and can be identified using histochemical staining methods (Scase 
et al., 2006, Simoes et al., 1994). By counting the number of AGNOR dots per 
nucleus hasbeen used to demonstrate the generation time (speed of cell cycle 
progression). AgNOR counts were correlated with survival times but did not allow 
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for the prediction of clinical behaviour independent of histological grade 
(Blackwood et al., 2012, Strefezzi et al., 2009).  
Ki-67 (also known as MKI67) is a cellular protein marker of proliferation. During 
the interphase, Ki-67 antigen can be exclusively detected within the cell nucleus, 
whereas in mitosis most of the protein is relocated to the surface of the 
chromosomes. Conversely, during G0 Ki-67 is not detectable. As a consequence of 
this it is considered to be a reliable marker of proliferation. Moreover, it generally 
strongly correlates with the degree of tumour malignancy (Dziegiel et al., 2005). In 
canine MCT, detection of KI-67 in association with cKIT is a recommended and 
routine prognostic method (Fonseca-Alves et al., 2015, Poggiani et al., 2012, 
Webster et al., 2007).  
1.7.2.4 Oncogenes  
Genes involved in neoplastic transformation are derived from proto-oncogenes that 
regulate normal cellular growth. Several oncogenes have been described; growth 
factor receptors are often over expressed in cancer (Hayes, 2012).  
The expression of the proto-oncogene cKIT has been extensively studied in MCT; 
it encodes a transmembrane receptor with tyrosine-kinase activity which binds with 
Stem Cell Factor (Blackwood et al., 2012, Strefezzi et al., 2009). This factor, also 
named the Mast cell growth factor or KIT-ligand, is a cytokine that activates the 
maturation and survival of mast cells as well as other cells such as haematopoietic 
stem cells and melanocytes (Blackwood et al., 2012, Costa Casagrande et al., 2015, 
Strefezzi et al., 2009).  
Mutation and genetic deletion within the juxtamembrane domain are responsible 
for the constitutive activation of the receptor and such activation leads to excessive 
cell proliferation and tumour formation (Blackwood et al., 2012, Strefezzi et al., 
2009).  
Mutations were detected and described as juxtamembrane domain duplications in 
MCT in dogs (Strefezzi et al., 2009). In 2000 Reguera et al. reported higher KIT 
levels as the tumour differentiation decreased and two immunohistochemical 
staining patterns: membranous or cytoplasmic, usually around the nucleus. Another 
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study detected mutations in MCT grades II & III and no mutations in grade I 
(Zemke et al., 2002). This study also proposed that KIT mutations and expressions 
can be associated with mast cell tumorigenesis and progression. A further study by 
Marconato et al., (2014) suggested that c-KIT mutation is associated with increased 
metastasis and local recurrence as well as a higher histological grade.  
Kiupel et al. (2004) suggested a new classification for canine cutaneous MCT based 
on the immunohistochemical KIT staining patterns. Three distinct patterns were 
described: (I) membrane associated staining, with minimal cytoplasmic staining; 
(II) intense focal or stippled cytoplasmic staining; and (III) diffuse cytoplasmic 
staining, obscuring other cytoplasmic features. The results of this research showed 
KIT-II and KIT-III patterns to be significantly associated with local recurrence and 
shorter survival times in dogs (Kiupel et al., 2004).  
There is limited information on prognostic approaches for local recurrence and/or 
metastasis of canine subcutaneous MCT. However, Thompson et al. (2011) have 
demonstrated that a panel of markers (KIT immunohistochemical labelling pattern, 
c-Kit mutational status (presence of internal tandem duplications in exon 11), and 
proliferation markers including MI, Ki-67 and AgNOR) can be used to assess the 
behaviour of subcutaneous MCT in dogs.  
1.8 Prognosis of equine cutaneous mast cell tumours  
In horses, the diagnosis of MCT is mainly based on histopathology and cytology 
(Cole et al., 2007, Scott and Miller, 2011c). The variable histopathological 
appearance of both benign and malignant MCT in large animals suggests that the 
canine classification system cannot be applied (Halse et al., 2014, Hill et al., 1991, 
Riley et al., 1991, Ritmeester et al., 1997, Tan et al., 2007). Indeed, one recent study 
concluded that there are no reliable diagnostic tools to characterise the different 
biological behaviour of equine MCT (Clarke et al., 2014). In contrast, Ressel et al. 
(2015), found that certain differentiation features, proliferative activity and c-Kit 
expression identify true, i.e. neoplastic MCT and that c-KIT expression might be a 
prognostic tool for cutaneous equine MCT.  
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1.9 Role, involvement and interaction of immune cells in eosinophilic 
granuloma  
Eosinophils, macrophages and, to a lesser extent, lymphocytes, are major players 
in inflammation and inflammatory reactions in EG lesions (Ackermann, 2017). In 
chronic inflammation, macrophages and T lymphocytes are the main immune cells, 
which release various cytokines, chemokines and proteins causing damage to living 
cells. They are also responsible for the initiation of cell-mediated immunity. Other 
cells are also involved in such immune responses, i.e. mast cells, eosinophils, and 
neutrophils (Murphy and Weaver, 2017, Tizard, 2013). Given this, the current 
chapter focuses on the interaction of eosinophils, macrophages, lymphocytes and 
mast cells, and is predominantly based on human literature.  
1.9.1 Eosinophils  
Eosinophils are multifunctional immune cells that originate from pluripotent 
progenitors in bone marrow and differentiate under the influence of cytokines such 
as interleukin (IL) 5, IL-3 and granulocyte-macrophages colony stimulating factor 
(GM-CSF) (Rosenberg et al., 2012). Eosinophils play a key role in the pathogenesis 
of numerous inflammation processes, microbial infections, and allergic reactions as 
well as immunoregulatory responses (Eng and DeFelice, 2016, Kita, 2011, Kita, 
2013, Long et al., 2016, Muniz et al., 2012, Rosenberg et al., 2012) .Their granules 
are also responsible for inflammation and tissue damage and are well known as the 
primary source of inflammatory mediators in type 1-hypersenstivtiy as well as the 
release of toxic substances by degranulation. Such a mechanism is responsible for 
combating parasitic infections (Kita, 2011, Kita, 2013, Long et al., 2016, Parker 
and Papenfuss, 2017, Stone et al., 2010). Furthermore, eosinophils can phagocytose 
small materials (yeast cell walls, foreign erythrocytes, and antigen–antibody 
precipitates), and has been demonstrated in horses (Archer and Hirsch, 1963). In 
addition, human eosinophils have been reported to phagocyte bacteria (Cline et al., 
1968, Shamri et al., 2011), as well as phagocytose and kill large parasites (Mauldin 
and Peters-Kennedy, 2016, Shamri et al., 2011). Furthermore, eosinophils produce 
transforming growth factor (TGF)-β which is frequently correlated with chronic 
inflammation (Halwani et al., 2011, Mauldin and Peters- Kennedy, 2016, Ohno et 
al., 1992, Yang et al., 2012). At the site of chronic inflammation, both pro-
Chapter 1: Introduction  
24  
  
inflammatory cytokines and chemokines work in coordination and attract mature 
eosinophils to the site (Barnes, 2008, Ghosh et al., 2013). Numerous mediators can 
induce chemotactic and/or chemokinetic processes and are known to induce 
eosinophil migration (Ghosh et al., 2013). The initiation as well as the maintenance 
of these migrant eosinophils depends on the nature of the signals. Receptors and 
receptor profiles on eosinophils also dictate which chemoattractants regulate 
mobility and induced movement. The promotion of receptors and the localisation 
of downstream signalling mediators as well as the binding of IL-5, IL-3 and GM-
CSF regulate and prepare eosinophil responses to chemoattractants and the 
initiation of mobility-movement by the chemotactic agent (Gregory et al., 2003, 
Simson and Foster, 2000, Uhm et al., 2012).  
Furthermore, eosinophil recruitment and production is largely due to the stimulation 
of Th2 lymphocytes, as well as numerous cytokines (i.e. IL-3, IL-4, IL-5, IL-13), 
and GM-CSF (Davoine and Lacy, 2014, Kita, 2013, Kita, 2011, Long et al., 2016). 
The primary function of IL-4 and IL-13 is to stimulate the production of 
immunoglobulin (Ig) E which promotes eosinophil recruitment by increasing the 
expression of eotaxin (CCL11 and CCL26) and endothelial cell vascular cell 
adhesion molecule 1 (VCAM1) (Stone et al., 2010).  
In contrast, IL-5 mediates the increase of eosinophil production, eosinophil 
mobility from bone marrow, and the activation and survival of eosinophils (Kouro 
and Takatsu, 2009, Kita, 2011, Long et al., 2016). Moreover, IL-5 is a cytokine 
specific for eosinophil development and IL-5 receptor expression as well as for 
eosinophil differentiation (Takatsu, 2011). In addition, extravasation via the 
endothelium is mediated by a system of molecules that function in chemotaxis and 
adhesion. These include α4 (CD49d), β2 (CD18) integrins and CC chemokines 
(CCL11/eotaxin) (Günther et al., 2011).  
The CC chemokine family is essential for eosinophil-enhanced-trafficking and 
infiltration to inflamed areas. As eosinophils highly expressing CCR3, a receptor 
that binds eosinophil specific chemokines including eotaxin, eotaxin-2, monocyte 
chemoattractant protein (MCP3, MCP-4), and regulated on activation, normal T 
cell expressed and secreted (RANTES or CCL5) (Weller, 2013, Ying et al., 1999). 
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The way of eosinophils trafficking to inflamed tissues is possibly monitored by T 
cells responding to antigen presenting cells (Eng and DeFelice, 2016).  
During apoptosis, eosinophils express phosphatidylserine on their plasma 
membrane, which leads to the recognition and engulfing of eosinophils by 
macrophages (Farahi et al., 2011, Haslett, 1999, Stern et al., 1992). Failure of the 
macrophages to clear apoptotic eosinophils can lead to secondary necrosis and the 
release of eosinophil granule proteins as well as other pro‐inflammatory mediators 
(Farahi et al., 2011, Stern et al., 1992).  
1.9.2 Macrophages  
Macrophage are major immune cells which play a central role in inflammation and 
the initiation of immune responses (Hao et al., 2012, Oishi and Manabe, 2016, 
Tizard, 2013, Ackermann, 2017). They represent the first line of defence and are 
the cells that come into contact with foreign invaders (Parisi et al., 2018). In 
addition, they are capable of chemotaxis (Fernando et al., 2014, Hao et al., 2012). 
This is attributed to their toll-like and scavenger receptors, which have broad ligand 
specificity for lectins, lipoproteins, proteins, oligonucleotides, polysaccharides, and 
other molecules (Duque and Descoteaux, 2014, Hao et al., 2012).  
Macrophages originate from stem cells of the granulocytic–monocytic lineage in 
bone marrow, and are exposed to certain cytokines (Ackermann, 2017, Tizard, 
2013). Their differentiation is associated with the expression of specific cytokine 
receptors, which are also essential for their function (Sieweke and Allen, 2013). 
Macrophages also mediate the unleashing of effective immune responses, link both 
innate and adaptive immunity and influence the microenvironment of cells (Duque 
and Descoteaux, 2014, Huynh et al., 2007). Such influential interaction has been 
reported in inflammatory and tumour lesions, which provides diverse signalling 
interactions that divert macrophages into “classically activated” (M1) or 
“alternatively activated” (M2) types (Duque and Descoteaux, 2014, Edholm et al., 
2017).  
In addition, macrophages express major histocompatibility complex (MHC) class 
II molecules on their surface, and present antigens to lymphocytes (Mantegazza et 
al., 2013, Suzuki and Luo, 2017). When macrophages engulf a microbe, its antigens 
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are processed and situated on the outer surface of the plasma membrane, where they 
will be recognised by T helper cells (Mantegazza et al., 2013). Following this 
recognition, T lymphocytes release cytokines that activate B cells, and activated B 
lymphocytes, then secrete antibodies specific to the antigens presented by the 
macrophages (Murphy and Weaver, 2017). These antibodies attach to antigens on 
microbes, or to cells invaded by microbes; in turn, these antibody-bound complexes 
are phagocytosed more avidly by macrophages (Duque and Descoteaux, 2014, 
Lacy, 2015, Tizard, 2013).  
Macrophages can be activated in different ways by a variety of stimuli. Their 
activity is increased by cytokines that are released by T helper cells as well as 
interferon (IFN)-γ (Martinez and Gordon, 2014, Tizard, 2013). Classic (M1) 
macrophages are involved in defensive processes against pathogens whereas the 
alternative (M2) cells contribute to tissue remodelling (Italiani and Boraschi, 2014, 
Parisi et al., 2018, Sica et al., 2008). The polarisation is similar to that of 
lymphocytes as M1 cells are generated from monocytes in response to IFN-γ while 
M2 cells develop in response to cytokines such as IL4 and IL-13 (Fernando et al., 
2014, Foucher et al., 2013, Mantovani et al., 2013, Parisi et al., 2018, Smith et al., 
2016). Macrophages are released in response to different kinds of chemokines such 
as CCL2, which in humans is responsible for their polarisation to M2 macrophages 
(Roca et al., 2009). However, such described polarisation does not restrict these 
cells’ range of existent phenotypes or the different related signalling factors 
required from the environment that lead to such range and variety (Galdiero et al., 
2014, Hao et al., 2012, Parisi et al., 2018). There are many aspects of polarised M1 
and M2 macrophages, which are reflected in multiple functional phenotypes, (i.e. 
parasite infections, allergic reactions, and tumours), and are expressed by the 
macrophages both in vivo and vitro (Parisi et al., 2018, Sica and Mantovani, 2012). 
The plastic nature of macrophages provides the shifts in the polarisation states of 
M1 and M2 during pathological courses (Biswas and Mantovani, 2010, Parisi et al., 
2018).  
Lymphocytes are the main regulator of the function and activity of tumour-
associated macrophages (TAMs); however, the pathways are variable in different 
organs (Sica and Mantovani, 2012). For example, a switch of macrophage function 
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was found to be mediated and influenced by IL-4 of Th2 cells in the skin (Andreu 
et al., 2010, Schioppa et al., 2011), and by antibody-producing B cells in breast 
cancer in humans (DeNardo et al., 2009, Pedroza-Gonzalez et al., 2011). Cancer 
progression can be promoted by B1 cells and macrophage polarisation, and tumour 
promotion can be regulated by fibroblasts (Biswas and Mantovani, 2010). In 
addition, other cell products in tumour tissues can also reshape macrophages in an 
M2-like cancer mode due to extracellular matrix components, IL-10, CSF-1, and 
various chemokines (e.g. CCL2, CCL18, CCL17, and CXCL4) (Sica and 
Mantovani, 2012).  
1.9.3 T lymphocytes  
T cells regulate adaptive immunity and are responsible for cell-mediated immune 
responses. T cells are generated in bone marrow, mature in the thymus and are 
activated in peripheral lymphoid organs (Day and Schultz, 2014, Murphy and 
Weaver, 2017, Tizard, 2013). They can be distinguished from other lymphocytes 
by the T cell receptor (TCR). This specific receptor is a heterodimer and most T 
cells express the α and β chains which recognise the peptide antigen only when it is 
bound in the context with a class I or class II MHC molecule. Further, the TCR 
connects with a complex of membrane proteins known as CD3 that are responsible 
for spreading an intracellular signal to TCR ligation. Moreover, each TCR connects 
with either a CD4 or a CD8 co-receptor, depending on the type of T cell. These two 
molecules bind to MHC (class I for CD8 and class II for CD4), which leads to 
further stabilisation of the interaction between T cells and antigen presenting cells 
(APC) (Ackermann, 2017, Covacu et al., 2016, Day and Schultz, 2014, Miles et al., 
2011, Murphy and Weaver, 2017, Tizard, 2013).  
In addition, α and β chains have three variable sites in the receptors known as 
complementarity determining regions (CDRs). These regions are immunoglobulin 
(Ig) hypervariable domains that determine specific antibody binding (Day and 
Schultz, 2014, Murphy and Weaver, 2017, Polonelli et al., 2008, Tizard, 2013). 
However, other T cells (approx. 5%) express the γδ combination (Tizard, 2013).  
T cell activation is mediated by TCR to produce a T cell that is capable of mediating 
immune protection via activation of naïve T cells. This involves coordinated 
interactions between a number of molecules on the T cell and an APC. An APC 
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(i.e. a macrophage or dendritic cell) detects, engulfs and digests pathogens into 
hundreds or thousands of antigen fragments. These are then transported to their 
surface as antigenic peptides and bound to a MHC class I or class II molecule. This, 
in turn, leads to the activation of naïve T cells and the initiation of their 
differentiation process (Day and Schultz, 2014, Murphy and Weaver, 2017, Tizard, 
2013).  
T cells differentiate into effector and/or memory cells after encountering their 
cognate antigen. The effector cells are further characterised as helper T cells that 
regulate immune responses, cytolytic or cytotoxic T cells that destroy cells 
expressing endogenous antigens, and regulator T cells that control the process 
(Chen and Kolls, 2013, Day and Schultz, 2014, Kara et al., 2014, Mahnke et al., 
2013, Murphy and Weaver, 2017, Tizard, 2013).  
The helper T cells (characterised by the expression of CD4 marker on their surface), 
secrete cytokines in response to antigenic stimulation. The latter stimulate the 
differentiation of T cells into various lineages and phenotypes, as well as other cells, 
including B cells and macrophages (Luckheeram et al., 2012, Pennock et al., 2013). 
There are three major subpopulation of T helper cells (Th1, Th2 and Th17). Th1 
cells are stimulated by IL12 and secret (INF-y) and promote cell-mediated 
response. Th2  (IL4, IL13 and IL10) secrete and promote antibody responses. In 
contrast, Th17 are stimulated by IL6, TGF-β and IL23 to develop and secrete IL17 
and promote neutrophil mediated inflammation (Day and Schultz, 2014, Murphy 
and Weaver, 2017, Tizard, 2013).  
Cytolytic or cytotoxic T cells are characterised by the expression of CD8 marker 
on their surface and kill cells that are infected and/or produce foreign antigens, such 
as viruses and other intracellular microbes (Chen and Kolls, 2013, Murphy and 
Weaver, 2017, Sharma et al., 2013, Zhu et al., 2010).  
The critical immune role of T cells is also in their functional helper role to B cells 
and to antibody responses, feedback to dendritic cells and elaboration of cytokines 
(Luckheeram et al., 2012, Pennock et al., 2013, Murphy and Weaver, 2017). They 
also enhance and maintain responses of CD8+ (cytotoxic) T cells and play a 
cytotoxic and defence role by mediating macrophage activation and inducing 
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associated genes (Flaherty, 2012, Luckheeram et al., 2012, Pennock et al., 2013, 
Murphy and Weaver, 2017).  
Migrating lymphocytes are important regulators for efficient immune responses. T 
cell trafficking is the first and initial response. In this process, naive T cells migrate 
through the specialised endothelium of secondary lymphoid organs and the primed 
T cells exert their function by infiltrating through capillary venules into the tissues 
and to their designated antigenic site (Carman and Martinelli, 2015, Oelkrug and 
Ramage, 2014). In addition, activation and differentiation of T cells into effector or 
memory lymphocytes induces the expression of specific receptors (Zhu et al., 
2010). Such migration processes from peripheral blood into tissue include various 
processes and mechanisms that include: tethering, rolling and adhesion followed by 
diapedesis through the endothelial barrier which lines the inner wall of blood 
vessels (Nourshargh and Alon, 2014, Schnoor et al., 2015, Slaney et al., 2014). 
Chemokines are typically involved in the recruitment of lymphocytes and their 
secretion by the tissue, and they have been proven to recruit certain T cells (Oelkrug 
and Ramage, 2014). The chemokine environment plays a pivotal role in controlling 
lymphocyte trafficking (Stein and Nombela-Arrieta, 2005).  
CCR5 ligands, CCL5 and macrophage inflammatory proteins (MIP-1α) are 
reported to be synthesised by activated dendritic cells and induce CXCR3 
expressions on activated lymphocytes (Oelkrug and Ramage, 2014). CCR5 and 
CXCR3 chemokine receptors may play a pivotal role in the regulation of leukocyte 
migration to inflammatory sites (de Oliveira et al., 2014).  
1.9.4 B lymphocytes  
B cells play a key role in inflammation and are essential in humoral and adaptive 
immunity (Chaplin, 2010, Murphy and Weaver, 2017, Tizard, 2013). They are 
generated and matured in bone marrow and differentiated in the spleen and lymph 
nodes into naïve, follicular, or marginal zone B cells (Murphy and Weaver, 2017, 
Pieper et al., 2013, Tizard, 2013). The marginal zone B cells are partially activated 
along macrophages and dendritic cells, and exposed to antigens present in the 
blood. They provide a rapid humoral response to any challenges (Cerutti et al., 
2013, Zouali and Richard, 2011, Muppidi et al., 2011). Marginal B cells contribute 
early in adaptive responses and, following activation, form short-lived plasma cells 
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that secrete antibodies (Cerutti et al., 2013, Hoffman et al., 2016, Murphy and 
Weaver, 2017, Tizard, 2013, Zouali and Richard, 2011).  
B cells become active when they encounter an antigen (internalise and process), 
and thence present the latter to a perfectly matched T-helper cell, which then assist 
in the activation of  the B cell (Hoffman et al., 2016, Murphy and Weaver, 2017, 
Tizard, 2013). They are activated by many antigens, especially monomeric proteins. 
The process requires both binding of the antigen by the immunoglobulin on the B 
cell surface, the B-cell receptor, and interaction of the B cell with antigen-specific 
helper T cells (Avalos and Ploegh, 2014, Murphy and Weaver, 2017, Tizard, 2013). 
During the differentiation of activated B cells, the antibody isotype can change in 
response to cytokines released by helper T cells, and the antigen-binding properties 
of the antibody can be changed by the somatic hypermutation of V-region genes 
(Schroeder Jr et al., 2013). Somatic hypermutation and selection for high-affinity 
binding occurs in the germinal centres of lymphoid follicles (Martin et al., 2015). 
Helper T cells control these processes by selectively activating cells that have 
retained their specificity for the antigen and by inducing proliferation and 
differentiation into plasma cells and memory B cells. Some non-protein antigens 
stimulate B cells in the absence of recognition by peptide-specific helper T cells 
(Bortnick and Allman, 2013). These thymus-independent antigens induce only 
limited isotype switching and do not induce memory B cells (Hoffman et al., 2016, 
Lange et al., 2012). Nevertheless, responses to such antigens have a major role in 
host defence mechanisms against pathogens with antigens unable to elicit peptide-
specific T-cell responses. Peptide fragments of the antigen, which is internalised 
and displayed by the B cells as peptide-MHC class II complexes, are typically 
recognised by helper T-cells (Murphy and Weaver, 2017, Tizard, 2013). 
Furthermore, B cells are induced and stimulated by the helper T-cells through the 
binding of CD40L on the T cell into CD40 on the B cell, the interaction of some 
TNF-TNF-receptor family ligand pairs, and by cytokines (Hoffman et al., 2016, 
Murphy and Weaver, 2017, Upadhyay et al., 2014). The initial interaction occurs 
in the T cell area of the secondary lymphoid tissue, where both antigen-specific and 
helper T cells and antigen-specific B cells are trapped as a consequence of binding 
antigen; further interactions between T cells and B cells occur after migration into 
the B cell zone or follicle, and the formation of a germinal centre (Murphy and 
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Weaver, 2017, Zhang et al., 2016). Helper T cells induce a phase of vigorous B cell 
proliferation and direct the differentiation of the clonally expanded progeny of the 
naive B cells into either antibody-secreting plasma cells or memory B cells. Helper 
T cells control these processes by selectively activating cells that have retained their 
specificity for the antigen and by inducing proliferation and differentiation into 
plasma cells and memory B cells (Elgueta et al., 2009, Hoffman et al., 2016, 
Murphy and Weaver, 2017).  
1.9.5 Mast cells  
Mast cells are a particular component of the immune system and play a major role 
in inflammatory and immediate allergic reactions, and acquired and innate 
immunity (Beghdadi et al., 2011, Dahlin and Hallgren, 2015, Gri et al., 2012, Metz 
et al., 2007, Tizard, 2013).  
Mast cells are situated in the skin and mucosa under normal circumstances and are 
localised in connective tissue. They develop and differentiate in bone marrow and 
mature upon stem cell factor (SCF) binding to the receptor (c-kit) and various 
interleukins (IL-3, IL4, IL-9, and IL-10). The latter also enhance their 
differentiation and proliferation (Ackermann, 2017, Amin, 2012, da Silva et al., 
2014, Dahlin and Hallgren, 2015, Krystel-Whittemore et al., 2015, Tizard, 2013).  
Mast cells are the only immune cells that express the SCF (c-Kit) receptor, the 
binding of which enhances the release of histamine and tryptase proteins that are 
particularly involved in allergic responses and the promotion of adhesion, 
migration, proliferation, and survival of mast cells (Amin, 2012, Theoharides et al., 
2012, Tizard, 2013).  
During inflammation, mast cells secrete inflammatory mediators (i.e. histamine, 
proteases, chemotactic factors, cytokines and metabolites of arachidonic acid) that 
act on the vasculature, smooth muscle cells, connective tissue, mucous glands and 
various leukocytes (da Silva et al., 2014). Mast cells also play a biovital role in 
controlling and regulating the immune system function and associated mechanisms 
such as inflammation, cell activation, cell migration, cell proliferation, apoptosis, 
and haematopoiesis (Abraham and St John, 2010, Ackermann, 2017, Amin, 2012). 
Mast cells are particularly involved in chronic inflammatory conditions of the skin; 
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their activation and release of effective mediators is linked to various factors 
(Beghdadi et al., 2011, Theoharides et al., 2012). Mast cells can also express cell 
surface ligands and receptors, which can be either proinflammatory or 
immunosuppressive (Galli et al., 2011). They can also recruit other immune cells 
such as T cells, neutrophils and eosinophils to the site of inflammation and stimulate 
the maturation of Langerhans cells and dendritic cells as well as their migration to 
lymph nodes (Gri et al., 2012, Palm et al., 2016). In addition, mast cells can migrate 
to draining lymph nodes and activate immune cells there (Amin, 2012, Harvima 
and Nilsson, 2011). They show remarkable plasticity in expressing different 
cytokines and TNF family ligands in skin inflammatory diseases (Abraham and St 
John, 2010, Galli et al., 2011, Harvima and Nilsson, 2011, Oskeritzian, 2015). 
Furthermore, mast cell–macrophage interactions are involved in tumour biology 
through releasing mediators that affect the production of collagenolytic enzymes by 
metastatic tumour cells, tumour-derived fibroblasts and stromal fibroblasts 
(Dabbous et al., 1995, Trivedi et al., 2013).  
1.10 Cytokines and chemokines in inflammation  
Cytokines play a vital role in regulating immune responses (primarily 
inflammation) in both health and disease (Coondoo, 2011). Cytokines are small 
proteins that act as signalling and regulatory molecules at picomolar or nanomolar 
concentrations to regulate inflammation and biological activities such as growth, 
survival, and cellular differentiation (Duque and Descoteaux, 2014, Coondoo, 
2011). Cytokines are diverse pro- or anti-inflammatory factors that are grouped into 
families based on receptors and structural homology (Coondoo, 2011). Chemokines 
are secreted proteins which are responsible for the induction of cell migration as 
well as being involved in chemoattraction and the trafficking of immune cells 
towards a site of injury and/or throughout the body (Duque and Descoteaux, 2014). 
Chemokines express particular biological activities by maintaining homeostasis and 
the induction of inflammation (Moser and Loetscher, 2001); based on their 
functions, two groups are recognised; homeostatic and inflammatory chemokines. 
Homeostatic chemokines are involved in immune cell migration through 
haematopoiesis and are constitutively expressed, whereas inflammatory 
chemokines are released in infections and/or as inflammatory stimulus and 
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contribute to the immune response process by targeting cells of the innate and 
adaptive immune system (Duque and Descoteaux, 2014, Chen et al., 2018, Ferretti 
et al., 2014, Sokol and Luster, 2015).  
The binding of a cytokine or chemokine to its cognate receptor results in the 
activation and initiation of signalling events which regulate numerous cellular 
activities such as cell adhesion, phagocytosis, cytokine secretion, cell activation and 
proliferation, cell survival and cell death, apoptosis and angiogenesis (Coondoo, 
2011, Geeta et al., 2013). Cytokines have functional redundancy where different 
cytokines share similar functions (Duque and Descoteaux, 2014). They are also 
pleiotropic as they can act on many different cells, and such cells may express more 
than one receptor for each cytokine (Dinarello, 2007, Khan, 2008). Cytokines are 
generally short-lived and act locally in an autocrine and paracrine fashion. Few 
cytokines are present in the blood that contributes to a systemic response – 
examples include erythropoietin (EPO), TGF-β, and monocyte colony stimulating 
factor (M-CSF) (Dinarello, 2007, Tizard, 2013). Cytokines are mainly produced by 
macrophages and lymphocytes as well as polymorph nuclear leukocytes (PMN), 
endothelial and epithelial cells, adipocytes, platelets, and vascular smooth muscle 
cells (VSMCs) (Duque and Descoteaux, 2014, Sprague and Khalil, 2009).  
Chemokines induce the migration of cells, such as lymphocytes, dendritic cells and 
macrophages (Ferretti et al., 2014, Sokol and Luster, 2015). Chemokines can also 
be involved in both immune and physiological trafficking of leukocytes (Ferretti et 
al., 2014, Stein and Nombela-Arrieta, 2005). However, certain chemokines are 
crucial inflammatory components of the microenvironment of tumours and play a 
pivotal role in their progression by enhancing the migration of tumour cells to 
distant organs (Raman et al., 2007, Song et al., 2017). Chemokines may also play 
a role during development by promoting angiogenesis, or by guiding cells to tissues 
that provide critical signals for a given cell’s differentiation (Coondoo, 2011). In 
inflammation and inflammatory responses chemokines are released by a variety of 
cells involved in both innate and adaptive immunity together with the typical 
release of chemokines induced by proinflammatory cytokines such as TNF, IL-6, 
and IL-1β (Arango Duque and Descoteaux, 2014, Comerford and McColl, 2011).  
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1.11 Mediators associated with inflammation and inflammatory responses, 
with a focus on the interaction between mast cells, eosinophils and 
macrophages  
During inflammation the immune cells secret inflammatory mediators (cytokines 
and chemokines), which play the most important role in controlling immune system 
functions (Ackermann, 2017, Day and Schultz, 2014, Murphy and Weaver, 2017, 
Tizard, 2013).  
Different inflammatory and regulatory molecules mediate inflammation and guide 
inflammatory responses. Of these, CCL5 also known as RANTES (Regulated upon 
Activation, Normal T cell Expressed, and Secreted) is a chemokine regulatory 
activator expressed normally by T cells as well as macrophages, eosinophils and 
mast cells (Aldinucci and Colombatti, 2014, Lacy, 2017). CCL5 plays a key role in 
recruiting many leukocytes into inflammatory sites. It is also chemotactic for T 
cells, macrophages, eosinophils and basophils (Bishara, 2012, Lv et al., 2013). It 
also has an effect in cancer cell proliferation, metastasis, and the formation of 
immunosuppressive microenvironments (Aldinucci and Colombatti, 2014).  
Macrophage inflammatory protein MIPα (CCL3) is another chemokine that can be 
secreted by mast cells, macrophages and eosinophils and attracts eosinophils, 
macrophages and some lymphocyte subpopulations to sites of inflammation (Baba 
and Mukaida, 2014, Murphy and Weaver, 2017). CCL3 is produced by mast cells, 
and can attract monocytes, macrophages, and neutrophils (Murphy et al., 2012). 
Together with other chemokines (CCL7, CCL13, CCL3, Rantes and eotaxin) it is 
responsible for the migration of eosinophils (Shakoory et al., 2004). Many T cell 
chemoattractants are produced by mast cells including CCL3, CCL4 and CCL5, 
which can activate the endothelium appropriately for recruiting T cells (Marshall, 
2004). Recruitment of eosinophils from the blood stream during inflammation and 
allergic processes was thought to be regulated by eotaxin and other chemokines 
including; CCL13, Rantes, eotaxin2, CCL3, and CCL7 (Schröder and Mochizuki, 
1999, Ying et al., 1999).  
In addition, eotaxin is synthesised by different cells (e.g. epithelial cells, 
macrophages, T cells, eosinophils and mast cells) and is the most potent 
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chemoattractant for eosinophils (Conroy and Williams, 2001, Jia et al., 1999).  It 
also attracts other cells such as mast cells and some T cell subsets (Uguccioni et al., 
1997). In addition, IL-4, IL-13 and the proinflammatory cytokine tumour necrosis 
factor (TNF)-α stimulate the generation of eotaxin (Atasoy et al., 2003, Conroy and 
Williams, 2001, Sato et al., 2004), whereas IFN-γ inhibits the production of eotaxin 
(Sato et al., 2004).  
IL-4 is mainly secreted by some T cells, mast cells and eosinophils and plays a 
pivotal role in the transmobility of eosinophils across the endothelium through the 
activation of adhesion pathways. IL-4 can also promote the production of other 
cytokines such as IL-5 and eotaxin (Sato et al., 2004) as well as inducing eosinophil 
chemotaxis and increasing the capacity of eosinophils to produce granule proteins 
(Atasoy et al., 2003). IL-4 and similarly IL-3 are synthesised by mast cells and can 
stimulate and amplify Th2 responses (Metcalfe, 2008, Wynn, 2003).  
IL-5 is mainly produced by T cells and mast cells (Murphy et al., 2012) and is 
necessary for the growth and selective differentiation of eosinophils (Ghosh et al., 
2013, Murphy et al., 2012). IL-5 enhances the growth and differentiation of 
activated B cells, however, its overexpression increases the quantity of eosinophils 
and elevates antibody levels (Takatsu and Nakajima, 2008, Takatsu, 2011). IL-5 
also induces eosinophil differentiation in bone marrow as well as enhancing the 
stimulation of eosinophil precursors to produce granule proteins (Rosenberg et al., 
2012). It is also responsible for the mobilisation and release of differentiated 
eosinophils from bone marrow into the bloodstream and, through so doing, 
increases the number of circulating eosinophils as well as their responsiveness to 
chemoattractants and activators.Whilst also inhibiying the apoptosis of eosinophils, 
thereby increasinging their survival in tissues for weeks (Rankin et al., 2000, 
Rosenberg et al., 2012, Shen and Malter, 2015).  
IL-5 is also important for the activation of eosinophils and may play a role in tissue 
infiltration by eosinophils; it shows functional synergy with eotaxin (Rosenberg et 
al., 2012, Shakoory et al., 2004). Mast cells are a good source of IL-5 and 
eosinophil-attracting chemokines (e.g. CCL5 (Rantes) and CCL11 (eotaxin) 
(Marshall, 2004). Mast cells also drive the survival of eosinophils through the 
release of GM-CSF and IL-5 (Brown et al., 2008).  
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A few cytokines (IL3, IL5 and GM-CSF) are important for signalling molecules 
produced by T cells (Asquith et al., 2008, Guthridge et al., 1998). Of these, IL-5 is 
most specifically responsible for the selective differentiation of eosinophils 
(Rothenberg and Hogan, 2006, Shen and Malter, 2015, Wen and Rothenberg, 
2016).  
T cells also secrete IL-13, which is considered functionally redundant with IL-4. 
However, some studies have demonstrated that IL-13 possesses several unique 
effector functions that distinguish it from IL-4 (Wynn, 2003). These functions 
include a variety of biological activities, such as tissue eosinophilia and 
mastocytosis and the prolongation of eosinophil survival through inducing 
autocrine production of IL-3, IL-5, and GM-CSF (SchmidGrendelmeier et al., 
2002, Shakoory et al., 2004, Wynn, 2003). Eosinophils notably expresses 
functional IL-13 in eosinophilic inflammatory diseases. IL-13 upregulates the 
vascular cell adhesion molecule (VCAM) on endothelial cells and stimulates 
epithelial cells to produce eotaxin (Rankin et al., 2000, Stone et al., 2010). Notably, 
allergic inflammation is driven by Th2 cells (Galli et al., 2008). Th2 cells produce 
IL-4, IL-5 and IL-13 (Vijayanand et al., 2012, Zhu, 2015).  
The dominant cytokines produced by leukocytes differ; basophils express abundant 
IL-4 and IL-13 but little IL-5, whereas mast cells produce IL-5 and IL-13 and less 
IL-4 (Stone et al., 2010). Furthermore, it has been proposed that the effect of IL-13 
might be chemokinedependent and a potent inducer of eosinophil-active 
chemokines, including eotaxin and Rantes (Pope et al., 2001). However, IL-13 also 
directly stimulates eosinophil activation, chemoattraction, and their survival in vitro 
(Park and Bochner, 2010, Schmid-Grendelmeier et al., 2002).  
Stem cell factor (SCF)/c-kit ligand is a critical growth factor and chemoattractant 
for mast cells which also regulates their activation, degranulation, survival and 
chemotaxis (da Silva et al., 2014). Fibroblasts as well as keratinocytes and 
endothelial cells secrete SCF (Welker et al., 1999), but other cells such as 
eosinophils and mast cells may also serve as a source of SCF (da Silva et al., 2006).  
T cells and macrophages are the main cells which produce TGF-β (Link and Xiao, 
1998), but other cells including mast cells and eosinophils also do so (Rich et al., 
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2012). TGF-β antagonises the effect of IL-5 on eosinophils (Luttmann et al., 1998, 
Xie Q, 2011). It also plays an important role in the deposition of extracellular matrix 
proteins during chronic inflammation and fibrosis, and modulates wound healing 
as well as tissue remodelling (Wynn, 2008).  
IFN-γ is the main cytokine of T cells and, among other functions, it is responsible 
for macrophage activation (Desport, 2010, Schoenborn and Wilson, 2007). It also 
inhibits eotaxin (Miyamasu et al., 1999, Sato et al., 2004).  
1.12 Overview of advanced diagnostic techniques applied in human and 
veterinary medicine  
Alternative advanced and diagnostic molecular tools provide excellent means to 
visualise transcript cellular molecules such as those produced by gene expression 
(Kukurba and Montgomery, 2015). Nowadays, a number of molecular tools are 
used for diagnostic assays and research purposes as they provide better quantitative 
results, and improved visualisation of more than a target in a single tissue and allow 
the demonstration of biomarkers (Cassidy and Jones, 2014). Immuno-
histochemistry (IHC) and in situ hybridisation (ISH) techniques are vital diagnostic 
tools to visualise disease-causing pathogens and to characterise the associated 
morphological changes that occur within the tissues (Maes et al., 2014).  
IHC is a vital diagnostic and research tool used to recognise specific proteins of 
pathogens in situ and detect, localise and quantify other antigens in fixed tissues 
with preserved morphology (Carvajal-Hausdorf et al., 2015, de Matos et al., 2010, 
McRae et al., 2009, Stack et al., 2014). ISH, on the other hand, is a molecular 
analysis method that allows in situ detection of nucleic acids in tissue sections, 
applicable to identify DNA, mRNA and microRNAs in cells (Jensen, 2014, Maes 
et al., 2014, Wang et al., 2012). Like PCR, ISH is used to identify and recognise a 
specific complementary sequence of nucleic acids of pathogens and markers within 
tissues (Jensen, 2014).  
Concurrently, advanced RNA-ISH approaches have been developed which use 
hybridisation with a signal amplification system to increase the sensitivity of the 
technique (Maes et al., 2014, Resende et al., 2017, Wang et al., 2012). This 
technique targets sets of up to 20 oligonucleotide pairs and aims to detect individual 
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mRNA molecules with single cell resolution and ultimately enables their 
visualisation through chromogenic and fluorescent applications. This method 
allows for considerable amplification of the signal and provides high sensitivity 
while reducing the non-specific binding of the preamplifier DNA; thereby reducing 
nonspecific background staining (Wang et al., 2012). This RNA-ISH technique has 
been applied successfully to diagnosis and research in human and animal medicine; 
especiallywith regard to the diagnosis of infectious diseases (Chang et al., 2015, 
Gaynor et al., 2016, Joshi et al., 2016, Luff et al., 2016, Palinski et al., 2016, Palmer 
et al., 2015).  
1.13 Aims and objectives  
Eosinophilic granuloma (EG) is a chronic inflammatory skin reaction in horses that 
is characterised by intensive infiltrates of eosinophils, macrophages as well as 
lymphocytes and plasma cells. In contrast, cutaneous mast cell tumours (MCT) are 
neoplastic processes that arise from neoplastic mast cells and their progenitors. In 
contrast to EG, MCT are rare in horses. Both conditions show overlapping 
histological features in horses. This can lead to misdiagnosis and confusion.  
The aim of this thesis is to thoroughly assess the histopathological features of EG 
and MCT in the skin so as to distinguish between the two lesions and enable the 
defining and description of morphological criteria for MCT and EG. A further aim 
is to investigate the interaction between inflammatory cells (eosinophils, 
macrophages, mast cells and lymphocytes) in equine EG and MCT. This may lead 
to a furtherance of existing understanding of the pathogenic mechanisms of the two 
lesions and the possible interactions that exist between them. In this study, a total 
of 191 lesions comprising equine eosinophilic granulomas and mast cell tumours 
were investigated. Histological, histochemical, immunohistochemical and 
molecular (RNA-ISH) investigations were undertaken.    
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CHAPTER 2: MATERIALS AND METHODS  
2. Materials and methods  
2.1. Source and origin of case material  
A total of 191 archived, formalin-fixed, paraffin embedded (FFPE) samples of 
MCT (n=62) and EG (n=129) from a total of 153 horses were re-examined for this 
project. Samples were taken from cases admitted and/or referred to the University 
of Liverpool Philip Leverhulme Equine Hospital and referral equine local 
veterinary practices between 2005 and 2015. Lesions were originally diagnosed as 
MCT or EG by the veterinary pathologists involved in the Veterinary Laboratory 
Services, Institute of Veterinary Science, University of Liverpool (VLS), based on 
their histological features.  
 2.2 Collection of clinical data  
Signalment and clinical information of the affected horses were collected from 
archived data from the VLS database as follows: age (years), breed, sex, neutering 
status, size of lesion (major axis; cm), single or multiple lesion, primary or recurrent 
lesion, and initial diagnosis (MCT or EG).  
 2.3 Histological examination  
2.3.1 Re-examination of archived diagnostic cases  
All cases were histologically re-assessed, using haematoxylin-eosin (HE) and 
toluidine blue stained archived sections, based on typical morphological and 
histological criteria (see 2.4). When the old slides exhibited insufficient staining 
quality (fading due to age and so on) and for more detailed examinations, new 
sections were prepared from the paraffin blocks and stained with HE (see 2.3.3).  
2.3.2 Preparation of tissue sections  
From all cases, consecutive sections (4 µm thickness) were prepared from paraffin 
blocks using a Leica RM2125 RTS microtome and mounted on microscopic slides. 
After drying at 37ºC for 30 minutes (for the full Histology Standard Operating 
Procedure, see Appendix I), sections were stained with HE and toluidine blue (TB) 
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(section 2.5.1.) Further sections were subjected to special stains, and for 
immunohistochemical staining (IHC) and mRNA-in situ hybridisation (mRNA-
ISH). For IHC, sections were mounted on poly Lysine treated slides (Solmedia, 
Shrewsbury, UK) and for RNA-ISH staining, they were mounted on SuperFrost® 
Plus slides (Thermo Scientific, Braunschweig, Germany).  
2.3.3 Haematoxylin-eosin staining  
The HE stain was performed by the Histology Laboratory, VLS, as a routine stain 
and according to its world-wide use in histopathological examinations (Fischer et 
al., 2008, Cardiff et al., 2014). The HE stain highlights cells’ nuclear structures in 
blue and the cytoplasm as well as many extra-cellular components in various shades 
of bright pink. The structures do not have to be acidic or basic to be called 
basophilic and eosinophilic; this terminology is based on the affinity of the 
structures and material to the dyes (Suvarna et al., 2012). Briefly, consecutive 
paraffin sections (4 µm thickness) were deparaffinised in xylene twice for 5 minutes 
each and rehydrated in descending grades of alcohol (100%, 96%, 85%, and 70%) 
to distilled water. Sections were then incubated in Mayer’s Haematoxylin (see 
Appendix 1) for 5 minutes, blued in running tap water for 6 minutes, and stained in 
eosin for 2 minutes. This was followed by quick dehydration through 96% alcohol 
for 3 times for 1 minute each (dip sections up and down to remove excess eosin) 
and 3 changes of 100% alcohol. After clearing in xylene, (2 changes, 3 minutes 
each), cover slips were mounted on the slides with DPX mounting medium (Thermo 
Scientific, LAMB/DPX).  
2.4 Categorisation and grouping criteria  
All cases (HE-stained sections) were histologically examined independently by the 
candidate (AM) and one supervisor (LR) who were both blinded to the initial 
histopathological diagnosis. The histological features were initially assessed in 
accordance with previously published work that describes equine EG and MCT 
(Goldschmidt and Hendrick, 2002, Maxie, 2007, Scott and Miller, 2011b, Scott and 
Miller, 2011c, Zachary and McGavin, 2012).  
Upon re-evaluation of the lesions, a diagnosis of EG was made based on the 
following criteria: nodular to diffuse focal infiltrates of eosinophils in association 
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with foci of collagen degeneration (flame figures) which were occasionally 
mineralised and surrounded by a granulomatous inflammation that sometimes 
formed a palisading granuloma with a centre composed of eosinophilic material 
(interpreted as degenerated eosinophils). This was variably associated with 
lymphoid nodules, with or without small aggregates of or individual mast cells.  
Lesions were classified as MCT according to the following criteria: Presence of 
large monomorphic aggregates of well-differentiated or poorly differentiated 
neoplastic mast cells, referred to as “mast cell aggregates” (MCA), often involving 
the dermis and subcutis and variably associated with variable numbers of mature 
eosinophils, and with focal to multifocal areas of EG.  
When lesions did not fulfil the above criteria and differed substantially from a 
diagnosis of EG or MCT, the cases were classified as new morphological entities. 
These were excluded from further analysis and described separately (see Appendix 
II-section B) as 4 cases with histiocytic morphological.  
Based on the histological findings, the cases were classified and grouped into five 
categories (Figure 1). A subpopulation of cases (n=95) was then selected (see 3.4) 
and subjected to further IHC examinations (see 3.5). Based on the staining quality 
and results of the latter, a total of 10 cases were then selected for the RNA-ISH 
study (see 3.6).  
 
 





2.5 Special stains  
A set of histochemical stains was used to highlight different features within the 
lesions.  
These included Toluidine blue stain, Lendrum’s stain (Carbol Chromotrope), Von 
Kossa stain, Masson Trichrome, and Perl’s Prussian blue stain (PERLS). The stains 
were prepared by the technical staff of the VLS Histology Laboratory.  
2.5.1 Toluidine blue (TB) stain for the demonstration of mast cell granules  
As a common and widely used histochemical stain, Toluidine blue (TB) stain was 
used to identify mast cells through demonstration of their metachromatic granules, 
(Bancroft and Gamble, 2008). Briefly, sections (4 µm) were deparaffinised and 
hydrated in distilled water. Slides were placed in TB working solution for 2-3 
minutes and washed three times in distilled water. This was followed by quick 
dehydration through 95% and twice 100% alcohol (10 dips each, since stain fades 
quickly in alcohol), and clearing in xylene, (2 changes, 3 minutes each). Cover slips 
Figure 1: Overview of the different categories, groups and diagnoses (classification), based on 
the presence and relative abundance of EGC and MCA 
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were mounted on slides with DPX. Upon bright field light observation, 
metachromatic stain (purple) was considered indicative of mast cell granules.  
2.5.2 Lendrum’s stain (Carbol Chromotrope) for demonstration of eosinophil 
granules  
Lendrum’s stain was applied, as it selectively and vividly stains the granules of 
eosinophils thereby confirming the presence of eosinophils (Lendrum, 1944). 
Briefly, sections were initially deparaffinised in xylene for 5 minutes and 
rehydrated through graded alcohol, then incubated in Mayer’s Haematoxylin (see 
Appendix 1) for 1 minute and blued in running tap water for 5 minutes. Sections 
were then stained in carbol chromotrope (Clin-Tech Ltd, 641550; Guildford, UK) 
for 1 h (see Appendix I for Solutions) followed by rinsing in distilled water. This 
was followed by dehydration with ethanol and clearing with xylene.  
Cover slips were mounted on slides with DPX. An intense red granular stain 
highlighted the granules of eosinophils, and a blue stain was indicative of nuclei.  
2.5.3 Von Kossa stain for confirmation of mineralisation  
The Von Kossa (calcium) stain was performed to confirm the presence of 
mineralisation, as it is used for the histological visualisation of calcium deposits in 
FFPE or frozen sections (Bancroft and Gamble, 2008). It also helps to accurately 
characterise the morphological features of localised mineral deposition in 
inflammatory foci (granulomas), degenerative tissue, and necrosis (Mauldin and 
Peters-Kennedy, 2016). Briefly, sections were deparaffinised in xylene for 5 
minutes and rehydrated through graded alcohol and distilled water. They were then 
incubated in 5% sliver nitrate and exposed to strong light (500-watt floodlight 
attached to a retort stand about 0.5 m above the sections) for 15 minutes, followed 
by washing in distilled water (3 changes) and counterstaining in 1% neutral red (see 
Appendix 1for solutions) for 1 minute. This was followed by washing in distilled 
water and blotting with fibre free paper and quick dehydration with ethanol and 
clearing with xylene. Cover slips were mounted on the slides with DPX. A dark 
black stain confirmed calcium salt deposition (mineralisation).  
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2.5.4 Masson trichrome stain to demonstrate collagen fibres  
The Masson trichrome stain was applied to demonstrate collagen fibres in EG areas, 
as a common and widely used histochemical stain to visualise collagen fibres FFPE 
tissues (Bancroft and Gamble, 2008). Briefly, sections were deparaffinised in 
xylene for 5 minutes and rehydrated through each graded alcohol with distilled 
water, then subjected to Celestine blue stain for 5 minutes. This was followed by 
rinsing with tap water and staining with Mayer’s Haematoxylin (see Appendix 1) 
for 5 minutes and blueing in tap water for 6 minutes. Sections were then subjected 
to cytoplasmic stain (see Appendix 1) for 7 minutes, rinsed with water and 
differentiated in 1% phosphomolybdic acid solution for 5 minutes and again rinsed 
with water. This was followed by counterstaining in 2% light green solution (see 
Appendix I) for 5 minutes, and differentiation in 1% acetic acid solution for 3-5 
minutes to remove excess green, and blotting with fibre-free blotting paper. 
Sections were then dehydrated rapidly in absolute alcohol, cleared, and cover slips 
were mounted with DPX. Collagen fibres were stained dark green, nuclei black, 
and the background appeared red.  
2.5.5 Perls’ Prussian blue stain for the demonstration of hemosiderin  
The Perls’ Prussian blue was performed to detect iron within macrophages 
(siderophages). Hemosiderin, is found in macrophages and degraded haemoglobin 
(Bancroft and Gamble, 2008). Briefly, after deparaffinisation in xylene for 5 
minutes and rehydration through graded alcohol and distilled water, sections were 
placed in plastic slide holders and flooded with a mixture of Ferro cyanide and 
hydrochloric acid (see Appendix I) for 30 minutes, followed by rinsing in running 
tap water for 5 minutes. Sections were counterstained with filtered neutral red stain 
for 1 minute (see Appendix I) and rinsed with distilled water. They were then 
dehydrated rapidly in absolute alcohol, cleared, and cover slips were mounted with 
DPX. Haemosiderin appeared as deep blue colour and identified macrophages with 
iron (hemosiderin), i.e. siderophages, within the lesions.  
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2.6 Morphological parameters  
 EG and MCT lesions were evaluated to assess a set of morphological criteria. For 
this purpose, a specific nomenclature was defined to characterise different areas in 
the sections:  
• “Lesion”: the area occupied by the pathological entity regardless of its 
classification  
• “EG”: a lesion diagnosed as eosinophilic granuloma  
• “MCT”: a lesion that is in its entirety diagnosed as mast cell tumour  
• “MCA”: aggregates of ≥5 mast cells forming clusters. These are present in 
both EG and MCT.  
• “EGC”: an eosinophilic granuloma component, composed of a core of 
eosinophils, degranulated and degenerated with and /or without collagen.  
  
Furthermore, after initial screening, a range of morphological features was 
observed. Subsequently, all lesions were evaluated systematically for their 
presence, extent, and distribution. These were as follows:  
• EGC and MCA within EG and MCT  
• Mitotic index (MI)  
• Density of viable eosinophils in mast cells aggregates (MCA)  
• Lymphocyte aggregates (presence and number of lymphocyte aggregates 
(nodules) within lesions)  
• Location of the lesion  
• Ulceration  
• Association of EGC with hair follicles  
• Mineralisation  
• Presence of collagen fibres within areas of EGC  
• Presence of individual mast cells (not forming aggregates)  
2.6.1 EGC and MCA within EG and MCT  
Briefly, the areas occupied by EG and MCA were measured in all lesions. First a 
low magnification digital scan (Slides 2 PC Express scanner; ION, Cumberland, 
USA) was acquired using an imaging software program (Media2 Arcsoft, Freemont 
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USA), then a low magnification digital picture was taken (captured) from all HE-
stained sections.  
Secondly, the low magnification digital picture (which was captured earlier) was 
further analysed by using an image analysis software program (Image 
JI.48V/JAVAL.6.0-20 (64bit) to obtain the area for each lesion; the size of the entire 
occupied area was measured as well as the area occupied by MCA and /or EGC.  
For cases with more than one section from the lesion, the most representative 
section was chosen. In lesions with more than one area of EGC and/or MCA, the 
sum of all areas was taken for each type of change. The same picture was labelled 
using Microsoft PowerPoint. A representative picture of the assessment is presented 




Figure 2: Representative of a scanned picture of equine eosinophilic granuloma lesion 
stained by HE stain 
This shows the labelled area (using Microsoft PowerPoint, as captured by the Ion.com 
software program) to be measured by software (Image JI.48V/JAVAL.6.020 (64-bit). 
Arabic numbers denote areas matched by colour and numbered for the purpose of 
analysis. 
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2.6.2 Mitotic index (MI)  
In MCA, the mitotic index (MI) was assessed in HE-stained sections, using a light 
microscope (Leica DM500; Leica Microsystems (Schweiz) AG, Heerbrugg, 
Switzerland). Thereafter by counting the number of mast cells exhibiting mitotic 
figures in 10 high power fields (HPF, x 400).  
2.6.3 Proportion of viable eosinophils in mast cells aggregates (MCA)  
The proportion of viable eosinophils within MCA was assessed in HE-stained 
sections by using the light microscope with high magnification (x 400), using a 
semi-quantitative scoring system ranging from 0-100% of the area occupied by the 
cells. This was done as a percentage (%) of the area occupied by viable eosinophils 
in 10 HPFs, and was thus not likely to have been affected by the “total number” of 
eosinophils. In lesions with more than one area, the sum of the scores was taken, 
then the average was calculated.  
2.6.4 Lymphocyte aggregates  
All lesions were assessed in HE-stained sections for the presence of lymphocyte 
aggregates, using the light microscope at x 200 magnification, and by counting the 
total number of lymphocyte aggregates for each lesion.  
2.6.5 Location of the lesion  
The location of the lesion within the dermis and subcutis was assessed in HE- 
stained sections, using a light microscope at x 200 magnification. A “scoring 
system” ranging from 1 to 4 according to the depth of lesion was applied.  
• Superficial dermis: the area of the dermis extending from the dermo-
epidermal junction to the level of the sebaceous glands [score 1];  
• Mid dermis: the area stretching from the sebaceous glands to the base of the 
hair bulb [score 2];  
• Deep dermis: the area below the hair follicle structures down to the subcutis 
[score 3];  
• Subcutis: the adipose tissue below the dermis [score 4].  
When the lesion stretched over more than one area, scores for each area were given, 
and the average was used to express a “depth score”.  
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2.6.6 Ulceration  
Lesions were assessed in HE-stained sections for the presence of ulceration with 
the light microscope on HE slides. For scoring purposes, 0 indicated an absence of 
ulceration and 1 indicated its presence.  
2.6.7 Association of EGC with hair follicles  
Lesions were examined in HE-stained sections for the presence of EGC in spatial 
association with hair follicles (i.e. EGC found in anatomical contact with any part 
of a hair follicle). For scoring purpose, 0 indicated an absence of EGC with hair 
follicles and 1 indicated its presence.  
2.6.8 Mineralisation  
Lesions were examined for the presence of focal mineralisation. This was initially 
evaluated in HE-stained slides, where it appeared as areas of granular basophilic 
amorphous material. This was later confirmed with the Von Kossa-stained sections. 
For scoring purposes, 0 indicated the absence of mineralisation and 1 indicated its 
presence.  
2.6.9 Presence of collagen fibres within areas of EGC  
Lesions were examined for the presence of collagen fibres within areas of EGC 
(represented by eosinophilic areas with cellular debris and bright fibrillar material 
(Scott and Miller, 2011b). Later this finding was further investigated with Masson’s 
Trichrome stain: collagen fibres were considered to be present when fibrillar bright 
green material was observed within the core of EGC, using a high magnification (x 
400). For scoring purposes, 0 indicated the absence, and 1 the presence, of collagen 
fibres within areas of EGC.  
2.6.10 Presence of individual mast cells  
The presence of individual mast cells independent of MCA was assessed in TB-
stained sections, using a light microscope at high magnification (x 400). For scoring 
purposes, 0 indicated the absence, and 1 the presence, of individual mast cells in 
EG (equine eosinophilic granuloma) lesions only.  
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2.6.11 Evaluation of different colours after Lendrum’s stain in the core of EG  
In Lendrum’s-stained sections, the granules of viable eosinophils were found to be 
bright red, as expected. However, different colours (purple to bright red areas of 
EGC together with pale red and colourless areas) representing degranulated or non-
viable eosinophils were observed in EGC areas.  
To assess the colour for each lesion the procedures were as follows: the areas 
occupied by EGC were measured in all lesions, first by using a low magnification 
digital scan (Slides 2 PC Express scanner; ION, Cumberland, USA) acquired with 
the Ion software program (Media2 Arcsoft, Freemont USA), then a low 
magnification digital picture was taken (captured) from all Lendrum’s-stained 
sections.  
Secondly, the low magnification digital picture (which was captured earlier) was 
further analysed using an image analysis software program (Image 
JI.48V/JAVAL.6.0-20 (64bit) to obtain the area for each single EGC within the 
lesion.  
Thirdly, the colour was assessed for each single EGC (which was measured earlier) 
based on the colour intensity (namely; purple, intense red, pale red and colourless) 
using a light microscope at x 200 magnification. Asemi-quantitative scoring system 
was adopted ranging from 0-100%. (i.e. for each single area of EGC represented as 
100% in total, the different colours were assessed semi-quantitatively. Area 
representative for each colour was estimated as a fraction of the total EGC area and 
expressed as percentage. This is further explained at 3.4.12.  
2.7 Immunohistochemistry (IHC)  
Immunohistochemistry (IHC) is a methodology widely used in diagnostics and 
research into veterinary pathology (Ramos-Vara, 2005). To investigate the different 
inflammatory cell populations involved in EG and MCT a set of immune-
histochemical stains was applied to identify relevant immune cells. These included: 
T cells (CD3-positive/CD79a1negative/Iba-1-negative), B cells (CD79a1-positive/ 
CD3 negative/Iba1-negative), and macrophages (Iba1-positive/CD3-negative/ 
CD79a1-negative). Other markers included proliferating cell nuclear antigen 
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(PCNA) to investigate cell proliferation, CD117 (c-Kit) for mast cells, mast cell 
tryptase for mast cell degranulation, lysozyme for tissue macrophages, and 
RANTES (CCL5) for T cells and macrophages. All stains were performed by the 
technical staff of the VLS Histology Laboratories apart from the staining for 
RANTES (CCL5) which was performed at the Histology Laboratory, Institute of 
Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, 
Switzerland. Details of the antibodies used and the cell population to which they 
are directed are shown in Table 2.  
Table 2: Antibodies used for immunohistological staining 
Ligand  
Antibody (incl. clone) and 
sources  
Specificity and references 
(horse)  
CD3  
Rabbit anti human CD3,  
DAKO A0452,  
Glosturp, Denmark (NI589)  
Pan-T cell marker (Collins Kelley 
et al., 1997, Delcambre et al., 
2016, Kappe et al., 2009)  
CD79a  
Mouse anti-human CD79 (AbD 
serotec, MCA2538H)  
Pan-B cell marker (Hinden et al., 
2012, Jones et al., 1993, Lee et al., 
2013)  
Iba-1  
Primary antibody Iba1 goat  
Anti-AIF1 (LifeSpan BioSciences 
Inc, LS-B2402)  
Pan-macrophage marker 





Mouse anti-PCNA, clone PC10, 
(DAKO, M0879)  
Proliferating cells in S phase, late 
G1 and early G2 phase (Kubben 
et al., 1994, Ressel et al., 2015)  
CD117 (c-
Kit)* 
Rabbit anti-human CD117, ckit 
(DAKO, A4502)  
Neoplastic mast cells (Ressel et 
al., 2015)  
Mast cell 
tryptase*  
Mouse anti-human mast cell 
tryptase, clone AA1, (Dako, 
M7052)  
Mast cells (Clements et al., 2012, 
Hinden et al., 2012, Pickles et al., 
2010)  
Lysozyme*  
Rabbit anti-human lysozyme 
(Dako, A0099)  
Tissue histiocytes (macrophages) 
(Kappe et al., 2009)  
RANTES 
(CCL5)  
Polyclonal rabbit antihuman 
RANTES (Abcam, ab83324): 
Cross-reacts with horse (90% 
homology with the equivalent 
horse peptide).  
T cells and macrophages 
(secreted).  
 *These antibodies were only used for the characterisation of the four tumours with unique 
features described in the manuscript in Appendix II, section B but excluded from the main 
study. 
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2.7.1 IHC staining protocols  
For all IHC staining, paraffin sections (4 µm) were prepared and mounted on Poly 
Lysine Coated Adhesive White Frosted Clipped Microslides (Solmedia, 
MSS61012S), except for RANTES which was mounted on SuperFrost® Plus slides 
(Thermo Scientific). The autostainer protocol (Agilent Technologies Ltd, 
Stockport, UK),was used for CD3, CD79a, Iba1, CD117(c-Kit), Mast cell tryptase 
and Lysozyme. The manual protocol was used for PCNA and RANTES.  
2.7.1.1 Deparaffinisation  
Sections were dewaxed in xylene (2 x 5 minutes), and rehydrated through graded 
alcohol: 100% ethanol (2 x 5 minutes), 96% ethanol (1 minute), 80% ethanol (1 
minute), 70% ethanol (1 minute), and distilled water (1 minute).  
2.7.1.2 Antigen retrieval  
When the autostainer was used, antigen retrieval was undertaken in Dako PT buffer 
high pH or low pH (Agilent Technologies Ltd, Stockport, UK), using a computer-
controlled antigen retrieval workstation (PT Link; Agilent Technologies Ltd) and a 
20 minutes incubation at 98°C. For the manual protocols, antigen retrieval was 
undertaken with citrate buffer pH 4 at 96ºC for 30 minutes; for RANTES (CCL5) 
sections were incubated in EDTA solution in a Pascal pressure cooker (Dako, 
Glostrup, Denmark) at 97ºC for 20 minutes.  
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Table 3: Antigen retrieval methods 
Ligands  Target retrieval solution  
CD3  
High pH  
citrate buffer, pH 9.0 (Dako, K8004)  
CD79a  
Low pH  
citrate buffer, pH 6.1(Dako, K8005)  
Iba1  
High pH  
citrate buffer, pH 9.0 (Dako, K8004)  
Proliferating cell nuclear antigen 
(PCNA)*  
Citrate buffer, pH 4.0 (Dako, PC10) 
CD117 (c-Kit)*  
High pH  
citrate buffer, pH 9.0 (Dako, K8004)  
Mast cell tryptase*  
Low pH  
citrate buffer, pH 6.1(Dako, K8005)  
Lysozyme *  
High pH  
citrate buffer, pH 9.0(Dako, K8004)  
RANTES (CCL5)  
High pH  
(EDTA buffer, pH 9.0; see Appendix I)  
 *These antibodies were only used for the characterisation of the four tumours with unique 
features described in the manuscript in Appendix II, section B but excluded from the main 
study. 
2.7.1.3 Blocking of endogenous enzymes 
 When the autostainer was used, blocking of endogenous enzymes was undertaken 
in Dako (Agilent Technologies Ltd, Stockport, UK), by using EnVisionTM FLEX 
Peroxidase-Blocking Reagent (SM801) for (CD3, CD79a, Iba1, CD117(c-kit), 
Mast cell tryptase and Lysozyme. For RANTES (CCL5) slides were washed in 
distilled water, assembled in Shandon Sequenza racks (Thermo Fisher Scientific) 
with Wash Buffer (Dako, S3006), incubated with Peroxidase-Blocking Solution 
(Dako, S2023) for 10 minutes at room temperature (RT), and washed with Wash 
Buffer for 10 minutes. For PCNA, slides were placed in cover plates in Sequenza 
racks and washed 3 times each for 2 minutes with Tris Buffered Saline (TSBT) 
(TBST + 0.05% Tween 20) (see AppendixI) followed by blocking with Peroxidase-
Blocking Solution (Dako, S2023) for 10 minutes at RT. 
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2.7.1.4 Antibody labelling and visualisation  
When an automated immunostainer was used (Link 48; Agilent Technologies Ltd), 
slides were then incubated with the primary antibodies, against CD3 (polyclonal 
rabbit anti-human CD3, Agilent Technologies Ltd (Dako A0452); 1:500), CD79a 
(monoclonal mouse anti-human CD79a, AbD Serotec (MCA2538H); 1:300), Iba-1 
(Anti-AIF1/IBA1; Bioscience (LSB2402); 1:500), KIT protein (rabbit anti-human 
CD117 [c-Kit], Agilent Technologies Ltd. [A4502]; 1: 500), lysozyme (rabbit anti-
human lysozyme, Agilent Technologies Ltd. [A0099]) and mast cell tryptase 
(mouse anti-human MCT, clone AA1, Agilent Technologies Ltd.; 1: 500); after 
blocking with 2.5% horse serum for 10 minutes. All antibodies were diluted in 
EnVisionTM FLEX Antibody Diluent (Dako, K8006).  
Slides were incubated for 20 minutes at RT. This was followed by a 20 minute 
incubation at RT with the secondary antibody and polymer peroxidase-based 
detection system (Anti Mouse/Rabbit Envision Flex+, Dako) and for Iba1, the 
secondary reagent was anti-goat IgG (ImmPRESS™ HRP Reagent Kit Peroxidase; 
MP-7405). The reaction was visualised with 3,3ʹ diaminobenzidine (Agilent 
Technologies Ltd).  
For RANTES (CCL5), sections were incubated overnight at 4ºC with a rabbit 
polyclonal anti-RANTES antibody (ab83324, Abcam) diluted 1:300 in antibody 
diluents (Dako, S0809). After primary incubation, slides were washed in wash 
buffer (Dako, S3006) for 10 minutes and incubated with EnVision-HRP anti-rabbit 
polymer (Dako, K4003) for 30 minutes at RT, then washed in wash buffer for 10 
minutes, removed from the Sequenza racks and put into distilled water. Then, slides 
were incubated with a DAB chromogen solution (Dako, K3468). For PCNA, 
sections were incubated overnight at 4ºC with the primary antibody diluted 1:100 
in TBST. Slides were then washed in TBST 3 times for 2 minutes each, then 
incubated for 30 minutes in EnVison-HRP anti-mouse polymer (Dako, K4001). 
After washing in TBST 3 times each for 2 minutes, slides were removed from the 
Sequenza clips and washed three times with distilled water. Slides were then 
incubated for 10 minutes in 3,3’ diaminobencidintetrahadrochloride (DAB, Fluka 
Chemie AG, Buchs, Switzerland) with 0.01% H2O2 (Perhydrol 30% H2O2P-a; 
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Fisher Scientific) in 0.1M imidazole buffer (pH7.2; Fluka Chemic AG; see 
Appendix I) at RT and washed in distilled water three times for 5 minutes each.  
2.7.1.5 Counterstaining  
For RANTES (CCL5), the slides were washed in wash buffer for 10 minutes and 
counterstained with Gill’s Haematoxylin II (Merck, 105175). For PCNA, the slides 
were counterstained with Papanicolaou’s heamatoxlin (Merck 1.09254.0500) for 1 
minute, then placed in running tap water for 5 minutes. All the other markers slides 
were counterstained with an autostainer using EnVisionTM FLEX Hematoxylin 
(Dako, K8008). 
2.7.1.6 Dehydration, clearing and mounting  
When the autostainer was used, slides were removed from the stainer and 
dehydrated through graded alcohols (96% ethanol for 1 minutes, 100% ethanol 
twice for 3 minutes), cleared in xylene (2 min, 2 x 3 min), and cover slipped with 
Distyeren Plasticiser Xylene (DPX, BDH brand, VWR International).  
For RANTES (CCL5), slides were dehydrated in ascending ethanol (70% ethanol 
for 1 minute; 95% ethanol for 1 minute; 100% ethanol twice for 2 minutes each), 
cleared in xylene (twice for 2 minutes each) and mounted with cover slips and 
xylene-based mounting medium. For PCNA, sections were dehydrated in ascending 
ethanol (96% for 1 minutes, 100% for 2 minutes and 3 minutes), cleared in xylene 
(for 2 minutes and twice 3 minutes), and cover slipped with DPX.  
2.7.1.7 Positive tissue controls  
Equine skin with normal mast cells and a lymph node served as positive controls 
for KIT, and Mast Cell Tryptase, respectively. Equine lymph node served as a 
control for CD3, CD79a, lysozyme, PCNA and Iba1. A positive control was run in 
all the experiments.  
2.7.1.8 Negative controls  
Consecutive sections incubated with non-immune rabbit serum or a murine 
subclassmatched unrelated monoclonal antibody served as negative controls. A 
negative control was run in all the experiments.  
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2.7.1.9 Determination of positive reactions and protein expression in tissue 
sections  
A distinct brown colour was considered indicative of a positive reaction if 
cytoplasmic (KIT, Iba-1, Mast cell tryptase, lysozyme, PCNA in mitotic cells), 
membranous (KIT) or nuclear (PCNA). The KIT expression pattern was determined 
according to previously described parameters (Ressel et al., 2015), where a 
membranous staining reaction is considered as normal, and a cytoplasmic, focally 
stippled or diffuse staining as aberrant.  
2.7.1.10 Quantitative assessment of immunohistochemical staining  
For T cells (CD3+), B cells (CD79a+) and macrophages (Iba-1+), cell numbers 
were estimated semi-quantitatively at 200 x magnification in 10 HPF selected areas 
of the sections. The semi-quantitative scoring system was adopted ranging from 0- 
100% (i.e. the total area represent as 100%, then the distributed positive cells were 
estimated in percentage related to the total area). In addition, an overall evaluation 
was performed at low power estimating the area of the section that was occupied 
by the respective cells.  
For RANTES (CCL5), the following scoring system was adopted by Dr Fernando 
RomeroPalomo as part of his postdoctoral project at the Institute of Veterinary 
Pathology, Vetsuisse Faculty, University of Zurich: the mean count of positive cells 
was determined in 25 fields of 0.2 mm2 (x400) and scored as follows: Score 0 (0 
cells), 1 (1-10 cells), 2 (11-20), 3 (21-40), 4 (41-50).  
2.8 Statistical analysis  
The statistical association between morphological parameters was investigated with 
the chi-square (for category variables) or Mann-Whitney U (for numerical 
variables) statistical tests, using the SPSS 13 Software (SPSS 13.0, SPSS Inc., IBM 
Chicago, Illinois, USA). Correlation between IHC marker (CD3, C79a and Iba1) 
and cytokine (IL5, IL13, IL4, CCl1, MIP1a and CCL5) scores was determined 
using Pearson’s Rho (R). Statistical significance was set at 5% (0.05) and 1% 
(0.01).  
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2.9 mRNA-in situ hybridisation (mRNA-ISH)  
RNA- ISH, a technique used to identify the location of mRNAs in fixed tissue 
sections with the help of anti-sense RNA probes specific for the mRNA target 
(Grabinski et al., 2015, Jensen, 2014), was used to obtain further information on 
the interaction of the involved immune cells (i.e. eosinophils, macrophages, 
lymphocytes and mast cells). RNA-ISH was performed by Dr. Fernando Romero-
Palomo at Institute of Veterinary Pathology, University of Zurich. The RNAscope® 
technology (Advance Cell Diagnostics - ACD Inc., USA) was applied based on the 
technology previously described by Wang et al., (2012) as shown in Figure 3.  
  
 
Figure 3: RNAScope technology overview 
Source: Fernando Romero-Palomo 
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RNA-ISH was performed on selected cases (see Appendix 2-section A) and 
comprised the following markers: MIP1α/CCL3, eotaxin/CCL11, interleukin 4 (IL-
4), interleukin 5 (IL-5), Stem Cell Factor (SCF) (aka cKIT ligand), transforming 
growth factor beta (TGF-β), and interleukin-13 (IL-13) (Table 4); the respective 
mRNA sequences were taken from the NCBI website (Table 5).  
Table 4: List of cytokines for which an RNA-ISH was established 
Cytokines/ Interleukin  Mainly cell producers  
CCL11 / Eotaxin 
Mainly secreted by epithelial cells macrophages, T cells, 
eosinophils, mast cells 
MIP1α/CCL3  Mainly secreted by epithelial cells, MPH, T cells, EOs, MCs  
Interleukin 4 (IL-4)  Mainly secreted by T cells and MCs (also described by EOs).  
Interleukin 5 (IL-5)  Mainly secreted by T cells and MCs  
Interleukin 13 (IL13)  Mainly secreted by T cells  
Stem cell factor  
(SCF)/c-kit ligand  
c-kit ligand: Mainly secreted by fibroblast, EOs and MCs  
Transforming growth 
factor beta (TGF-β)  
Mainly secreted by T cells and MPH (also EOs, MCs…)  
Table 5: Probes and mRNA sequences of the selected chemokines/cytokines 
Probe name 
(target molecule)  
NCBI  reference 
sequence  





number of ZZ 
oligoprobes  
CCL11 / Eotaxin  NM_001081871.1   514 bp   7 ZZ  
CCL3 / MIP1α  NM_001114941.1  367 bp   7 ZZ  
IL-4  NM_001082519.1   414 bp   9 ZZ  
IL-5  NM_001082499.1   405 bp   8 ZZ  
IL-13  NM_001143791.1  402 bp   8 ZZ  
SCF  NM_001163962.1   1407 bp   20 ZZ  
TGFβ  NM_001081849.1  1187 bp   20 ZZ  
PPIB  NM_001099761.1   853 bp   19 ZZ  
Pp: Base Pair.      




2.9.1 RNA-ISH protocol  
For the mRNA detection of the different cytokines and chemokines, an mRNA ISH 
manual protocol was followed (Advance Cell Diagnostics, Inc. RNAscope® 2.5 
HD assay), according to the manufacturer’s instructions.  
Briefly, tissue sections were deparaffinised in xylene (twice, 5 minutes each), 
incubated in 100% ethanol (twice, 1 minute each) and air dried for 5 minutes at RT. 
Subsequently, sections were incubated in RNAscope® Hydrogen Peroxide 
(322335) (10 minutes, RT) to inhibit all endogenous peroxidase activity, washed 
twice in distilled water, and subjected to target retrieval pre-treatment in a pressure 
cooker with RNAscope® Target Retrieval Reagent (322000) (15 minutes, 100ºC). 
Subsequently, slides were washed twice in distilled water, incubated in 100% 
ethanol and air dried at RT. A hydrophobic barrier was drawn around each section 
with an Immedege™ pen (H-4000, Vector, Peterborough, United Kingdom). The 
sections were then covered with RNAscope® Protease Plus (322331), placed in a 
HybEZ™ Humidity Control Tray/Slide Rack (310012 and 310014), and incubated 
on a HybEZ™ Oven (310010 (110VAC) at 40ºC for 30 minutes to allow for cell 
permeabilisation and additional target retrieval. Slides were washed twice in 
distilled water, covered with the corresponding probes, and subjected to probe 
hybridisation in the HybEZ™ system (humidity control tray, slide rack and oven) 
at 40ºC for 2 hours. After hybridisation, slides were washed twice in RNAscope® 
Wash Buffer (310091) and subjected to the following incubation cycles for signal 
amplification in the HybEZ™ system, using the Amp reagents provided by the 
manufacturer for the Brown (DAB) kit (322310): Amp1 reagent (30 minutes at 
40ºC), Amp2 reagent (15 minutes at 40ºC), Amp3 reagent (30 minutes at 40ºC), 
Amp4 reagent (15 minutes at 40ºC), Amp5 reagent (30 minutes at 40ºC), and Amp6 
reagent (15 minutes at 40ºC). Between each amplification step, slides were washed 
twice (2 minutes each) in wash buffer. After the last wash, slides were incubated 
with a DAB solution for 10 minutes at RT for visualisation of the hybridised probes, 
and subsequently washed in tap water, and counterstained with 50% Gill’s 
haematoxlin II (Merck, 105175). The sections were dehydrated in an ascending 
ethanol series (70% ethanol for 1 minutes; 95% ethanol for 1 minutes; 100% ethanol 
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twice, 2 minutes each), twice cleared in xylene (2 minutes each) and mounted with 
cover slips and xylene-based mounting medium.  
A probe directed against equine PPIB (housekeeping gene coding for peptidylprolyl 
isomerase B) served as a positive control and was used to confirm mRNA 
preservation in the sections/tissue. A negative control probe directed against DapB 
(ACD, 310043) (bacterial gene coding for dihydrodipicolinate reductase) was also 
applied to all cases in order confirm the specificity of the hybridisations. A positive 
signal was represented by a dark brown granular reaction in the cytoplasm of the 
cells. A scoring system to quantify the mRNA expressed was based on the number 
of cells exhibiting a positive signal. It was based on the total number of positive 
cells/cm2 (taking also into account the total size of the section) as score 0 (0), 0.5 
(1-10), 1 (11-100), 2 (100-500), 3 (500-1000), 4 (1000-3500).  
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 CHAPTER 3: RESULTS  
3. Results  
3.1 Clinical data and association with diagnosis  
Overall, 153 cases met the inclusion criteria; for the majority of these horses 
information as to their breed, sex, age, and the location of individual lesions was 
available.  
 3.1.1 Diagnosis at the time of initial diagnostic examination  
According to the diagnoses made upon the initial diagnostic examination, a total of 
191 lesions were examined from the 153 horses, with a diagnosis of mast cell 
tumour (MCT) being made for 62 lesions and eosinophilic granuloma (EG) for 129 
lesions. Of the 129 EG, 71 (72%) represented single lesions, and 48 MCT (87%) 
occurred as single lesions. When more lesions were observed in the same animal, 
they were always of the same type. 
 3.1.2 Breed distribution  
The breed was known for 77% (118) of the cases, whereas it was not specified for 
35 horses (23%). The breeds were as follows: 15 Thoroughbreds and 13 
Thoroughbred cross (Thoroughbreds in total: 28/118; 27.3%); 15 Arabian and 4 
Arabian cross (Arabian in total: 19/118; 16.1%). These were the most frequently 
represented breeds. These were followed by Warmbloods (14/118; 11.8%), 7 Welsh 
and 2 Welsh cross (Welsh in total: 9/118; 7.6%), Irish Sport Horse (6/118; 5%), 
Cob (5/118; 4.2%), Pony and Appaloosa (each 3/118; 2.5%). Two horses each were 
of Hanoverian, Irish Draft, Irish draft crossed with Thoroughbreds and Andalusian 
breed (2/118; 1.7%), and there was each one of Belgian, Holstein, Riley, CohnX, 
Connemara, Criolla, Dales, French Breed, Grey Pony, Icelandic, Morgan, New 
Forest Cross, Oldenburg, Selle Français, Shetland Pony, Show Horse, Skewbald, 
Spanish, Polo Pony, Sport horse, Welsh cob, Welsh cross Thoroughbreds, and Irish 
Sport Pony.  
Among the 118 horses of which the breed was known, 75 were initially diagnosed 
with EG and 43 with MCT. The breeds most frequently represented among EG 
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cases were Thoroughbreds and Thoroughbreds crosses (16/75; 21.3%) and 
Warmbloods (12/75; 16%), followed by Arabian and Arabian crosses (8/75; 
10.6%), Irish Sport Horse (5/75; 6.6%); Welsh and Welsh cross (4/75; 5.3%), Cob 
(3/75; 4%), AND Appaloosa, Pony, Hanoverian, Irish Draught (2/75; 2.6% for 
each). Breeds most frequently represented among MCT cases were Thoroughbreds 
and Thoroughbreds cross (12/43; 28%) and Arabian and Arabian cross (11/43; 
25.6%), followed by Welsh and Welsh cross (5/43; 11.6%), Warmbloods and Cob 
(each 2/43; 4.7). The full results are tabulated in Table 6.  
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Table 6: Number of horses diagnosed with EEG or MCT of different breeds 
Breed  EG  MCT  
Thoroughbred and Thoroughbred cross  16  12  
Arabian and Arabian cross  8  11  
Warmbloods  12  2  
Welsh and Welsh cross  4  5  
Cob  3  2  
Irish Sport Horse  5  1  
Appaloosa  2  1  
Pony  3  1  
Hanoverian  2  0  
Irish Draught  2  0  
Irish Draught cross Thoroughbred  1  1  
Andalusian  1  1  
Skewbald  1  0  
Belgian  1  0  
Shetland Pony  1  0  
Connemara  1  0  
Selle Français  1  0  
Oldenburg  1  0  
Polo Pony  1  0  
Riley  1  0  
Morgan  1  0  
Criolla  1  0  
New Forest cross  1  0  
Sport horse  1  0  
Dales  1  0  
Icelandic  1  0  
Spanish  1  0  
Show Horse  0  1  
Holstein  0  1  
French Breed  0  1  
Irish Sports Pony  0  1  
Cohn-X  0  1  
Welsh cross Thoroughbred  0  1  
Welsh cob  1  0  
 
3.1.3 Age distribution  
Animals included into the study ranged in age from 2 to 25 years, with a mean age 
of 3 years. For animals with a diagnosis of EG the age ranged from 2 to 23 years, 
with a mean age of 9 years. For animals with a diagnosis of MCT, ages ranged from 
3 to 25 years, with a mean age of 11.3 years.  
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For Thoroughbred and Thoroughbred cross with a diagnosis of EG, the recorded 
ages ranged between 2 and 20 years (mean age: 9 years) and between 9 and 21 years 
(mean age: 13 years). For Arabian and Arabian cross with a diagnosis of MCT, the 
ages ranged from 5 to 23 years (mean age: 13.5 years) with a diagnosis of EG, 
between 3 and 21 years (mean age: 10 years) .For Warmblood, the age ranged 
between 5 and 18 years (mean age: 7.3 years) with a diagnosis of EG, and between 
4 and 18 years (mean age: 11 years) for MCT; Welsh and Walsh cross, the age 
ranged between 8 and 22 years (mean age: 9.5 years) with a diagnosis of EG, and 
between 7 and 13 years (mean age: 9.5 years) for MCT.  
In addition, for breeds affected with EG only, the age range 6-10 years for Cobs 
(mean age: 8 years), 10 -20.5 years for ponies (mean age: 15.2 years), 9.6-13 years 
for Irish (mean age: 7.5 years), 7-11 years for Appaloosas (mean age: 9 years), 6-7 
years for Hanoverians (mean age: 6.5 years), and 5-9 years for Irish Draughts (mean 
age: 7 years).  
The age of each one horse affected by MCT (Cob, Pony, Irish, Appaloosa, and 
Andalusian) was 12, 11, 13, 10 and 6 years, respectively. For Hanoverian and Irish 
Draught, no MCT was diagnosed, and the age was not available for the Andalusian. 
For Irish draft crossed with Thoroughbreds and Andalusian, one horse was affected 
with EEG and ages were 7 and 6 years, respectively.  
The data also for other breeds (one horse for each) were grouped together and 
showed the following age: age range between 4 and 15 years (mean age: 8.3 years) 
for EG (Skewbald, Belgian, Grey Pony, Shetland Pony, Connemara, Selle Français, 
Oldenburg, Polo Pony, Riley, Morgan, Criolla, New Forest, Cross Sport horse, 
Dales, Icelandic, Spanish, Welsh cob); ages ranged between 7 and 22 years (mean 
age: 14 years) for MCT (Show Horse, Holstein, French Breed, Irish Sports Pony, 
Cohn-X, Welsh cross Thoroughbred). A summary is provided in Table 7.  
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Table 7: Age (mean and range) in each breed with both types of lesions 
Breed  
EG age (years)  MCT age (years)  
Mean  Range  Mean  Range  
Thoroughbred/cross  9  2-20  13  9-21  
Arab/cross  13.5  5-23  10  3-21  
Warmblood  7.3  5-18  11  4-18  
Welsh/cross  13  7-22  9  7-13  
Cob  8  6-10  * 12    
Pony  15.2  10-20.5  * 11    
Irish  7.5  9.6-13  * 13    
Appaloosa  9  7-11  * 10    
Hanoverian  6.5  6-7  “    
Irish Draught  7  5-9  “    
Irish Draught cross Thoroughbred  * 7    * 6    
Andalusian  * 6    “  “  
  
3.1.4 Sex distribution  
The sex was known for 142 horses out of the total of 153. Of those where the sex 
was known, 90/142 (63%) were male and 52/142 (37%) were female. Horses 
diagnosed with MCT were mainly males (65%; 36/55), the difference between 
sexes was less evident for horses with EG, where 55% (54/98) were male (Table 
8).  
  
Both types of lesions (EG and MCT) after initial diagnosis; * = one case recorded, “= 
no case recorded 




Table 8: Summary of the case material selected on the basis of the initial diagnosis 
 Total number (%) MCT EG 
Horses  153  55  98 
Male  90 (63%)  36 (65%)  54 (55%)  
Female  52 (37%)  14 (25%)  38 (39%)  
Not stated  11 (7%)  5 (10%) 6 (6%)  
  
Comparing single and multiple lesions, the sex distribution was similar: the number 
of males (39/67; 58.2%) was similar to females (28/67; 41.8%) in single lesions; 
this was comparable with the results obtained for those horses that exhibited 
multiple lesions (males: 15/25; 60%; 10/25; 40%).  
In MCT there were 44 single lesions; males (33 /44; 75%) were overrepresented in 
exhibiting single lesions, whereas multiple lesions seemed to be equally distributed 
between the sexes (males: 4/7, 57%; females 3/7, 43%).  
 3.1.5 Location of lesions  
The lesions diagnosed as EG were distributed among the body as follows: trunk 
(18/98; 18.4%), head (6/98; 6%), eyelid and limbs (3/98; 3% for each location); 
conjunctiva (1/98; 1%). Five horses had more than one lesion. These were 
distributed as follows: eyelid and conjunctiva; neck, trunk and head; neck and trunk; 
eye, neck and trunk; eyelid and shoulder. Information on the location was not 
available for 63.2% (62/98). MCT were widely distributed across the body but most 
commonly reported on the head (14/55; 25.4%), and eye (10/55; 18.2%, 5 each at 
conjunctiva and eyelid), trunk (5/55; 9%), neck (3/55; 5.5%) and limb (3/55; 5.5%). 
In 20 horses (36.4%), information on the location of the legion[s] was not available.  
 3.1.6 Size of lesions  
The major diameter of EG clinically investigated at the time of surgical 
procedure/sampling and reported with clinical information ranged from 5mm to 
9cm, with a mean major diameter of 2.4cm. For MCT, the size ranged from 2mm 
to 10cm, with a mean major diameter of 2.3cm. For 19/98 EG and 8/55 MCT, 
information on size was not available.  




3.2 Histopathological examination and case review  
Based on the hypothesis that, to date, there has been no definite proof that EG and 
MCT in the skin of horses are two different entities, and in order to establish clear 
diagnostic guidelines, all cases were re-examined, with the examiner being 
‘blinded’ in that she did not have access to the initial diagnoses.  
The morphological examination revealed variable histological features (Table 9).  
Assessment of the dermal location showed that the majority of lesions involved the 
mid 98/191 (51%) and/or the deep 123/191(64%) dermis, whereas only 47/191 
(25%) involved the superficial dermis and 41/191(22%) the subcutis. As many as 
93/191 (49%) lesions occupied more than one layer.  
Of the 191 lesions, the great majority 176/191 (92%) exhibited areas consistent with 
EG; 15/191 (8%) did not exhibit any evidence of EG components (EGC). By 
comparison, only 76/191(40%) showed mast cell aggregates (MCA), suggesting 
that 115 /191 (60%) cases were EG only. In cases with MCA, the size and number 
of EG areas and MCA varied gradually within the population without a clear cut 
off.  
Individual mast cells were found distributed throughout the lesion in 32/191 (17%) 
of all lesions. In 55/176 (31%) of the cases with an EGC there was evidence of EGC 
association with hair follicles, and in 122/176 (69%), the EGC seemed to contain 
embedded collagen. Mineralisation was observed in 67/191 (35%) of all lesions. A 
few cases 31/191 (16%) exhibited ulceration of the epidermis. All lesions with 
MCA exhibited infiltrating eosinophils within the MCA; this was variable and mild 
(1%-20% of the area represented by infiltrating eosinophils on average) in 35 
lesions, moderate (20%-50% of the area represented by infiltrating eosinophils on 
average) in 22, and marked (50%-95% of the area represented by infiltrating 
eosinophils on average) in 19 lesions. Lesions with MCA were assessed for 
proliferation of the mast cell population; in 64/76 (84.2%), mitotic figures were 
observed. 70/191 (37%) of the lesions exhibited lymphocyte aggregates associated 
with the lesions.  
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Notably, there were four lesions that exhibited unique morphological features 
characterised by marked eosinophil infiltration (95% of the area represented by 
infiltrating eosinophils on average) and an embedded mast cell population that was 
characterised by large pleomorphic mast cells. These are described separately from 
the study population and are referred to as histiocytic-like atypical mast cell 
tumours (see APPENDIX II - section B). The results of the morphological 
evaluation of the 191 cases are summarised in Table 9.  
Table 9: Summary of morphological finding, based on HE and TB stain for 191 lesions 
Histological Features  Number  Percentage  
Location    
Superficial dermis  47/191  25%  
Mid dermis  98/191  51%  
Deep dermis  123/191  64%  
Subcutis  41/191  22%  
Presence of EG/eosinophils and MCT/MCA    
EG  176/191  92%  
MCT and/or mast cell aggregates (MCA)  76/191  40%  
Pure MCT (without EG component)  15/191  8%  
No evidence of MCA  115/191  60%  
Scattered individual mast cells  32/191  17%  
EGC associated with hair follicles  55/176  31%  
Infiltrating eosinophils in MCA  76/76  100%  
Mineralisation  67/191  35%  
Ulceration  31/191  16%  
Collagen in EG areas  122/176  69%  
Proliferation of mast cells (mitotic figures) in cases with 
MCA  
64/76  84%  
Lymphocyte aggregates  70/191  37%  
Cases with dominance of mast cells  with 
macrophage/histiocyte appearance (atypical cases)  
4/191  2%  
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3.2.1 Selection of the case material for detailed investigations and 
development of a system to classify the lesions based on the histological 
features  
From all of the 191 examined cases, 95 lesions were selected based on their tissue 
preservation, the completeness of the lesions on the section, and the presence of 
surrounding normal tissues. These 95 cases were selected for further analysis 
(Appendix II - section A).  
The presence and relationship between the EGC and MCA components was used 
to establish five morphological categories, to which all lesions were subsequently 
allocated regardless of initial diagnosis. This also conferred a (new) diagnosis. The 
five categories and their basic criteria were as follows:  
• Category I:  Areas of EGC, without MCA  
• Category II:  EGC and MCA present; EGC total area larger than MCA 
area  
• Category III:  EGC and MCA present; EGC total area equal to MCA area  
• Category IV:  EGC and MCA present; EGC total area smaller than MCA  
area  
• Category V:  MCA only  
Based on these categories, three major groups (and diagnoses) were created:  
• Group 1:  Cases with EGC only (Category I)  
• Group 2:  Cases with EGC and MCA (Categories II+III+IV)  
• Group 3:  Cases with MCA only (Category V)  
Based on these three groups, the following two diagnoses were established:  
• Eosinophilic granuloma (EG):   Group 1 (i.e. Category I)  
• Mast cell tumour (MCT):   Groups 2 and 3 (i.e. Categories II-V)  
  
After the establishment of the five categories, the 95 cases selected for further 
investigations were allocated to the different categories; 31 to Category I, 14 to 
Category II, 13 to Category III, 23 to Category IV, and 14 to Category V.  
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Among these cases were 11/95 (~10%) in which the (new) diagnosis did not match 
with the initial diagnosis. Ten cases previously diagnosed as EG were reclassified 
following the new classification as MCT based on the identification of MCA within 
large EG areas (Groups 2 and 3). Of these, seven were assigned to Category II, and 
one each to Categories III, IV and V. One single lesion that was previously 
diagnosed as MCT was reclassified as EG and fell into Category I based on (TB) 
stain that lesion lack evidence of MCA. Information on all individual cases is 
presented in Appendix II – section A.  
 3.3 Clinical data for groups and diagnoses  
The 95 lesions were from 78 horses. The breed was known for 62 of these animals. 
There were 43 males and 30 females (for five horses, information on the sex was 
not available), and the age ranged from 3 to 25 years (mean age: 11 years). For all 
further assessments, the lesions were arranged in Groups (1-3) and according to the 
final diagnosis (EG and MCT).  
3.3.1 Breed distribution  
In Group 1 (EG), the breed was given in 23 of the 30 horses. Most frequently 
represented were Thoroughbreds and Thoroughbreds crosses (8/23; 34.7%), 
Arabian and Arabian crosses (3/23; 13 %), followed by Warmbloods (2/23; 8.7%) 
and Cobs (2/23; 8.7%). There was one each of; Irish Draught, New Forest Cross, 
Oldenburg, Selle Français, Spanish, Irish Sport, Welsh cob, and Irish draft crossed 
with Thoroughbred.  
In Group 2 (EGC with MCA), the breed was given in 34/42 horses. Most frequently 
represented were Arabian and Arabian crosses (10/34; 29.4 %) and Thoroughbreds 
and Thoroughbreds crosses (5/34; 14.7 %), Welsh with Welsh cross (5/34; 14.7%) 
followed by Appaloosa (2/34; 6 %), Pony (2/34; 2%) and Warmbloods (2/34; 6%). 
There was one each of; Show horse, Welsh crossed with Thoroughbred, Irish draft 
crossed with Thoroughbred, Holstein, Andalusian, French breed, Cob and Cohn-x.  
For Group 3 (pure MCT) the breed was known for 5 of the 6 horses. Most of the 5 
were Arabian with Arabian crosses (3/5; 60%), with the other two horses being a 
Thoroughbred cross, and an Appaloosa.  
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Looking at the diagnosis of MCT (Groups 2 and 3), the breed was known for 39 of 
the 48 horses. The breed distribution among the newly categorised EG (Group 1) 
and MCT (Groups 2 and 3) is summarised in Table 10.  
Table 10: Breed distribution among EG (Group 1) and MCT (Groups 2 and 3) 
Breed  EG MCT 
 Andalusian  0 1 
 Cob  1 0 
Appaloosa  0 3 
Arab  2 13 
Arab cross  1 3 
Cob  1 0 
Cob Cross  0 1 
Cohn-X  0 1 
French Breed  0 1 
Grey Pony  0 1 
Holstein  0 1 
Irish draft cross  1 1 
Irish Draught  1 0 
Irish Sports  1 0 
New Forest cross  1 0 
Oldenburg  1 0 
Pony  0 1 
Selle Français  1 0 
Show Horse  0 2 
Spanish  1 0 
Thoroughbred  4 2 
Thoroughbred cross  4 12 
Warmblood  3 2 
Welsh  0 1 
Welsh cross  0 5 
Welsh Cob  1 0 
Welsh cross Thoroughbred  0 2 
Unknown  7 9 
Total  31 64 
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Arabs with Arab cross as well as Thoroughbred with thoroughbred cross were 
overrepresented in MCT compared to EG. There was no statistical association 
between Thoroughbred and MCT while a significant increase in the number of 
Arabian exhibiting MCT was found. 
3.3.2 Age distribution  
For Group 1, the age of affected horses ranged from 5 to 18 years, with a mean of 
9 years. For Group 2, the age ranged from 3 to 25 years (average: 12 years), whereas 
in Group 3, affected animals ranged between 12 and 21 years of age, with a mean 
age of 15 years. Considering the separate categories there was a significant increase 
in the mean age of animals within Groups IV and V with lesions compared to 




Figure 4: Box and whisker plots showing the difference in age among categories 
*=P<0.05, **=P<0.01, Statistical test (Mann-Whitney U) 
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In addition, horses with EG (Group 1) were significantly younger than horses with 
MCT (Groups 2 and 3) as shown in Figure 5.  
 
3.3.3 Sex distribution  
For group 1 lesions, the sex was known for 28 out of the 30 affected horses; there 
were 14 affected male horses and 14 affected female horses. Among the 41/42 
horses with group 2 lesions with known sex, the majority (23; 55%) were male, 
with 18 being female (45%). All six animals with group 3 lesions were males. With 
reference to MCA there were 29 male horses and 18 female horses.  
Horses with MCT (groups 2 and 3) were, in the majority, male (42/64; 65%) with 
only 19 females and three with unknown sex. Despite the 3 to 1 ratio of males with 
a diagnosis of MCT, the difference was not found to be significant.  
3.3.4 Location of the lesion  
For Group 1 lesions (EG), information on the location was only available for 9/31 
lesions (29%). Single lesions originated from the trunk (6/31; 19.3%) and 
Figure 5: Box and whisker plots show the difference in age between EG 
and MCT 
*=P<0.05, Statistical test (Mann-Whitney U) 
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conjunctiva (1/31; 3.2%). In two horses with more than one lesion they were 
reported to originate from the eyelid and conjunctiva as well as the neck and trunk.  
For Group 2 lesions, information on the location was available for 27/50 lesions 
(54%). They were located on the head (17/50; 34%), trunk (3/50; 6%), leg 2/50, 
neck (2/50; 4%), eyelid (2/50; 4%), and conjunctiva (1/50; 2%).  
For Group 3 lesions, information on the location was available for 4/14 lesions 
(29%). They were located on the head (2/14; 14.3%) and eyelid (2/14; 14.3%).  
For MCT (Groups 2 and 3), lesions were located on the head (19/64; 30 %), trunk 
(3/64; 5%), leg 2/64, neck (2/64; 3%), eyelid (4/64; 6%), and conjunctiva (1/64; 
2%).  
3.4 Assessment of morphological features in Categories (I-V)  
3.4.1 Size (area) of the lesions and proportion (area) of EGC and MCA 
within lesions  
The size and number of EGC and MCA were evaluated by counting the number of 
EGC present in the lesion and measuring the area (pixels) occupied by each EGC 
and MCA. This was achieved using low power scanning at the same magnification 
and measured using computer software (Figure 6).  
  
Figure 6: Representative picture of low power scanning of two sections 
Labels indicate the objects where the area for EGC (A) Case No. 09L-3297 EG 
(Category I) and MCA (B) Case No. 07L-3494 MCT (Category V) was assessed. 
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Considering all the lesions, the pure MCT (Category V) were significantly the 
smallest lesions, while MCT in Category III and IV were the largest (Figure 7). 
 
  
Figure 7: Box and whisker plots showing the difference in area (pixels) of lesions  
of the different categories 
*=P<0.05, **=P<0.01. Statistical test (Mann-Whitney U) and the numbers 
representing outliers. 
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Considering the area of EGC, their size was larger in Categories II and III compared 
to IV, as expected (Figure 8). 
  
  
Figure 8: Box and whisker plots showing the difference in EGC area (pixels) in lesions 
of the different categories 
*=P<0.05, **=P<0.01. Statistical test (Mann-Whitney U) and the numbers representing 
outliers. 
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The number of EGC within a lesion was variable within the categories but only a 
weaker statistical association was found in Category III which contained more EGC 










Figure 9: Box and whisker plots showing the difference in EGC numbers 
between the different categories 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
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When the MCA area was measured, there was a significant increase in MCA size 
in Category IV with a possible trend from Categories II to IV. MCA in Category V 









Figure 10: Box and whisker plots showing the difference in MCA area (pixels) 
between the different categories with MCA 
**=P<0.01. Statistical test (Mann-Whitney U) and the numbers representing outliers. 




The number of MCA among groups was similar between Categories II and IV, 
while there was a significant increase in the number in Category III. In contrast, 
pure MCT (Category V) were almost exclusively comprised of one single MCA 





Figure 11: Box and whisker plots showing the difference in MCA numbers between 
the different categories 
*=P<0.05, **=P<0.01. Statistical test (Mann-Whitney U) and the numbers representing 
outliers. 
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3.4.2 Location of lesions within skin and subcutis  
Lesions often involved more than one location (65/95; 68.4%). A comparison of 
the five categories with regards to the location (i.e. involvement) of the lesions in 
the skin and subcutis showed that EG (Group 1; Category I) were more frequently 
located in the superficial dermis than lesions containing MCA (Categories I-IV). 
Interestingly, pure MCT (Group 3; Category V) were exclusively located in the 
dermis, mainly the mid and deep dermis. Involvement of the subcutis increased 
from Categories I to IV. Overall, the deep dermis was involved most commonly 
(Figure 12 and Table 11).  
 




  Category    
I (n=31)  II (n=14)  III (n=13)  IV (n=23)  V (n=14)  
Superficial dermis  21/95  45% (14)  7% (1)  0  13% (3)  21% (3)  
Mid dermis  53/95  74% (23)  28% (4)  38% (5)  43% (10)  79% (11)  
Deep dermis  73/95  81% (25)  78% (11)  69% (9)  78% (18)  71% (10)  






























1 II III IV V 
Superficial Mid Deep Subcutaneous 
Figure 12: Histogram showing the percentage of lesions involving a specific layer for 
each category (a single lesion can extend to more than one layer) 




Within all the lesions examined, 65 involved more than one layer; Category I 
(24/31: 77.4%), Category II (7/14; 50%), Category III (7/13; 54%), Category IV 
(17/23; 74%), Category V (10/14; 71.4%). When the “depth score” was applied to 
the lesions, which weighed the involvement of multiple layers, no significant 
differences were found between the five categories (Figure 13).  
  
  
Figure 13: Box and whisker plots to compare the depth scores between lesions of 
the different categories 
*=P<0.05, **=P<0.01. Statistical test (Mann-Whitney U) and the numbers 
representing outliers. 
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3.4.3 Presence of individual mast cells disseminated in the lesions  
Individual mature mast cells (not forming aggregates) were found disseminated 
throughout the lesions in all 14 cases (100%) of Category II. They were also 
observed in 42% (13/31) of the pure EG (category I), but were absent in the lesions 










    
Figure 14: Case No. 11L-2439 EG (Group 1, Category I): Individual mast cells 
(arrows) are found scattered within the lesion. Toluidine blue stain, 400x. 
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3.4.4 EGC in association with hair follicle structures  
In almost half of the EG (16/31; 52%; Category I, Group 1) the EGC involved hair 
follicles, often effacing the hair follicle in a “furunculosis-like” pattern (Figure 15).  
The statistical analysis confirmed a highly significant (P<0.001) association of EGC 
in pure EG (Group 1) with hair follicles compared to EGC in MCT (Categories II-






A2   
B1 
  
A 1  
Figure 15: Case Nos. 14L-4109 (A) and 11L-0931 (B) 
Association between EGC and hair follicle in two cases. Low power (A1 and B1) and 
high power (B2 and B2) views of EGC involving hair follicles (arrows). HE stain, 
100x (A1, B1) and 400x (A2, B2). 
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3.4.5 Mineralisation  
Focal areas of mineralisation were identified within EGC. Assessment of HE-
stained sections identified focal areas of mineralisation in 64.5% of lesions in 
Category I, 8% of lesions in Category III and 21% of lesions in both Categories II 
and IV. Mineralisation was not identified in the pure MCT (Category V) (Table 12), 
as these did not contain areas of EGC. Using the von Kossa stain to specifically 
illustrate calcium salts (Figure 16), it became obvious that even more lesions 
exhibited focal areas of mineralisation (a total of 64 lesions). In Categories I to IV, 
their frequency varied between 61% and 100%. However, Category V lesions were 
confirmed to be free of mineralisation.  
  
  .   
Figure 16: Case No. 05L-1008. Case of MCT with EGC (Category II) 
The low power scan illustrates the presence of several focal areas of mineralisation 
(arrows). Von Kossa stain, 10x. 
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Table 12: Frequency of focal mineralisation in EG (Category I) and MCT comprised 
of MCA and EGC (Category II-IV), as identified in HE- and von Kossa-stained 
sections 
Mineralisation, 
identified in  
No. of 
total 
 Category  
I (n=31)  II (n=14)  III (n=13)  IV (n=23)  
HE stain  27/81  64.5% (20)  21% (3)  8% (1)  21% (3)  
Von Kossa stain  64/81  84% (26)  100% (14)  77% (10)  61% (14)  
  
Based on the results obtained from the von Kossa-stained sections, there was a 
significant association between the frequency of mineralisation in Group 1 (EG) 
lesions compared to the other groups (P<0.001); this was lacking in MCT (Groups 
2 and 3).  
When the presence of mineralisation was correlated with the average size of the 
EGC lesion, no statistical association was found (Figure 17). This suggests that 
mineralisation is not dependent on the size of an EGC area.  
  
Figure 17: Box and whisker plots showing the lack of association between EGC area 
(pixels) and presence or absence of mineralisation 
Statistical test (Mann-Whitney U) and the numbers representing outliers. 
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3.4.6 Ulceration  
As shown in Table 13 and Figure 18, in a few cases within each category, ulceration 
was seen without statistically significant differences between the groups. Ulceration 
was not always directly associated with the lesions, suggesting it was mechanically 
induced.  
Table 13: Presence of ulceration in lesions of all five categories 
Ulceration, 
identified in  
No. of 
total 
  Category   
I (n=31)  II (n=14)  III (n=13)  IV (n=23)  V (n=14)  
HE stain  13/95 13% (4)  14% (2)  15% (2)  13% (3)  14% (2)  
  
3.4.7 Presence of collagen in EGC areas  
Among all types of lesions that contained EGC (Categories I to IV) were some cases 
that exhibited evidence of collagen fibres within areas of EGC in the HE stained 
sections. This was further assessed in the Masson Trichrome-stained sections which 
confirmed the presence of collagen fibres (or fragments) in these areas in a large 
proportion of lesions (Figure 19). They were very frequent in lesions of Categories 
I and II, but rather rarer in the other Categories (III and IV) (Table 14). The 
  
  
Figure 18: Case No. 06L0445, Category V 
Focal area of ulceration in one representative lesion (arrows). HE, 200x. 
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difference in the results obtained from HE stain and Masson’s Trichrome stain was 
due to the different methodological approaches that they use to identify collagen 
fibres/fragments. The HE stain relies on the morphological identification of fibrillar 
eosinophilic material (which can be misinterpreted as other material such as fibrin). 
In contrast, the Masson’s Trichrome stain identifies collagen more precisely as 
green stained fragments, but since some collagen fibres may stain red (in particular 
when degenerated) this could lead to possible underestimation.  
  
  
Table 14: Presence of collagen within EGC areas in the five categories, based upon 
HE and Masson trichrome stain 
Collagen in EGC,  
identified in  
No. of 
total 
 Category  
I (n=31)  II (n=14)  III (n=13)  IV (n=23)  
HE stain  56/81 81% (25)  100% (14)  85% (11)  26% (6)  
Masson Trichrome 
stain  
57/81 93% (29)  93% (13)  46% (6)  40% (9)  
  
Figure 19: Case No. 09L-3757, Category II. Fragments of collagen fibres within an 
EGC area (arrows). Masson Trichrome stain, 400x 
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The statistical analysis, based on the results obtained from the Masson Trichrome 
stained sections, showed a significantly higher frequency of collagen fragments 
with EGC areas in Group 1 (EG) than in Groups 2 and 3 (MCT).  
3.4.8 Lymphocyte aggregates  
A proportion of cases exhibited aggregates of lymphocytes within the lesions. 
These were most frequent in Category I lesions and were occasionally present in 
lesions in Categories II and IV; they were not identified in lesions in either Category 
III or Category V (Table 15). The aggregates were often relatively large and 
resembled lymphoid follicles (Figure 20). They were either found intermingled with 
the EGC or close to the periphery of the lesions.  
  
Table 15: Presence of lymphocyte aggregates in lesions of the five categories 
Lymphocyte 
aggregates, 






  I (n=31) II (n=14) III (n=13) IV(n=23) V (n=14) 





Figure 20: Case No. 06L-4011, Category I. Large lymphocyte aggregate 
(arrow) close to an EGC area (white arrow). HE stain, 200x 
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In cases where lymphocyte aggregates were present, these were counted. Statistical 
analysis showed that Category I lesions (Group 1, EG) contained significantly more 
lymphocyte aggregates than all the other lesions (Groups 2 and 3 (MCT), 






Figure 21: Box and whisker plots to compare the number of lymphocyte 
aggregates in EG (Group 1) and MCT (Groups 2 and 3). 
**=P<0.01. Statistical test (Mann-Whitney U) and the numbers representing outliers. 






3.4.9 Infiltrating viable eosinophils in MCA  
Mast cell aggregates (MCA) were seen in Categories II to V (i.e. in MCT). All 
MCA contained viable eosinophils in different proportions. The percentage of area 
occupied by viable eosinophils measured in representative 10 HPFs within MCA 
increased from an average of only 15% in Category II lesions to 45% in Category 
V lesions (Table 16). There was, as the table also notes, a gradual increase from 
Categories II to V. The difference was statistically significant between Category II 
and V lesions (Figure 23). 
 
 
Figure 22: Box and whisker plots to compare the number of lymphocyte 
aggregates in EG (Category I) and in all other lesions (Categories II-V). 
Statistical test (Mann-Whitney U) and the numbers representing outliers. 


















II (n=14)  III (n=13)  IV (n=23)  V (n=14)  
HE stain  64/64 15%  30%  35%  45%  
  
  
Based on the percentage of area occupied by viable eosinophils measured in 10 
representative HPFs within MCA. 
Figure 23: Box and whisker plots to illustrate the difference in the proportion of 
viable eosinophils in MCA in MCT (Categories II-V) 
Based on the percentage of area occupied by viable eosinophils measured in 10 
representative HPFs within MCA. *=P<0.05. Statistical test (Mann-Whitney U) and 
the numbers representing outliers. 
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Further statistical analysis showed a direct correlation between the size of the MCA 
(see 3.4.1) and the proportion of viable eosinophils in the MCA (P=0.012).  
3.4.10 Proliferation of mast cells (mitotic figures) in MCT  
 All lesions diagnosed as MCT (Categories II-V) were assessed for the proliferative 
activity of the mast cells, based on the number of mitotic figures (Figure 24). In 
category II there was only one case in which mitoses were seen. However, these did 
not exceed 1/10 HPF. In Categories III-V, mitotic figures became progressively 
more frequent, increasing from 1-2/10 HPF in 3/13 Category III lesions to 8-9/10 








Figure 24: Case No. 06L0445, MCT (Category V). A mitotic figure is evident among 
neoplastic mast cells (arrow). HE stain, 400x 
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Table 17: Proliferative activity of mast cells in MCT (Categories II-V) 
Mitotic 









II (n=14)  III (n=13)  IV (n=23)  V (n=14)  
 HE stain  29/64 
1 (8%)  
1/10 HPF  
3 (23%)  
1-2/10 HPF  
13 (57%)  
4/10 HPF  
12 (86%)  
8-9/10 HPF  
The number of mitotic figures progressively increased from Categories II to V, and 
the difference was significant between Category V and all the others, as well as 
between Categories IV and II (Figure 25).  
  
The number of mitotic cells per 10 high power fields (HPF) was counted in those cases 
where mitoses were detected, and an average provided.  
Figure 25: Box and whisker plots to illustrate the difference in the number of mitotic 
figures in MCA between the different categories representing MCT (II-V) 
*=P<0.05, **=P<0.01. Statistical test (Mann-Whitney U) and the numbers 
representing outliers. 
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3.4.11 Phagocytosis of eosinophils by macrophages in cases with MCA  
Phagocytosis of eosinophils by macrophages was observed within MCA in a 
proportion of MCT in Categories IV and V, where it was seen in 39% (9/23) and 
7% (4/14) of lesions, respectively. Phagocytosed eosinophils were generally found 
within the cytoplasm of the macrophages and occasionally exhibited morphological 
features of apoptosis, such as shrinking associated with chromatin condensation 







Figure 26: Case No. 15L-4057, Category IV. Several macrophages within 
the eosinophilrich MCA contain phagocytosed eosinophils (arrows) 
The inset shows a higher magnification of a macrophage with phagocytosed 
eosinophils that exhibits features of apoptosis. HE stain. 400x and 1000x. 
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3.4.12 Further analysis of eosinophils and EGC in Lendrum’s-stained 
sections  
The Lendrum’s stain highlighted the granules of eosinophils; they appeared bright 
red (Figure 27).  
 
However, the Lendrum’s stain also highlighed areas within the EGC that exhibited 
different distinct staining intensities; these were categorised as “intense red” (the 
actual stain of viable eosinophils), “purple”, “pale red” and “colourless” (Figure 
28).  
A  B  
Figure 27: Case No. 15L-4057, Category IV. The cytoplasmic granules of 
eosinophils stain bright red. Lendrum’s stain. A, 40x; B, 200x 
* 
  





Figure 28: Case No.07L-2956, category III. The ECG exhibits areas with different 
staining intensities. 
* = purple; ** = intense red; *** = pale red; **** = colourless. Lendrum’s stain. 100x.  
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The evaluation of all the lesions with EGC areas (Categories I-IV) identified these 
areas to be arranged in irregular concentric rings, with a colourless centre, 
surrounded by a pale and then intense red zone and separated from other tissue by 
a purple outer rim. It is evident that the internal part of EGC does not have a regular 
centrifugal development, but an “irregular onion ring” arrangement, according to 
the difference in staining as highlighted by Lendrum’s stain (Figure 29).  
  
  
Figure 29: Case No.06L1943, category III. “Onion ring”-like arrangement of zones 
with different staining intensity in an EGC. Lendrum’s stain. 40x 
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The comparative examination of the Lendrum’s stained sections with a consecutive 
von Kossa-stained section showed that the purple areas in the Lendrum’s stain were 
identical to the von Kossa-positive areas, i.e. represent mineralisation (Figure 30).  
 
The assessment of all lesions stained with both special stains showed a significant 
correlation between the von Kossa-positive areas and the areas that were purple 
with the Lendrum’s stain. This confirmed that both detected areas had 
mineralisation (Figure 31).  
Figure 30: Case No.3595, Category III. In the EGC, the purple areas highlighted by the 
Lendrum’s stain (A; arrow) correlates with the von Kossa-positive areas (B; arrow). 
40x 
Figure 31: Box and whisker plots to illustrate the difference in the percentage of 
Lendrum’s purple stained areas between cases exhibiting or not exhibiting von Kossa 
positive areas of mineralisation in EGC 
**=P<0.01. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
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The fading red colour, from intense red through pale red to colourless, was 
tentatively interpreted as representative of degranulation/degeneration of 
eosinophils, suggesting the following staining pattern in Lendrum’s stained 
sections:  
• Purple = mineralisation  
• Intense red = viable eosinophils  
• Pale red  = early degenerating/degranulating eosinophils  
• Colourless = late degenerating/degranulated eosinophils  
Assessing that the lesions that contained eosinophils (Categories I to IV) for the 
area within EGC covered by the four different staining patterns confirmed that the 
larger areas of mineralisation (purple colour) were more abundant within Category 
I lesions (on average 50% of EGC area). Intense red staining areas (representing 
aggregates of viable eosinophils) were most abundant in Categories II and III (31% 
and 44% of EGC area), whereas the pale red areas that were indicative of 
accumulations of early degranulating eosinophils increased from Category I (20%) 
over Categories II and III (33% and 31%) to Category IV (45%). Areas composed 
of degenerated (i.e. late degenerating) eosinophils were least abundant in Category 
I (5%), and accounted for 15%/14% in Categories II and III, and for 10% of the 
area in Category IV (Figure 29). The findings confirm that mineralisation is most 
pronounced in pure EG (Category I), and suggests that EGC areas in Categories II 
and III contain more viable eosinophils than the pure EG and EGC of Category IV 
lesions. Nonetheless, areas with degranulated eosinophils (early stage) became 
gradually more abundant from Categories II to IV. Interestingly, areas with 
eosinophils in late degranulation were again most abundant in Categories II and III 










The statistical analysis confirmed the above findings and highlighted that 
mineralisation was significantly more abundant in pure EG (Category I) than in 
MCT with EGC (Categories II-IV), while intense red, pale red and colourless areas 
were significantly more abundant in EGC areas within MCT (Categories II-IV) 
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Purple  Intense red Pale red colourless 
Figure 32: Comparison of the proportion of EGC areas with the different 
staining intensities after the Lendrum’s stain (N=81) 
Figure 33: Box and whisker plots to illustrate the difference in percentage of 
Lendrum’s purple stained areas in EGC within categories (A) and EG (Group 1) vs. 
MCT (Groups 2 and 3) (B) 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 



















Figure 34: Box and whisker plots to illustrate the difference in percentage of 
Lendrum’s dark red stained areas in EGC within categories (A) and EG (Group 
1) vs. MCT (Groups 2 and 3) (B) 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
Figure 35: Box and whisker plots to illustrate the difference in percentage of 
Lendrum’s pale red stained areas in EGC within categories (A) and EG (Group 1) vs. 
MCT (Groups 2 and 3) (B) 
**=P<0.01. Statistical test (Mann-Whitney U) and the numbers representing outliers. 

















When all the 724 individual EGC areas that were found in all the lesions were 
examined, the Lendrum’s stain results were further confirmed. There was a strong 
trend to associate dark purple areas (mineralisation) with Category I lesions (EG; 















Figure 36: Box and whisker plots to illustrate the difference in percentage of 
Lendrum’s colourless areas in EGC within categories (A) and EG (Group 1) vs. MCT 
(Groups 2 and 3) (B) 
**=P<0.01. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
Figure 37: Box and whisker plots to illustrate the difference in the percentage of 
Lendrum’s purple areas in EGC (n=724) among categories 
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3.4.13 Correlation of lesion size, mineralisation and possible age of the lesion  
The above results led to the formation of the following hypothesis: that a larger 
EGC lesion would be older and therefore more prone to dystrophic mineralisation.  
However, correlating the size of and the presence of mineralisation in EGC in the 
von Kossa-stained sections failed to find a general association between size and 
mineralisation of EGC areas (Figure 17). Interestingly, this was different when 
Category I lesions were examined on their own. Here, a correlation between size 






Figure 38: Box and whisker plots to illustrate the difference in EGC area (pixels) 
between cases of category I with Von Kossa positive or negative stain. 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers.  
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In the other categories there was no significant difference. In Category IV lesions, 


























Figure 39: Box and whisker plots to illustrate the difference in EGC area between 
cases of Category IV with or without Von Kossa positive stain in EGC 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
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3.5 Immunohistochemical detection of T cells (CD3+), B cells (CD79a+) and 
macrophages (Iba1+) in the different categories and groups  
 3.5.1 T cells  
T cells (CD3-positive) were found within lesions of all categories. They were found 
scattered throughout the lesions and associated predominantly with EGC areas 




*   
Figure 40: Case No.13L-3963, Category I. CD3 positive T cells infiltrating the 
surrounds of an area of EGC (asterisk). Immunoperoxidase, 200x 




There was an increase in CD3 positive cell density infiltrating Category I lesions 
compared to Categories II-V whether ollowing examination over 10 HPFs or 
assessed as an overall percentage of lesion area occupied by CD3 positive cells; 











Figure 41: Case No. 09L3044, Category III. CD3 positive T cells infiltrating a 
MCA area. Immunoperoxidase, 400x 
Figure 42: Box and whisker plots to illustrate the difference in CD3 positive cell density 
among categories evaluated in multiple HPFs (A) or at low power (B) 
                      A                                                                    B 
Statistical test (Mann-Whitney U) and the numbers representing outliers. 
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Comparing T cell (CD3-positive) density between EG (Group 1) and MCT (Groups 
2 and 3), a significant difference was found, with EG exhibiting an increased CD3 
positive cell density (Figure 43).  
 
3.5.2 B cells  
B cells (CD79a- positive) were only occasionally seen in association with the 
lesions. They were almost always clustered, forming follicle-like structures, with 
overlapping that was identified morphologically as lymphocyte aggregates (Figure 
44). These were either found intermingled with the lesions or close to their 
periphery.  
Figure 43: Box and whisker plots to illustrate the difference in CD3 positive cell 
density between EG and MCT evaluated in multiple HPFs (A) or at low power (B) 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
Figure 44: Case No. 11L-2349, Category I. CD79a positive B cells forming a 
discrete, follicle-like aggregate. Immunoperoxidase, 200x 
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Considering cases with at least one CD79a positive cell, the vast majority of cases 
was in Category I (Table 18).  











Percentage and numbers of cases in the indicated 
category 
  
 I (n=31)   II (n=14)   III (n=13)  IV (n=23)  V (n=14)  
CD79a 
IHC stain  
23/95 
 
 48% (15)  21.4% (3)   0   21% (5)   0  
 
When these cells were quantified there was a higher density of CD79a positive cells 
in Category I compared to the other categories (Fig.3.42). Due to the low number 
of cases exhibiting CD79a positive cells at all, a significant difference was only 
detected comparing EG (Group 1) against MCT (Group 2) (Figure 46).  
 
  
Figure 45: Box and whisker plots to illustrate the difference in CD79a positive cell 
density among categories evaluated in multiple HPFs (A) or at low power (B) 
                             A                                                                     B 
Statistical test (Mann-Whitney U) and the numbers representing outliers. 





















3.5.3 Macrophages  
Iba1-positive cells were large and pleomorphic, and morphologically consistent 
with macrophages. Iba1 was consistently expressed by epithelioid macrophages 
forming EGC and surrounding degenerated eosinophils, in addition to more 
random, scattered, and more peripheral macrophages (Figure 47).  
 
Figure 46: Box and whisker plots to illustrate the difference in CD79 positive cell 
density among EG and MCT evaluated in multiple HPFs (A) or at low power (B) 
 A B 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
Figure 47: Case No.11L-3991, Category I. Iba1 positive macrophages palisading 
around the core of an EGC, and are also found scattered as individual cells in its 
periphery. Immunoperoxidase, 200x 
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Iba1- positive macrophages were also consistently detected infiltrating MCA in 
association with mast cells (Figure 48). A variable mild positive reaction was also 





Figure 48: Case No.07L-3335, Category IV. Iba1- positive macrophages scattered in 
between mast cells in a MCA area. Immunoperoxidase, 200x 
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Comparing the different categories as well as EG against MCA, there was no 
difference in the number of Iba1-positive cells (Figure 49), except for a higher 




Figure 49: Box and whisker plots to illustrate the differences in Iba1 positive cell density 
among categories evaluated in multiple HPFs (A) or at low power (B) 
                               A                                                                       B 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
Figure 50: Box and whisker plots to illustrate the difference in Iba1 positive cell 
density among EG and MCT evaluated in multiple HPFs (A) or at low power (B) 
                         A                                                                      B 
*=P<0.01. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
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3.6 Cytokine and chemokine expression in EG and MCT  
This part of the study aimed to reveal a range of mechanistic and pathogenetic 
aspects of both MCT and EG, using an in situ approach based on the differential 
expression of a range of cytokines and chemokines that can be expected to influence 
the interplay between eosinophils, and other relevant cell populations in both 
entities (i.e. mast cells, macrophages and lymphocytes).  
While a commercial antibody was available for RANTES/CCL5, these lacked for 
the remaining markers of interest. Accordingly, an mRNA-ISH (RNAscope® 
technology) approach was taken, using a representative cohort of 10 cases 
(Appendix II –section A).  
3.6.1 Expression of RANTES/CCL5 (IHC)  
RANTES/CCL5 is known to be expressed in T cells, MPH, EOs and MCs, and to 
exert mediating effects to all these cells. We tested the antibody in the unaltered 
lymph node of a horse, and compared the staining with a consecutive section stained 
for the expression of the pan-T-cell marker CD3. The results indicate that RANTES 




Figure 51: Comparison of RANTES (A, C) vs CD3 (B, D) expression in a 
control lymph node 
Whereas abundant T cells comprise the paracortical T cell zones, only a minor 
subpopulation of these cells express RANTES (C). C and D represent higher 
magnifications of the insets of pictures A and B, respectively. IHC, immune-
peroxidase, A, B 50x; C, D, 400x.  




Indeed, RANTES expression was also observed mainly in lymphocytes in both 
types of lesions. However, in EG, as well as in palisading macrophages were found 
to be positive (Figure 52).  
 
RANTES-positive cells were significantly more numerous in EG (Category I) than 
in MCT (Categories III-IV) (Figure 53).  
 
(A) RANTES expression was observed mainly in lymphocytes and in palisading 
macrophages. 200x. (B) MCT. RANTES expression is restricted to some scattered 
lymphocytes. 400x. IHC immunoperoxidase.  
A B 
Figure 52: RANTES. (A) Case No. 09L-3297, Category I. (B) Case No. 06L1257 
(MCT-4). 
Figure 53: Box and whisker plots to illustrate the difference in the number of 
RANTES positive cells in EG (n=5) and MCT (n=5). 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
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3.6.2 Expression of Eotaxin/CCL11  
Eotaxin was generally expressed intensely in lymphocytes, macrophages and 
fibroblastoid cells in EG (Figure 54A). In contrast, MCT only very rarely 
exhibitedpositive cells, and only in some ulcerated lesions with infiltrating 
neutrophils, where focal eotaxin expression was seen in macrophages and 
fibroblastoid cells (not included in the cell counts). The MCA themselves always 






Figure 54: Eotaxin. (A) Case No. 13L-4160, Category I. (B) Case No. 11L-4484, 
Category IV. 
(A) Eotaxin expression was observed in lymphocytes, macrophages and fibroblastoid 
cells. (B) Focal eotaxin expression in macrophages and fibroblastoid cells in an MCT 
with infiltrating neutrophils (inset). The rest of MCA remain negative. mRNA-ISH, A 
600x, B 400x and 1000x (inset).  
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The eotaxin expression pattern suggests a major role of this chemokine in EG, but 
not in MCT. However, this difference was not statistically significant (Figure 55).  
  
  
Figure 55: Box and whisker plots to illustrate the difference in the average number 
of eotaxin positive cells in EG (n=5) and MCT (n=5) 
Statistical test (Mann-Whitney U). 
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3.6.3 Expression of MIPα/CCL3  
MIPα expression was detected in scattered lymphocytes, macrophages and some 
palisading macrophages in EG (Figure 56, A, B). In MCT, a very weak MIPα 
mRNA signal was detected in some lymphocytes (Figure 56, C)  
  
In both entities, the number of positive cells was very low. Nonetheless, the 
expression of MIPα was more intense in EG compared to MCT (Figure 57).  
  
A C B 
Figure 56: MIPα. (A, B) Case No. 13L-4160, category I. (C) Case No. 06L-1257, 
category IV. 
MIPα. (A, B) MIPα expression was detected in scattered lymphocytes and 
macrophages (A) and in some palisading histocytes (B) in EG.  
(C) Minimal expression of MIPα mRNA was detected in some lymphocytes in MCT. 
mRNA-ISH, A 400x, B200x, C100x and 1000x (inset). 
Figure 57: Box and whisker plots to illustrate the difference in MIPα positive cells 
between EG (n=5) and MCT (n=4) 
*=P<0.05. Statistical test (Mann-Whitney U) and the number representing outlier. 
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3.6.4 Expression of interleukin 4 (IL-4)  
IL-4 mRNA was detected in scattered lymphocytes in EG (Figure 3.55 A, B). 
Interestingly, no expression was seen in any cells in any of the MCT.  
  
A minimal expression of IL-4 was observed in this study, and only very few 




Figure 58: IL-4. (A) Case No. 11L-2439, category I. (B) Case no. 13L-4160, category I. 
IL-4 expression was detected in very scattered lymphocytes in EG. RNA-ISH, A 100x, 
B 100x and 1000x (inset). 
Figure 59: Box and whisker plots to illustrate the difference in IL-4 positive cells 
between EG (n=5) and MCT (n=3). 
Statistical test (Mann-Whitney U). 
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3.6.5 Expression of interleukin 5 (IL-5)  
In EG, IL-5 expression was restricted to some scattered individual lymphocytes 
(Figure 60, A). In MCT, a strong IL-5 signal was seen in a few scattered 
lymphocytes, and a less intense signal (faint dots) in some mast cells (Figure 60, 
B); overall, the expression was more intense than in EG.  
  
IL-5 expression was seen in significantly higher numbers of cells in MCT than in 
EG (Figure 61).  
  
A B 
Figure 60: IL-5. (A) Case No. 09L-3297, category I. (B) Case No. 15L-1571, category 
III 
(A) IL-5 expression in EG was restricted to some scattered lymphocytes (inset). (B) In 
MCT, IL-5 showed a strong reaction in a few scattered lymphocytes (arrow), and a less 
intense signal (faint dots) in some mast cells (arrowheads, inset). mRNA-ISH, A 100x, 
B 400x and 1000x (inset). 
Figure 61: Box and whisker plots to illustrate the difference in IL-5 positive cells 
between EG (n=5) and MCT (n=5) 
*=P<0.05. Statistical test (Mann-Whitney U) and the numbers representing outliers. 
Chapter 3: Results  
117 
 
Interestingly, a strong relation between the density of viable eosinophils (% of the 
area with eosinophils in HPFs) and IL-5 expression was observed within MCA 








Figure 62: Correlation between IL-5 mRNA-positive cells and viable eosinophils in 
MCA (n=5) 
Statistical test (Pearson correlation).  
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3.6.6 Expression of interleukin 13 (IL-13)  
EG showed intense IL-13 expression, mainly through lymphocytes and some 
palisading macrophages (Figure 63, A). In MCT, expression was less intense and 
restricted to some scattered lymphocytes (Figure 63, B).  
  
The difference in the number of IL-13 positive cells was statistically significant 




Figure 63: IL-13. (A) Case no. 09L-3297, category I. (B) Case No. 06L-1257, 
category IV 
(A) Intense IL-13 expression, mainly by lymphocytes (arrows) and fewer 
macrophages and palisading histiocytes (arrowheads). (B) A low expression of IL-13 
was observed in MCT, restricted to some scattered lymphocytes. mRNA-ISH, A400x, 
B 400x.  
Figure 64: Box and whisker plots to illustrate the difference in IL-13 positive cells 
between EG (n=5) and MCT 
Statistical test (Mann-Whitney U) and the number representing outlier.  
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3.6.7 Expression of transforming growth factor beta (TGF-b)  
TGF-β was found to be constitutively expressed in many different cell types, 
including mast cells and palisading macrophages in EG. Due to this generalised 
expression, a quantitative assessment was not attempted (Figure 65).  
  
3.6.8 Expression of stem cell factor (SCF/cKIT-L)  
SCF was found to be weakly constitutively expressed by endothelial cells and some 
vascular smooth muscle cells. Due to this generalised expression, a quantitative 
assessment was not attempted (Figure 66).  
  
 
Figure 65: TGFb. Generalised expression of TGFb in many cell types, including 
palisading histiocytes in EG (arrowheads) 
  
A B 
(A), Case No. 13L-4160, category I and mast cells (inset); (B), Case No. 11L-4696, 
category III. mRNA-ISH, A 400x, B 400x and 1000x (inset) 
A B 
Figure 66: SCF. (A) Case No. 15L-4903, Category I. (B) Case No. 06L-1257, Category 
IV 
Generalised weak expression of SCF in all cases in endothelial cells and some vascular 
smooth muscle cells. mRNA-ISH, A 400x, B 600x and 1000x (inset). 
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Table 19: Summary of the results obtained for the expression of cytokines and 
chemokines in EG and MCT 
 
 
 Abbreviations (cell type): Mast cells (MC), eosinophils (EO), macrophages 
(MΦ), lymphocytes (LC), endothelial cells and vascular smooth muscle cells 
(EC), palisading histiocytes (pHC), fibroblasts (spindle cells) (FB), other cell 
types (OC).  
Abbreviations (markers): RANTES (regulated on activation, normal T cell 
expressed and secreted), MIP1α (macrophage inflammatory protein-1α), 
SCF/cKIT-L (stem cell factor/c-KIT ligand), TGF-β (transforming growth 
factor-ß).  
  
3.6.9 Correlation between inflammatory cells and cytokine/chemokine 
expression  
When the inflammatory cells and the different cytokines and chemokines were 
analysed alongside each other to test for any correlation (Table 20), it became 
obvious that T cells (CD3-positive) were associated with RANTES and IL4 
expression (green shadow), and B cells (CD79-positive) were associated with 
RANTES, eotaxin, IL-4, and IL-13 expression (blue shadow). There was a direct 
correlation between the increase of eotaxin and IL-4 expression (yellow shadow), 
the increase of RANTES and IL-4 (grey shadow), and the increase in RANTES and 












Table 20: Cytokines and Inflammatory cell correlation (all cases) Spearman’s Rho 
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 CHAPTER 4: DISCUSSION  
4. Discussion  
The following discussion is based on the results obtained after the re-examination 
of the cases, following the creation of the categories and groups noted in Chapter 
Three. 
 4.1 Clinical data  
The clinical data collected in this study was based on the information provided by 
the referring veterinarian. Evaluation of the clinical data and case history 
information of all the 191 cases initially examined was undertaken without 
considering the final diagnosis after re-examination showed Thoroughbred (cross) 
and Arabs (cross), followed by Warmbloods, were most frequently represented and 
that males were more frequent in the study population than females. These results 
were confirmed when a subpopulation of 95 cases (for which a final diagnosis was 
obtained) were assessed.  
4.1.1 Breed, age and sex in horses with eosinophilic granuloma  
In the literature, eosinophilic granuloma had been reported as representing between 
3.5% and 12% of submissions to diagnostic laboratories (Valentine, 2005, Schaffer 
et al., 2013). Breed predilections had not been reported (Stannard, 2000; Pilsworth 
and Knottenbelt 2005; Scott and Miller 2011b, Wobeser 2015). In addition, 
investigations into nodular skin disease in horses did not identify any breed to be 
predominant in a cohort of 68 horses (van Der Zaag and Sloet Van Oldruitenborgh-
Oosterbaan, 2012). In the present study, Thoroughbreds (cross) and Warmbloods, 
followed by Arabians (cross) were the most frequently represented breeds among 
horses with a final diagnosis of EG. However, the study also showed that a large 
variety of different breeds could be affected. Nonetheless, even without performing 
a statistical risk association, our results suggest that the above listed breeds were 
overrepresented. The reason for the apparent higher incidence of EG in these three 
breeds is unclear. However, their frequency in the study cohort might simply 
represent their frequency among the horse population in the UK. This suggestion is 
given greater validity by a recent study that investigated global horse populations 
Chapter 4: Discussion  
123  
  
and tried to identify those breeds at risk of extinction. That study showed that the 
prevalence of different breeds varies around the world and not only showed that 
Arabians and Thoroughbreds are the most common breeds in European countries, 
but also that Warmblood horses that originated in Europe now represent 18% of 
horse breeds in the world (Khadka, 2010). Another reason could be that these 
represent more expensive horses for which owners would not spare the costs of a 
histological examination when a skin lesion was removed. In any case, a lack of a 
breed predilection for equine EG is in line with the findings in other species affected 
by eosinophilic granuloma: in neither cats nor dogs has there been any evidence of 
a breed predilection for EG (Bonello et al., 2012, Buckley and Nuttall, 2012, 
Mauldin and Peters-Kennedy, 2016).  
Most previous studies on equine EG did not find evidence of an age predilection 
(Stannard, 2000, Pilsworth and Knottenbelt, 2005, Scott and Miller, 2011b, 
Wobeser 2015), though one reported age as a possible factor to develop EG; the 
author found that horses affected with EG were predominantly younger than 10 
years (Valentine, 2005). Another study found that the mean age of horses with EG 
was 8.3 years, with an age range of 3-14 years (Van Der Zaag and Sloet Van 
Oldruitenborgh-Oosterbaan, 2012). In our study cohort, the mean age of horses with 
EG was 9 years, which is similar to the previous study, but showed a wider age 
range (2- 23 years) (Van Der Zaag and Sloet Van Oldruitenborgh-Oosterbaan, 
2012). There are differences compared to our study: first of all, we re-classified true 
EG and excluded lesions where aggregates of mast cells were present. Secondly 
there are a range of possible factors that may have influenced the results in the 
previous studies: Valentine (2005) confirmed that the number of EG was relatively 
small and that the data might be biased by the low numbers. Similarly, Van Der 
Zaag and Sloet Van Oldruitenborgh-Oosterbaan (2012) had a cohort of only seven 
cases examined within eight years from among a study population of 68 horses. 
Considering that EG is looked upon as a common disease in horses, it is surprising 
that these studies dealt with such low case numbers. However, it was suspected that 
attending veterinarians felt competent to make a diagnosis without a surgical biopsy 
when they observed grossly suggestive lesions in the saddle area or girth region 
(Van Der Zaag and Sloet Van Oldruitenborgh-Oosterbaan, 2012). The present study 
generated data from a substantially larger number of EG cases (n=98) and applied 
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a very strict diagnostic regime. It follows, ceteris paribus, that the data obtained is 
more likely to be more representative of the true age range of EG. However, it also 
confirms EG as a condition of middle-aged horses, though with a wide general age 
range. It has previously been argued that the incidence and nature of inflammatory 
skin lesions in horses may be influenced by geographical differences (Valentine, 
2005), and that environment and exposure to different causative agents may 
modulate the incidence of EG irrespective of the age (Schaffer et al., 2013). In cats, 
eosinophilic granuloma can occur at any age but is more common at younger ages 
(Bonello et al., 2012, Mauldin and Peters-Kennedy, 2016). In dogs, most authors 
agree that there is no age predilection (Vercelli, Cornegliani et al., 2005, Mauldin 
and Peters-Kennedy, 2016). That said, a few studies reported that EG is more 
common in young male Siberian Huskies and Cavalier King breeds (Bredal et al., 
1996).  
Most previous studies on equine EG did not report any sex predilection (Stannard, 
2000, Pilsworth, and Knottenbelt, 2005, Scott and Miller, 2011b, Schaffer et al., 
2013, Wobeser, 2015), though one found evidence that EG is more common in 
males (Valentine, 2005). Similarly, the current study does not suggest any sex 
prevalence. This is similar to the previous studies upon dogs and cats, where one 
study reported a higher incidence in females (Bonello et al., 2012), followed by 
another study which concluded that there was no sex predisposition in cats and dogs 
with EG (Mauldin and Peters-Kennedy, 2016).  
4.1.2 Breed, age and sex in horses with cutaneous mast cell tumour  
In contrast to EG, mast cell tumousr are relatively rare, representing only 3-7% of 
cutaneous and muco-cutaneous neoplasms (Scott and Miller, 2011c, Kiupel, 2017). 
In addition, in our study, MCT are far less frequent than EG (36% vs 64%).  
Most studies of equine MCT did not observe a breed predilection (Scott and Miller 
2011c, Van Der Zaag and Sloet Van Oldruitenborgh-Oosterbaan, 2012, Schaffer, 
2013). However, some recent studies have suggested that Arabians were more 
frequently affected. In one study this association was not statistically significant 
(Mair and Krudewig, 2008), whereas another showed that Arabian horses were 5.1 
times more likely to develop a MCT than other equine breeds (Clarke et al., 2014). 
A third study found MCT most frequently in Arabian (cross) and Thoroughbred 
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(cross) horses, but without a statistical risk association (Ressel et al., 2015). The 
latter results were carried further when a statistical correlation between breed and 
MCT was reported for Thoroughbred (cross) and Arabian (cross) horses (Knowles 
et al., 2016). This study also showed associations between MCT and Cob (cross) 
horses (Knowles et al., 2016). 
Our results are in line with those of the recent studies as Thoroughbreds and Arabian 
horses were the most affected breeds with MCT, followed in frequency by Welsh 
horses. The reason for the obvious MCT predisposition of different breeds might 
be due to a number of factors including the geographical area in which the case 
cohort was collected, and the length of the study. Interestingly, one study reported 
no cases of MCT in Thoroughbreds, although this breed accounted for 50% of the 
population (Scott and Miller, 2011c). As an additional observation, it is interesting 
to note that similar breeds are overrepresented in both EG and MCT. This supports 
the contention that one reason for overrepresentation might be a common genetic 
background.  
In the present study population, horses with MCT exhibited a higher mean age (11 
years) compared to those diagnosed with EG (9 years). This is in line with previous 
studies that have shown increasing age in horses to be a risk factor in the develop 
ment of neoplasia in general (Silva and Furr, 2013, Knowles). In addition, several 
studies on MCT showed mean ages ranging between 7 and 15 years, with age ranges 
from 1 to 30 years (Valentine, 2005, Clarke et al., 2014, McEntee, 1991, Van Der 
Zaag and Sloet Van OldruitenborghOosterbaan, 2012, Millward et al, 2010). In our 
study, we observed a similarly wide age range (3 – 25 years) which suggests that 
MCT may develop at any age in horses, like EG.  
For MCT, the present study found male horses to be more frequently affected than 
females. This finding is in agreement with previous studies (Mair and Krudewig 
2008, Scott and Miller, 2011c, Wobeser, 2015, Clarke et al., 2014, Ressel, 2015). 
However, one study disagreed and found no sex predisposition in a 10 year 
retrospective cases series; MCT comprised 2% of all tumours in the data set 
(Schaffer, 2013). No gender difference in dogs and cats affected with MCT has 
been reported (Blackwood, 2015, Kiupel, 2017). So far, there have been no studies 
into the possible reasons for this difference. The present study does not address this 
Chapter 4: Discussion  
126  
  
feature. However, considering what is known from humans regarding the role of 
mast cells in hypersensitivity and the crosstalk between eosinophils and mast cells, 
several studies have found correlations between sex and allergic inflammation, such 
as asthma involving oestrogen, eosinophils and mast cells (Cai et al.,2012, 
Keselman and Heller, 2015). A study demonstrated the possible role that oestrogen 
in the stimulation of Th2 cytokine production and eosinophil regulation in 
developing chronic inflammation, such as allergy and asthma, changes reported to 
be more frequent in females (Cai et al., 2012) but there are no data in regard to 
tumour development. However, oestrogen affects eosinophils in different ways and, 
depending on the receptors engaged, this can be different in different animal, and 
also differ between tissues in which the signalling is taking place, it also depends 
on whether the cells are analysed in vivo or in vitro (Keselman and Heller 2015). It 
is possible that such different signalling plays a role in the early stages of MCT 
development, but this needs further study.  
4.1.3 Body location, size and number of lesions  
Eosinophilic granuloma has been reported to be most commonly diagnosed on the 
neck and trunk (withers and back) of horses (Stannard, 2000, Pilsworth and 
Knottenbelt, 2005, Scott and Miller, 2011b, Mauldin and Peters-Kennedy, 2016). 
However, they can occur anywhere and may also be multifocal (Stannard, 2000, 
Mauldin and Peters-Kennedy, 2016). One study reported the specific location of 
seven EG cases and found four in the axillary region, and one each on nose, 
shoulder and buttock (Van Der Zaag and Sloet Van OldruitenborghOosterbaan, 
2012). In the present study, the trunk was the most common location, but eyelid, 
head, and limb and in conjunctiva were also affected in some cases.  
Equine cutaneous MCT are commonly found on the head, trunk and limbs (Mair 
and Krudewig, 2008, Scott and Miller, 2011c, Wobeser, 2015, Kiupel, 2017), but 
have also been reported in the eye, affecting the conjunctiva, sclera, Membrana 
nictitans, limbal area, cornea, third eyelid and the entire globe (Martin and Leipold 
1972, Hum and Bowers, 1989, McEntee, 1991, Ward et al., 1993, Malikides et al., 
1996, Bosch and Klein, 2005, Mair and Krudewig, 2008, Smiech et al., 2009, Halse 
et al., 2014, Kiupel, 2017, Shnaiderman-Torban et al., 2017, Flores et al., 2017). 
Tumours typically present as solitary immovable nodules on the head, trunk, neck, 
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and limbs, where they are often found close to joints (Scott and Miller, 2011c, 
Kiupel, 2017). Most tumours are neither painful nor pruritic and may be 
hyperpigmented, alopecic, or ulcerated (Mair and Krudewig, 2008, Kiupel, 2017).  
Usually, mast cell tumours in horses are benign and excision is curative as 
recurrence is uncommon (McEntee, 1991, Kiupel, 2017). Apart from affecting the 
skin, MCT occur at other body sites in horses, such as the mucous membranes and 
even testes (Brown et al.,2008), bone (Ritmeester et al.,1997), synovial membranes 
(Taylor et al., 2005) and in multicentric forms (Reppas and Canfield 1996, Tan et 
al.2007, Millward et al.,2010). Interestingly, one study even reported there was no 
apparent site of predilection for mast cell tumours (Schaffer et al., 2013). In the 
species most commonly affected by MCT, dogs and cats, MCT develop most 
frequently in the skin and subcutis at any site of the body (Blackwood et al, 2012, 
Kiupel, 2017, Sabattini and Bettini, 2010, Blackwood, 2015).  
The results of the present study also found the head to be the most frequently 
affected site, which is in line with previous studies (Valentine, 2006, Clark et al, 
2014, Ressel et al., 2015). However, different from others reports (Mair and 
Krudewig, 2008, Hales et al., 2014, Knottenbelt et al., 2015), the eye (conjunctiva 
and eyelid) was the second most commonly affected location (18.2%), followed by 
trunk, neck, and limbs. In the eye, the limbal area and occasionally the eyelids were 
found to be affected by MCT (Knottenbelt et al., 2015). There are a few case reports 
describing MCT in the conjunctiva (Hum and Bowers, 1989, McEntee, 1991) and 
eyelids (Van Der Zaag and Sloet Van Oldruitenborgh-Oosterbaan, 2012, Smiech et 
al., 2009, Shaiderman-Torban et al., 2017). MCT located in the eye belonged to 
Categories II-V in our population. The reason why the eye was more affected in our 
results compared to other studies is unclear. Interestingly, all but one ocular MCT 
case in existent literature were reported in females horses when the sex was stated 
(Worad et al., 1993, Hum and Bowers, 1989, Smiech et al., 2009; Halse et al., 2014, 
Shaiderman-Torban et al., 2017, Flores et al., 2017). In contrast, there is evidence 
of a predilection for male horses (Mair and Krudewig, 2008, Scott and Miller, 
2011c, Clark et al, 2014, Kiupel, 2017). In our cohort of MCT in the eye, four were 
found in females (conjunctiva (3) and eyelid) and six in males (conjunctiva (2) and 
eyelid (4), which does not confirm the trend indicated in the literature, suggesting 
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that MCT in the eye do not differ from those in other locations. The same is true 
with regard to age; the mean age of the ocular cohort was 11.5 years, and the range 
was 10 – 15 years.  
In the present study, the size of EG ranged from 5mm to 9cm in their major 
diameter, which is similarly to the size described (less than 1cm to more than 10cm) 
reported by, amongst others, Scott and Miller (2011b), Wobeser, (2015), and 
Mauldin and Peters-Kennedy, (2016). Similarly, MCT were reported to range from 
0.5mm to 20cm (Mair and Krudewig, 2008, Scott and Miller, 2011c, Clark et al., 
2014, Ressel et al., 2015). In the present study the MCT were equally variable, with 
size ranging from 2mm to 10cm.  
In the literature, there is no data as to the prevalence of single or multiple lesions 
with regards to EG and MCT. However, it is known that EG can present as single 
and multiple lesions (Scott and Miller, 2011b, Mauldin and Peters-Kennedy, 2016), 
while MCT usually occur as solitary lesions (Mair and Krudewig, 2008, Scott and 
Miller, 2011c). In the current study, EG were more common as single lesions, but 
also occurred as two or more lesions (25 cases). Interestingly, male horses were 
particularly overrepresented in cases of multiple lesions (60% of the males). The 
vast majority of MCT were single lesions (86%), with only 7 cases of multiple 
lesions.  
4.2 Morphological features  
The systematic morphological re-examination of a uniquely large cohort of 191 
cases with an initial histopathological diagnosis of MCT and/or EG revealed a 
number of features that would suggest strict criteria for a diagnosis of EG and MCT, 
respectively. Ultimately, the presence of mast cell aggregates (MCA) would lead to 
the diagnosis of MCT which could comprise more or less large proportions of EG 
components, whereas the diagnosis EG would exclude the presence of MCA. Based 
on the subsequent detailed examination of 95 cases, five categories of lesions were 
defined which were then grouped together into three groups of lesions and, 
ultimately, allocated to the two diagnoses, EG and MCT.  
Using this new scheme, the original diagnosis in the diagnostic reports was changed 
in 11 lesions (10.6%) from EG to MCT lesions, and from MCT to EG in 1% of 
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lesions. In most instances, this implied a shift from Category I to II and was 
therefore based on the identification of MCA within large EG areas, leading to 
reclassification from EG to MCT. The reasons for the reclassification could be the 
absence of strict criteria for the diagnosis so far, and an overlooking of MCA in EG. 
In the section that follows, the morphological features leading to the new 
classification are discussed.  
4.2.1. Size of lesion and proportion of EGC and MCA  
The results of the present study indicate that there are differences in lesion size and 
the number of EGC and MCA between categories. Lesions in Category I (i.e. “pure” 
EG) were predominantly small, and there was an increase in size from MCT 
belonging to Categories II, III, and IV. This suggests a potential temporal relation, 
making Categories II, III, and IV consecutive stages of MCT proliferation. 
Interestingly, Category V lesions were again smaller. This could be due to two 
reasons: first, that Category V lesions (“pure” MCT) could represent an earlier stage 
of Category II and III lesions. Second, that MCT size is influenced mainly by the 
associated EGC (present in Categories III and IV, but not in V). However, when the 
results of the measurements of EGC and MCA in the same lesion were compared, 
it appears that the component that drives the size of the lesion in Categories II and 
III is indeed the MCA. Further investigations with a known timeframe of lesion 
development is needed to better understand these differences.  
4.2.2. Location of lesions in skin and subcutis  
The morphological evaluation showed that the deep dermis is the most common 
location of all five categories, followed by the mid dermis and the subcutis. Despite 
this, it was also evident that lesions were rarely confined to one layer. As a 
consequence,  when the “depth score” was applied – it considered the depth of the 
lesion weighing all the layers involved, there was no difference between categories, 
groups or EG vs. MCT. This suggests that lesions can, in principle, extend to all the 
different layers. However, there is a clear tendency of lesions in Category I (“pure” 
EG) to extend to the superficial dermis, which was not seen in the lesions found in 
the other categories. This adds more precise information to that which is known 
from existent literature and states that EG exhibit nodular to diffuse areas of 
eosinophilic, granulomatous inflammation in the dermis and often the panniculus 
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(Scott and Miller, 2011b, Wobeser, 2015, Mauldin and Peters-Kennedy, 2016). It 
is also in line with another finding in the present study, the involvement of hair 
follicle in EG (see Chapter 4.2.4.).  
MCT are described as dermal and subcutaneous mast cell nodules (Doran and 
Collins, 1986, McEntee 1991). The subcutaneous layers are often involved, and the 
underlying superficial musculature may sometimes be infiltrated as well (McEntee 
1991, Ward et al.,1993, Mair and Krudewig, 2008, Millward et al., 2010, Scott and 
Miller, 2011c). Our study confirms the previous findings. According to Mauldin 
and Peters-Kennedy, (2016) mast cells are present in large numbers in dermis and 
subcutis of horses (Mauldin and Peters-Kennedy, 2016). This finding suggests these 
cells are likely to be the cells of origin of these neoplasms. Furthermore, Hales 
(2014) and Flores (2017) suggested that normal mast cells are present in the lamina 
propria of the conjunctiva, and these are likely to be the origin of this tumour in 
equine eyes (Hales et al., 2014, Flores, 2017).  
4.2.3. Presences of individual mast cells in areas of EG  
The present study found individual mast cells scattered throughout only 13 lesions 
(42%) of Category I (EG), while they were present in all lesions within Category II 
(MCT with EG > MCT components), and absent in all the other categories.  
Infiltrating mast cells have previously been described in EG (Brown, et al., 2007, 
Johnson, 1998). However, these studies did not apply the strict criteria that the 
present study has adopted. This, in turn, precludes a direct comparison. Our finding 
of individual mast cells within pure and thereby MCA-free EG is surprising as mast 
cells are not likely to play any role in the pathogenesis of eosinophilic granuloma 
formation. In this context it is possible that mast cells themselves or TAMs play a 
role in developing EG in MCT (see further discussion in Chapter 4.3.3.).  
Among MCT, only Category II lesions with small mast cell aggregates as the only 
MCT components exhibited individual mast cells within the EGC areas. If it is 
hypothesised that Category II lesions represent earlier MCT stages than Category 
III and IV lesions, then it  would follow that the the individual mast cells are single 
cells scattered part of the MCA in the early stages of lesions. However, such a 
hypothesis does not fulfil the general dogma of neoplastic cell growth where a 
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clonal and, therefore, centrifugal expansion is believed to be the driving force of 
the nodular formation of lesion. However, it is reported that in MCT neoplastic mast 
cells are arranged not jujst in ribbons or nests but may also sometimes be more 
individual (Clark et al., 2014, Kiupel, 2017). These could represent individual 
neoplastic cells or they might have invaded adjacent tissue.  
4.2.4. Association of EG with the hair follicle  
The literature does not report on an association between EG and hair follicle 
structures, a feature for which the results of the present study provide strong 
evidence. The present study observed a direct spatial association identified in more 
than half (52%) of the Category I lesions (EG) with hair follicle structures. UIt also 
recorded that this was entirely absent in all other Categories (II-IV, MCT). This 
result suggests that horses may have a specific form of furunculosis that is driven 
by eosinophils and macrophages. Considering the two main cellular components of 
EG, two potential pathogenetic mechanisms can be considered to underpin at least 
a proportion of EG cases. This could represent a different first line of sight against 
bacteria, which could represent the initiating trigger for the formation of the EG in 
Category I lesions.  
Interestingly, in some EG, free hair shafts have been reported in the dermis. These 
are usually linked to a history of body clipping prior to the occurrence of the lesions, 
which suggests a causal relationship (Stannard, 2000, Scott and Miller, 2011b) and 
that traumatically introduced hair fragments can provoke the inflammatory 
response (Mauldin and Peters-Kennedy, 2016).  
Folliculitis, i.e. inflammation of the hair follicle, is further classified into mural 
folliculitis (inflammation of the follicular epithelium), luminal folliculitis 
(inflammation in the follicular lumen), and perifolliculitis (inflammation around, 
but not significantly impinging on the follicle). Furunculosis is often associated 
with dermal inflammation which follows from the destruction of the follicular 
epithelium and leads to the release of luminal content into the dermis. Furunculosis 
has been observed in bacterial infections, dermatophytosis, demodicosis, and 
trauma (Scott and Miller, 2011a, Mauldin, and Peters-Kennedy, 2016). 
Furunculosis can also occur as a foreign body-type reaction to free keratin and hair 
shafts and is often associated with moderate numbers of eosinophils (Scott and 
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Miller, 2011a). In this context it is noteworthy that eosinophils play a relevant role 
in host defence and diseases: studies in humans have demonstrated that eosinophils 
contribute to defence against multiple (exogenous) agents, such as parasites, 
bacteria, viruses and fungi (Park and Buchner, 2010, Shamri et al., 2011). 
Eosinophils have antibacterial capacities, through ingestion of bacteria, or the 
release of bactericidal mediators (Shamri et al., 2011).  
Eosinophil granules play a key role against bacteria. Both major basic protein 
(MBP) and eosinophil cationic protein (ECP) were shown to cause permeabilisation 
of the outer and inner membranes of Escherichia coli. The same study also found 
evidence that the granules can translocate ECP and MBP into phagocytic vacuoles, 
thereby supporting ingestion of phagocytosed bacteria (Lehrer et al., 1989). On the 
other hand, Nakajima et al., (2001) showed that eosinophil RNases have in vitro 
bactericidal activity against E.coli and Staphylococcus aureus. In fact, through the 
production of superoxide in a nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase- and eosinophil peroxidase (EPO) - (but not nitric oxide) 
dependent manner, eosinophils can rapidly kill E. coli in in vitro studies (Persson 
et al., 2001). In addition, in vitro, all cationic granule proteins of eosinophils have 
shown to have bactericidal activity (Shamri et al., 2011).  
Furthermore, both Gram-negative and Gram-positive bacteria were shown to 
activate eosinophils, particularly E. coli, which can induce eosinophil chemotaxis, 
degranulation and respiratory burst (Svensson and Wenneras 2005, Hogan, et al., 
2013). MBP and EPO can be released from eosinophils even in the presence of low 
bacterial quantities, whereas higher bacterial numbers are required for the release 
of ECP (Svensson and Wenneras, 2005).  
Similarly, isolated mouse eosinophils were shown to possess anti-pseudomonal in 
vitro properties through the release of cationic secondary granule proteins (Linch et 
al.,2009). In addition, hypereosinophilic IL-5 transgenic mice exhibited a better 
ability to clear Pseudomonas aeruginosa from the peritoneal cavity, while 
eosinophil-deficient mice showed a weak ability to clear bacteria even after the 
adoptive transfer of eosinophils. The administration of material from eosinophil 
granules increased the ability of bacterial clearance in vivo (Linch et al., 2009). 
Eosinophils are also described to behave like neutrophils in forming NETs 
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(Neutrophilic extracellular traps) – like structured (i.e. mitochondrial DNA and 
granule proteins) that can trap and kill bacteria (Yousefi et al., 2008).  
Esinophils also express the necessary cellular machinery (innate immune receptors, 
proinflammatory cytokines, antibacterial proteins and DNA traps) to mount an 
efficient antibacterial response. However, the rapid decline in eosinophil numbers 
following acute systemic bacterial infection suggests a very limited role for 
eosinophils in bacterial responses, leaving many open questions on the role of 
eosinophils in bacterial infection also in humans (Hogan, et al., 2013).  
This large body of literature suggests that there is major role for eosinophils in 
antimicrobial defence. From this it can be concluded that eosinophils might 
contribute to effective immunity against bacteria through the coordination of 
antibacterial inflammatory cascades as well as the recruitment and activation of 
other cells (i.e. macrophages), via cytokines, chemokines and lipid mediators. It is 
possible that in horses, eosinophils are more involved in the antimicrobial defence 
than in other species. This, it is suggested, is particularly true with regard to contact 
infections of the hair follicles which can lead to an EG when the bacteria cannot be 
fully eliminated and the process becomes chronic.  
4.2.5. Focal mineralisation  
Focal mineralisation was a frequent feature of Category I lesions (64%). It was 
found in only 8%-21% of Category II-IV lesions and was entirely absent in 
Category V (“pure” MCT). The statistical evaluation confirmed a significant 
association of mineralisation with EG, which was not seen in MCT (Groups 2 and 
3). Mineralisation was only seen in areas of EGC, and may possibly be interpreted 
as dystrophic mineralisation.  
In general, mineralisation (calcium deposits) is a term used to describe the 
deposition of insoluble, inorganic minerals which consist of calcium in combination 
with phosphate or carbonate. The terms ‘mineralisation’ and ‘calcification’ are 
often used interchangeably as calcium is the dominant mineral in the deposit. 
Mineralisation is further classified into four basic forms; dystrophic, metastatic, 
idiopathic, and iatrogenic (Reiter et al., 2011, Kumar et al., 2015, Hargis and 
Myers, 2017).  
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The literature describes marked dystrophic mineralisation in older EG lesions and 
comments that this may be common and can lead to misdiagnosis as calcinosis 
circumscripta or mast cell tumours (Scott and Miller, 2011b, Wobeser, 2015, 
Mauldin and Peters-Kennedy, 2016). In equine MCT, dystrophic mineralisation is 
described to be frequently seen in areas of collagen degeneration and necrosis 
(McEntee 1991, Ward et al.,1993), old lesions seem to predominantly consist of 
fibrosis and dystrophic mineralisation, with only small packages of mast cells 
remaining (Mair and Krudewig, 2008, Scott and Miller, 2011c, Mauldin and Peters-
Kennedy, 2016). Some tumours may be dominated by an extensive stromal 
response (i.e. collagen bundles, fibroplasia), areas of dystrophic mineralisation, and 
large aggregates of eosinophils and foci of necrosis (Kiupel, 2017).  
So far, no studies have found differences in the presence and extent of 
mineralisation between EG and MCT.  
In the previous studies the HE stain was used as a means of identify mineralisation. 
The mineralised material itself varies from amorphous to granular and is variably 
basophilic (depending on the stage of mineralisation). Authors report that in 
granular areas, one can see a transition from intact eosinophils, to eosinophil 
granules and nuclear debris, to completely amorphous material (Scott and Miller, 
2011a). In dystrophic mineralisation, calcium salts deposit as basophilic, 
amorphous, granular material along collagen fibrils (Mauldin and Peters-Kennedy, 
2016, Scott and Miller, 2011a). However, the HE stain does not allow us to 
specifically identify calcium salt deposition. As a consequence, areas of 
mineralisation may not be evident or may be misinterpreted, and special stains such 
as the von Kossa stain should be applied (Zachary and McGavin, 2012).  
The present study extended its investigation into the focal mineralisation in EG and 
MCT. We hypothesised that if there is a link between age of the lesion and the 
extent of mineralisation (as suggested in previous publications), there should also 
be a link between the size of the lesion and the extent of mineralisation. However, 
the statistical analysis found no association between the presence of mineralisation 
(von Kossa positive areas) and the size of the EGC. Further analysis based on the 
purple stained areas in Lendrum’s’ stained sections (see Chapter 4.2.12.) suggested 
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that there is a link between size of EGC and mineralisation only in Category I 
lesions, but not in the lesions of the other categories.  
All these results suggest that mineralisation is a process that is relevant only in 
Category I lesions (EG). This is because it is only in this category that it is directly 
proportional to the size. This further implies that it is increasing with the age of the 
lesion. In contrast, in lesions of Category II-IV, mineralisation is not always part of 
the process of eosinophil degeneration within the granuloma core formation, while 
in Category I the vast majority of lesions exhibit mineralisation. Despite the 
presence of cellular debris within the granuloma core, (which could suggest that the 
mineralisation is dystrophic and related to cell necrosis), a different pathogenetic 
mechanism cannot be ruled out. This is particualrl true when one considers that 
primary degeneration of collagen can be a cause for the development of the 
eosinophilc granuloma in the first place (Stannard, 2000).  
One of the hypotheses for the causes of EG is degeneration of collagen (Stannard, 
2000). Mineralisation can affect individual or groups of collagen fibres, resulting 
in increased basophilia and fragmentation of fibres in HE-stained sections. Calcium 
deposits can trigger a granulomatous inflammatory response - as a foreign-body 
reaction to the deposit (Hargis and Myers, 2017).  
Dystrophic mineralisation occurs because of injury or degeneration of cellular and 
extracellular components, with normal serum calcium concentrations and calcium 
metabolism (Kumar et al., 2015, Hargis and Myers, 2017). It is often seen in 
granulomas and calcinosis cutis as well as with hyperadrenocorticism. Trauma can 
cause tissue mineralisation as a final consequence (Zachary and McGavin, 2012, 
Hargis and Myers, 2017). Metastatic mineralisation occurs with hypercalcemia due 
to abnormal concentrations of calcium metabolism, phosphorus, or vitamin D, 
without preceding tissue injury or degeneration. This type of mineralisation is 
usually seen in soft tissue with chronic renal disease or other pathology that leads 
to parathyroid hyperplasia (Zachary and McGavin, 2012, Hargis and Myers, 2017). 
The term “idiopathic calcification” is used when there is deposition of calcium salts 
without underlying tissue damage or abnormal calcium or phosphorus metabolism, 
with unknown causes. Iatrogenic calcification occurs in human patients that are 
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receiving calcium or phosphate containing substances (Zachary and McGavin, 
2012).  
It is clear that different factors can cause mineralisation in EG and MCT. 
Considering that IL-5 was observed expressed more frequently in MCT compared 
to EG (see Chapter 4.2.14.), and that mineralisation is associated with EG/EGC 
rather than with MCA, the following interpretation can be made: In view of the role 
of IL-5 in maintaining the viability of eosinophils, dystrophic mechanisms are 
likely to be the key to mineralisation in Category I lesions. However, further studies 
are needed in order to investigate whether or not this is correct and to ascertain as 
to whether different or additional mechanisms, such as collagen degeneration 
followed by mineralisation, are involved.  
4.2.6. Focal ulceration  
The present study identified focal ulceration of the skin in association with both EG 
and MCT. With EG lesions, skin and haircoat are typically unaltered, and the 
lesions are not associated with signs of pain or pruritus (Stannard, 2000, Scott and 
Miller, 2011b, Mauldin and Peters-Kennedy, 2016). However, if challenged by 
traumatic injury (which is a likely event due to the fact that they are exophytic), 
lesions may ulcerate and necrosis may develop as well as crusts and alopecia at the 
site of the nodules (Stannard, 2000).  
In MCT lesions, the overlaying skin is usually normal and intact, but 
hyperpigmentation, alopecia or ulceration can occur (Riley et al., 1991, Mair and 
Krudewig, 2008, Millward et al., 2010, Scott and Miller, 2011c, Mauldin, and 
Peters-Kennedy, 2016, Kiupel, 2017). Lesions are generally painless or non-
pruritic, but are reported to occasionally discharge caseous material (Mair and 
Krudewig, 2008, Scott and Miller, 2011c).  
Based on the previous reports and our findings, ulceration is considered a secondary 
event that is most likely unrelated to the pathogenesis of the two conditions. Rather, 
it is perceived to be a consequence of mechanical forces (trauma) on the surface of 
the nodule; a likely event in horse skin.  
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4.2.7. Presence of collagen fibres within EGC areas  
Collagen fibres or their fragments were found embedded in almost all EG lesions 
(93%) using Masson Trichrome-stained sections. In addition, Category I (EG only) 
showed significantly more collagen fragments within the granuloma core than the 
other categories within their EGC. This suggests that collagen may be involved in 
granuloma formation in true EG, but not in the development of EGC areas in MCT. 
However, it is possible that collagen is also an innocent bystander in some lesions, 
especially if not degenerated.  
A link between degenerate collagen fibres and a granulomatous host response has 
been made before regarding collagen acting like a foreign body (Stannard, 2000). 
When previously reported, collagen fibres within equine EG appeared to be normal 
in size, surface contour, and consistency when stained with trichrome (Fernandez 
et al., 2000, Scott and Miller, 2011a).  
As a result, collagens fibres which have been shown to exhibit irregularities, 
granularity and fuzziness in HE-stained sections are likely to be coated with red-
staining material, masking the classical green stain in Masson’s trichrome stained 
sections. This phenomenon is, however, believed to not be necessarily associated 
with “collagen degeneration” or “collagenolysis” (Fernandez et al., 2000, Scott and 
Miller, 2011a).  
The term “flame figure” refers to an area of collagen which is surrounded by 
eosinophils and eosinophil granules, (Fondati et al., 2001, Scott and Miller, 2011a, 
Scott and Miller, 2011b, Ackerman 2017). The eosinophilic material varies in shape 
(i.e. annular to oval, to a radiating configuration (“starburst”) appearance). These 
areas consist of intact eosinophils, eosinophil granules and nuclear debris and 
completely amorphous material (Scott and Miller, 2011a, Ackerman, 2017). 
Collagen fibres within flame figures can appear normal, but can also be swollen, 
irregular or fuzzy, and granular (Fondati et al., 2001, Scott and Miller, 2011a, 
Ackerman 2017).  
Other findings regarding the structure of the collagen fibres are at ultrastructural 
level (using transmission electron microscopy) and were generated on feline 
eosinophilic granuloma (FEG) complex lesions. These indicate that fibres can be 
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disrupted, but not degenerated (Bardagi et al., 2003). Furthermore, studies on 
Wells’ syndrome in humans and FEG suggested that insoluble eosinophil granules 
provoke the granulomatous reaction seen around flame figures (Brehmer-
Andersson et al., 1986, Fondati et al., 2001). In addition, recruitment and 
degranulation of eosinophils were suggested as the primary events in FEG and 
collagen fibres are unlikely to play any actual role in the pathogenesis of this disease 
complex. Rather, they act as bystanders that play a secondary role (Bardagi et al., 
2003).  
The results of the present study indicate that collagen fibres are morphologically 
normal within the area of flame figures in the granuloma core in equine EG, which 
suggests no causative role of collagen in the granulomatous inflammation. It 
indicates, similar to what has been speculated for FEC, that eosinophil 
degranulation is indeed the primary event in the pathogenesis of EG. However, 
further studies are needed to elucidate this aspect.  
4.2.8. Lymphocytes aggregates  
Lymphocytes aggregates (which were characterised as consisting of B cells, (see 
Chapter 4.2.13.2 B cells) were mainly a feature of EG (Category I) rather than of 
MCT (Groups 2 and 3). This suggests that B cells’ response dose not play a role in 
MCT.  
Previous studies did not investigate the lymphocyte populations in equine EG and 
only reported that EG can contain lymphoid aggregates and that they may be 
prominent (Scott and Miller, 2011b, Mauldin and Peters-Kennedy, 2016). The 
present study confirms the presence of lymphoid aggregates in Category I (65% of 
lesions). These were almost entirely composed of B cells (see Fig. 3.42). In 
addition, a few lesions (three lesions in Category IV) exhibited lymphoid 
aggregates, a feature that has so far only been reported in feline MCT. A study in 
cats detected lymphocytic foci in 40% of well-differentiated MCT, 85% of 
pleomorphic MCT and in all atypical MCT. However, the potential role of these 
lymphoid aggregates in feline MCT is still unclear (Sabattini and Bettini, 2010). 
Due to the rarity of the phenomenon in our population, it cannot be excluded that 
this is an incidental and unrelated finding, especially since no statistical association 
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was found between lymphocytes aggregates and in any of the categories apart from 
Category I.  
B cells play a defensive role against exogenous agents, such as bacteria, and activate 
the production of antibodies (i.e. through plasma cells) thereby supporting the 
immune function of T helper cells (Tizard, 2013, Murphy and Weaver, 2017). 
Considering the frequent association of Category I lesions (EG) with thesuperficial 
dermis and hair follicles with “furunculosis-like” granuloma formation discussed 
above, the presence of B cell aggregates further supports an exogenous cause for a 
proportion of EG cases.  
4.2.9. Infiltrating viable eosinophils in MCA  
The present study found evidence of an increase in the proportion of viable 
eosinophils infiltrating MCA within higher category numbers. There was aksi an 
increasingly large MCA component in the MCT. Within existent literature MCT 
are usually reported to contain large numbers of viable eosinophils between the 
neoplastic mast cells (Scott and Miller, 2011c). In both large and small animals, 
MCT are infiltrated by eosinophils, which is believed to be the effect of chemotactic 
factors and cytokines (Hill et al., 1991, Riley et al., 1991, Ritmeester et al., 1997, 
Govier, 2003). In our study, the more MCA dominate the lesions compared to EGC, 
the more eosinophils are infiltrating the MCA, which suggests that mast cells play 
a relevant role in recruiting eosinophils into the lesion. As a consequence, in EG 
(Category I lesions), the recruitment of eosinophils into the lesion to form the core 
of the EG must be mediated by other cells and mechanisms. Considering the 
increased expression of IL-5 by tumour cells or TAMs in the MCT compared to 
EG, it is likely that cytokine plays a role in eosinophil recruitment into MCT, but 
not in EG. Indeed, IL-5 is the most important cytokine produced by mast cells in 
humans and animals and is particularly responsible for the survival of eosinophils 
(Tai et al., 1991, Bagley et al., 1997, Park and Bochner, 2010, IImarinen, et al., 
2014, Shen and Malter, 2015, Wen and Rothenberg, 2016).  
4.2.10. Mitotic figures in MCA  
The assessment of mast cells in MCT (Categories II-V lesions) for their 
proliferative activity based on the presence of mitotic figures showed obvious 
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differences between the categories, with significantly higher numbers in Category 
V lesions (8-9/10 HPF) compared to the number of lesions in all other categories, 
and in Category IV (4/10 HPF) compared to Category II (1-2/10 HPF). This result 
indicates that proliferative activity is proportional to the relative abundance of MCA 
in MCT.  
Within existent literature only a few studies have investigated the mitotic activity 
in larger cohorts of MCT in horses. McEntee (1991) investigated 30 MCT and 
found that mitotic figures varied (1-10/HPF). Another study investigated 72 MCT 
and only found three (4%) with more than two mitoses in 10 HPF (Clark et al., 
2014). Similarly, Ressel et al., (2015) investigated 45 cases and found 18 horses 
exhibiting a number of mitotic figures up to 6 per 10 HPFs. These findings suggest 
a variable growth rate in equine MCT. Further systematic studies are needed to 
assess whether this also results in differences in biological behaviour.  
4.2.11. Macrophages phagocytosing eosinophils  
In some MCT, macrophages engulfing eosinophils were observed. This was not a 
feature in EG. Several studies suggest that the phacogytosis of eosinophils follows 
programmed cell death (apoptosis) of these cells (Stern et al., 1992).  
Apoptosis is an essential mechanism to limit cell numbers in human and animals 
and is the most common form of physiological cell death (Park and Bochner, 2010). 
It has been proposed as a potential mechanism that contributes to the resolution of 
eosinophilic inflammation (Simon et al., 1997). There is abundant data in humans 
and animal models which demonstrates the underlying mechanisms for the different 
pathways that lead to eosinophil apoptosis and death (Park and Bochner, 2010). 
Eosinophils die by passive apoptosis (spontaneous) which includes IL-5 and its 
signalling pathway, mitogen-activated protein (MAP) kinase, caspases, and Bcl-2 
family members (Ilmarinen et al., 2014, Park and Bochner, 2010). In contrast, 
active apoptosis involves Fas, Siglec-8 and Siglec-f, TGF-β, CD30, corticosteroids, 
lidocaine, and IRp60/CD300a (Park and Bochner, 2010).  
The key cytokines for eosinophil survival are IL-5, IL-3 and GM-CSF with CD125, 
CD123 and CD116 as their respective receptors. These receptors have a specific α-
chain, but share the β-chain which causes an overlap in their functions and leads to 
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mediate transduction signals to initiate apoptosis of eosinophils (Geijsen et al., 
2001, Shen and Malter, 2015). The intracellular pathways (Lyn, Jak2, Raf1 and 
MAP kinases) are vital to inhibit apoptosis and allow eosinophil survival under the 
influence of IL-5, IL-3 and GM-CSF (Simon and Alam, 1999). A study 
demonstrated that eosinophils exhibit prolonged survival depending on Lyn 
tyrosine Kinase phosphorylation (Simon et al., 1998).  
Caspases are a family of conserved cysteine proteases that play a major role in 
apoptosis (Pop and Salvesen, 2009, Salvesen, 2002). Functionally, caspases are 
classified into initiators (caspase 8, 9 and 10) and effectors (caspase 3, 6 and 7). 
These cysteine proteases are present within cells as inactive zymogens which need 
to be cleaved to generate free catalytic subunitsthat associate and form active 
heterotetramers to induce apoptosis (Fuentes, Prior and Salvesen, 2004, Park and 
Bochner, 2010, Salvesen, 2002). Eosinophils have been described to express 
caspases 3, 6, 7, 8 and 9, and these caspases are associated with spontaneous 
eosinophil apoptosis (Dewson et al., 2001, Ilmarinen et al., 2014). In addition, Bcl-
2 family members are crucial to monitor intracellular damage and for mitochondrial 
membrane permeabilisation (MMP) in the intrinsic pathway of apoptosis. Several 
studies suggest that eosinophils contain small numbers of mitochondria, which are 
involved in the induction of apoptosis (Ilmarinen et al., 2014, Park and Bochner, 
2010, Tait and Green, 2010).  
Many factors can significantly prolong eosinophil survival and delay spontaneous 
apoptosis, such as pathogens, cytokines (i.e TNF-α, leptin, interferons) and 
allergens (Ilmarinen et al., 2014). In contrast, there is active apoptosis by Fas 
(CD95, APO-1), a cell surface receptor expressed on eosinophils as well as many 
other cells such as T cells and fibroblasts. Fas mediates apoptosis when ligated by 
agonistic antibodies or its natural ligand, FasL (Park and Bochner, 2010). Fas has 
been shown to be able to modify eosinophil survival and induce apoptosis of 
eosinophils (Matsumoto et al., 1995). In addition, eosinophils apoptosis by Fas can 
be only partially overcome by IL-5 (Letuve et al., 2001), and it can be further 
promoted by glucocorticoids (Druilleh et al., 1996).  
Glucocorticoids are pharmacological agents that are able to cause a marked 
reduction in eosinophil numbers in vivo (Schleimer, 1990). This effect can only be 
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overcome by high concentrations of IL-5 (Welsh and Wardlaw, 1997). 
Glucocorticoids accelerate eosinophil apoptosis and engulfment by lung 
macrophages (Megahaer et al., 1996). They inhibit eosinophils to respond to GM-
CSF (Lamas et al., 1991) and inhibit cytokine-mediated eosinophil survival 
(Wallen et al., 1991). Interestingly, horses with EG respond to steroid 
(glucocorticoid) therapy, but not horses with MCT (Kiupel, 2017). Furthermore, 
other agents can induce and mediate eosinophil apoptosis, including Siglec 8TGF-
β (Alma et al., 1994), CD30 (Matsumoto et al, 2004) and Lidocaine (Okada et al., 
2004).  
Regardless of the mechanism involved, during apoptosis, eosinophils express 
phosphatidylserine on their plasma membrane which leads to their recognition and 
engulfment by macrophages. This process is important as the failure of 
macrophages to clear these cells may lead to secondary necrosis and the release of 
eosinophil granule proteins as well as other pro‐inflammatory mediators (Farahi et 
al., 2011).  
Notably, in a study conducted in 1992 by Stern and colleagues about the 
programmed cell death of eosinophils, eosinophils were recognised and ingested as 
intact cells (phagocytosis) by macrophages in vitro. This study described the 
mechanism of apoptosis for aged human eosinophils but not fresh or aged pre-
apoptotic eosinophils, which eventually leads to phagocytosis of the whole cell by 
macrophages. This process was regulated under the influence of IL-5. Furthermore, 
this study showed evidence that IL-5 plays a major role in supporting eosinophil 
survival but does not prevent the apoptosis mechanism completely. The researchers 
concluded that apoptosis and ingestion by macrophages could represent a 
mechanism whereby tissue longevity and removal of eosinophils is controlled 
(Stern et al., 1992).  
Interestingly, it was then shown that IL-5 enhances the phagocytosis by 
macrophages and that it also increases the ability of macrophages to kill bacteria. 
Such observations suggest that IL-5 augments the macrophage functions in MCT 
to engulf eosinophils (Linch et al., 2012). These observations support the present 
finding that there is higher IL-5 production in MCT which increases eosinophil 
survival. However, the eosinophils will eventually die due to apoptosis, which leads 
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to recognition of the eosinophils and phagocytosis (ingestion) by macrophages as 
intact cells (Stern et al., 1992).  
4.2.12. Further analysis of eosinophils and EGC in Lendrum’s stained 
sections 
The present study demonstrated that Lendrum’s stain highlights the eosinophil 
granules and also yielded different staining colours (purple, intense red, pale red) 
or colourless areas in EGC. In HE stained sections of EGC, the central necrotic 
granuloma core usually exhibits granular to amorphous eosinophilic material, 
which consists of intact eosinophils, eosinophils granules and nuclear debris, and 
entirely amorphous material (Scott and Miller, 2011a). However, no real difference 
in colour is appreciable.  
The Lendrum’s stain is used routinely in diagnostic laboratories to assess the 
presence of eosinophils (Bancroft and Gamble, 2008, Crocker and Burnett, 2005). 
It has been used effectively to count eosinophils in dental disease-associated 
syndromes such as TATE (tumour associated tissue eosinophilia) (Alkhabuli and 
High, 2006, Peter et al., 2015, Vaibhav et al., 2018). However, eosinophils in tissue 
usually have an amoeboid or “medusa” cell shape, especially in fibrous tissue or 
inflammatory infiltrates. It follows that their identification in routinely stained 
sections may be hard (Lorena et al., 2003, Lowe et al., 1981, Lendrum 1944). 
Lendrum’s stains eosinophils selectively and intensely, which enhances the ease of 
counting (Peter et al., 2015, Ladke Vaibhav et al., 2018).  
Surprisingly, the morphological evaluation of EG using Lendrum’s stain 
demonstrated that the granuloma core does not follow a regular centrifugal 
development as expected, but an “irregular onion ring” like arrangement, with 
different orders of colour change, overlapping each other. Purple areas in 
Lendrum’s stain overlapped perfectly with von Kossa positive areas. This result 
shows the capability of Lendrum’s stain to demonstrate mineralisation. In the 
present study it identified mineralised necrotic material deriving from eosinophils.  
In addition, in the present study, EGC areas in both EG and MCT exhibited different 
colours and yielded four patterns (purple, intense red, pale red and colourless). This 
leads to the hypothesis that eosinophil granules lose their affinity for Lendrum’s 
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stain in a way that is proportional to their degree of degeneration. This hypothesis 
was supported by the fact that, despite the complex and onion-ring like 
arrangement, there was always a continuity between colours with the following 
sequence being noted: intense red - pale red - colourless, from the external portion 
to the core. When purple (mineralisation) was present, this tended to be at the 
periphery.  
This result demonstrates that it is more likely that there will be mineralisation in 
true EG and on the other hand eosinophils intact or with fading/lacking granules 
(degenerating/degranulating) in MCT. The presence of more mineralisation in the 
core of EGC of Category I may suggest that there is more dystrophic mineralisation 
in those areas, possibly coming from eosinophils necrosis. In contrast, the increased 
intense red stain in MCT compared to EG coupled with higher numbers of 
infiltrating viable eosinophils may suggest the ability of neoplastic mast cells to 
keep eosinophils survival due to IL5 and eventually eosinophils dies by apoptosis.  
4.3 Assessment of T cells, B cells and macrophages  
4.3.1 T cells  
CD 3 was used as a marker to identify T cells in the present study. T cells regulate 
adaptive immunity and are responsible for cell-mediated immune responses 
(Tizard, 2013, Day and Schultz 2014, Murphy and Weaver, 2017). Migrating 
lymphocytes are important regulators for efficient immune responses. T cell 
trafficking is the first and initial response. In this process, naïve T cells migrate 
through the specialised endothelium of secondary lymphoid organs and the primed 
T cells exert their function by infiltrating through capillary venules into the tissues 
and to their designated antigenic site (Oelkrug and Ramage, 2014, Carman and 
Martinelli, 2015). In addition, activation and differentiation of T cells into effector 
or memory lymphocytes induces the expression of specific receptors (Zhu et al., 
2010). The chemokine environment plays a pivotal role in controlling lymphocyte 
trafficking (Stein and Nombela-Arrieta, 2005). Chemokines are typically involved 
in the recruitment of lymphocytes, and their secretion by tissue has been proven to 
have an effect on the recruitment of certain T cells (Oelkrug and Ramage, 2014). 
Furthermore, macrophages express major histocompatibility complex (MHC) class 
II molecules on their surface, and present antigens to lymphocytes (Mantegazza et 
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al., 2013, Suzuki and Luo, 2017). When macrophages engulf a microbe, its antigens 
are processed and exposed on the outer surface of the plasma membrane where they 
will be recognised by T helper cells (Mantegazza et al., 2013). At the site of chronic 
inflammation, both pro-inflammatory cytokines and chemokines work in 
coordination and attract mature eosinophils to the site (Barnes, 2008, Ghosh et al., 
2013). It is also the case that eosinophil recruitment and production is largely due 
to the stimulation of Th2 lymphocytes, as well as numerous cytokines (i.e. IL-3, IL-
4, IL-5, IL13), and GM-CSF (Davoine and Lacy, 2014, Kita, 2013, Kita, 2011, 
Long et al., 2016). The way of eosinophil trafficking to inflamed tissues is 
monitored by T cells responding to antigen presenting cells (Eng and Deflice, 
2016).  
Imunosurveillance by T cells is the fundamental process which the immune system 
uses for defence against cancer. However, T cell-mediated responses against 
tumour cells are usually slow and less efficient than responses against pathogen 
antigens (Govers, et al., 2010).  
The evaluation of the distribution of T cells (CD3-positive) in lesions of the five 
categories, demonstrated a high numbers of T cells in Category I lesions. These 
diminished to a minimum in Category V. T cells were higher in number in EG than 
in MCT. This result suggests more intense T cell recruitment into EGC of EG, and 
this is likely to be a consequence of different kinds of stimuli (exogenous and/or 
endogenous, as suggested by involvement of hair follicles and hitherto discussed). 
It is also possible that T cells are involved in eosinophil recruitment into EG more 
than into MCT. However, relevant numbers of T cells are also present in MCT and 
this suggests that T cells are involved in the cell crosstalk in both types of lesions, 
with a suspected major role in EG. In fact, interaction with eosinophils and mast 
cells is reported to play a major role in the modulation, activation and recruitment 
of T cells (Rothenberg and Hogan, 2006).  
4.3.2 B cells  
In this study, CD79a was used as a marker to identify B cells. B cells play a key 
role in inflammation and are essential in humoral and adaptive immunity (Chaplin, 
2010). They are generated and matured in bone marrow and differentiate in the 
spleen and lymph nodes into naïve, follicular or marginal zone B cells (Pieper et 
Chapter 4: Discussion  
146  
  
al., 2013). The marginal zone B cells are partially activated in conjunction with 
macrophages and dendritic cells, and exposed to antigens present in blood. In turn 
they provide a rapid humoral response to any challenges (Muppidi et al., 2011, 
Cerutti et al., 2013, Zouali and Richard, 2011). Marginal B cells contribute early in 
the adaptive response and following activation, and form short-lived plasma cells 
that secrete antibodies (Cerutti et al., 2013, Hoffman et al., 2016, Murphy and 
Weaver, 2017, Tizard, 2013, Zouali and Richard, 2011). B cells become active 
when they encounter an antigen (internalise and process). Thereafter they present it 
to a perfectly matched T-helper cell which then helps to activate the B cell 
(Hoffman et al., 2016, Murphy and Weaver, 2017, Tizard, 2013). They are activated 
by many antigens, especially monomeric proteins. The process requires both 
binding of the antigen by the immunoglobulin on the B cell surface, the B-cell 
receptor, and interaction of the B cell with antigen-specific helper T cells (Avalos 
et al., 2014, Murphy and Weaver, 2017). B cells are the sources of antibodies and 
also act as antigens to other effector cells, modulating antibody-mediated rejection 
(Lim et al., 2015).  
However, little is understood so far about B cell-eosinophil interaction and the 
ability of eosinophils to travel to the rich B cells areas has not, to date, been 
illustrated (Prussin et al., 2013). Interestingly, a study in human and animal models 
in vitro demonstrated that eosinophils play a role to regulate the humoral immunity 
via their impact on B cell homeostasis and proliferation upon activation (Wong et 
al., 2014).  
The evaluation of the distribution of CD79a-positive B cells in the five categorise, 
demonstrated CD79a-positive B cells in only few lesions; these were almost 
exclusively EG (Category I). Some Category I lesions exhibited follicle-like B cell 
accumulations and a spatial relation of EGC to hair follicles. Such B cells could 
represent a component of the more generic response against the causative agent 
which leads to the formation of the EG. It is possible that there is no direct role for 
B cells in the genesis of the EGC, and that this represents the humoral part of the 
immune response generated by the causative agent.  
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4.3.3 Macrophages  
In the present study, Iba1 was used as a marker to identify macrophages. The 
evaluation of the density of Iba1-positive macrophages in the five categorise 
demonstrated large numbers of macrophages infiltrating both EG and MCT. There 
was a slightly higher macrophage density in EG compared to MCT.  
Macrophages play a role in granuloma formation. Macrophages are detected 
forming a palisading layer of cells surrounding the granuloma core (epithelioid 
macrophages) and are also responsible for the formation of inflammatory giant cells 
often associated with this type of inflammation (Hilhosret et al., 2014). Presumably, 
difficult-to-eliminate antigens lead to the induction of monocytes and macrophages 
to form a complex granuloma structure based on activating signals from other cell 
populations (Williams and Williams, 1983). Granulomatous infiltrates reflect 
typical immune responses and are associated with inflammation and the potential   
for tissue destruction (Gordon, 2003). In inflammation, granuloma predominately 
consists of macrophages, and is based on the sources of the substances 
granulomatous diseases classified into: infectious granulomatous (i.e. Bacteria and 
fungi) and non-infectious granulomatous (i.e. keratin, suture and degenerated 
tissues) (Asai, 2017).  
Granulomas structure may transform into necrotic or fibrotic tissues. However, the 
precise mechanism of progression and regulation is still unclear (Pagán and 
Ramakrishnan, 2018). Macrophages polarisation was found to be a key pathogenic 
factor in infectious granulomas in vivo and in vitro model studies which recognised 
that M1 macrophages promote granuloma formation and macrophage bactericidal 
activity, whereas (M2 macrophages) inhibit these effects (Huang et al., 2015). 
Furthermore, macrophage polarisation suggested to maybe play a role in 
histopathogeneses in non-infectious granulomas (Barros et al., 2013). Several 
studies demonstrated an active role of macrophages in eosinophils recruitment 
(Lukacs et al., 1995).  
When such roles are taken together, it can be concluded that macrophages are key 
players to form granuloma structures in infectious and non-infectious diseases and 
that many factors can influence their polarisation and immune responses. The 
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presence of macrophages was high in EGC and suggests that they have a major role 
in recruiting eosinophils to the site of inflammation.  
Interestingly, in addition to the macrophages associated with the EGC, there was a 
large number of macrophages infiltrating between the neoplastic mast cells in MCT.  
Macrophages are the most abundant inflammatory cells in tumours (tumour 
associated macrophages, TAMs), and are able to adapt to distinct functions and 
plasticity within tissues (Nielsen and Schmid, 2017, Noy and Pollard, 2014). 
According to existent literature, TAMs have tumour-supporting or anti-tumour 
functions (Ramanathan and Jagannathan, 2014, Parisi et al., 2018).  
In carcinogenesis, macrophages play a role in controlling the initial stage of cancer 
cell proliferation (i.e. carcinogenesis) cooperation with T lymphocytes (Vesely et 
al., 2011). In contrast, the subverted macrophages or TAMs play a major role in 
dictating the progression of tumours through different mechanisms that vary 
according to the type of tissue, and inflammatory mediators (Yang and Zhang, 
2017, Parisi et al., 2018). Non-resolving chronic inflammation, which is a feature 
and marker of cancer, is associated with tumour microenvironment (TME) 
(Hanahan and Weinberg, 2011). This is considered to be a key element that links 
both chronic inflammation and the progression of cancer (Mantovani et al., 2008, 
Ruffell and Coussens, 2015). Lymphocytes are the main regulator of the function 
and activity of tumour-associated macrophages (TAMs). However, the pathways 
are variable in different organs (Sica and Mantovani, 2012). For example, a switch 
of macrophage function was found to be mediated and influenced by IL-4 of Th2 
cells in the skin (Andreu et al., 2010, Schioppa et al., 2011), and by antibody-
producing B cells in breast cancer in humans (DeNardo et al., 2009, Pedroza-
Gonzalez et al., 2011). Cancer progression can be promoted by B1 cells and 
macrophage polarisation whilst tumour promotion can be regulated by fibroblasts 
(Biswas and Mantovani, 2010). In addition, other cell products in tumour tissues 
can also reshape macrophages in an M2-like cancer mode due to extracellular 
matrix components, IL-10, CSF-1, and various chemokines (e.g. CCL2, CCL18, 
CCL17, and CXCL4) according to Sica and Mantovani (2012).  
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Macrophages express activities that can prevent the establishment and spread of 
tumour cells. They can also elicit functions to support tumour growth and 
dissemination. This paradoxical relationship between macrophages and tumour 
cells reflects the functional plasticity of these cells; they can express different 
functional programmes in response to different micro-environmental signals. The 
presence of macrophages in MCT suggests that they play a major role in preventing 
and/or initiating tumour growth through different mechanisms and inflammatory 
mediators as demonstrated in other neoplasms. It may also be the case that they play 
a role in eosinophils recruitment.  
4.4 The role of cytokines and chemokines in the EG and MCT  
The present and previous studies have shown that cutaneous MCT in horses are 
consistently infiltrated by high numbers of eosinophils (Hubert, 2006), and in some 
cases also by other leukocytes, i.e. lymphocytes (mainly T cells) and 
macrophages.They also showed that equine MCT are frequently associated with 
EG-like lesions (Scott and Miller, 2011c). This association suggests that one lesion 
(most likely the MCT) may trigger the development of the other (most likely the 
EGC). In the attempt to unravel this close relationship, the present study aimed to 
understand the pathogenesis and development of both MCT and EG, using an in 
situ approach based on the differential expressions of a range of cellular mediators 
(cytokines, chemokines and growth factors) that likely influence the interplay 
between eosinophils and other relevant cell populations in both entities (e.g. mast 
cells, lymphocytes, and macrophages).  
Due to cost considerations and the often poor RNA preservation in older paraffin 
blocks, this part of the project was performed on a limited number of cases. This, 
nonetheless, enabled the discovery of some general patterns that may help our 
understanding of the pathogenesis of MCT and EG. In general terms (without 
differentiation between groups), RANTES was the marker expressed by the highest 
numbers of cells (up to 23 cells/HPF), followed by eotaxin (up to 2049 cells/cm2), 
IL-13 (up to 777 cells/cm2), IL-5 (up to 472 cells/cm2) and MIP1α (up to 
147cells/cm2). In contrast, the number of cells that showed IL-4 transcription was 
very low (30 cells/cm2), suggesting that this cytokine is not a main ruler in the cell 
interplay that occurs in these lesions.  
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SCF is a critical growth factor for MCs, regulating their activation, degranulation, 
survival, and chemotaxis (Meininger et al., 1992). Several cell types can produce 
SCF (da Silva et al., 2006), but within the lesions in the present study, only slender, 
often spindle shaped cells compatible with endothelial cells, fibroblasts and some 
vascular smooth muscle cells were found to express SCF mRNA (visible as faint 
dots) in all cases. Due to this generalised, obviously constitutive expression, it was 
not possible to attribute a specific role in either entity to this mediator.  
TGF-β is a pleiotropic immunoregulatory cytokine that, for instance, antagonises 
the effects of IL-5 on eosinophils (Alam et al., 1994), and exerts an important role 
in extracellular matrix protein deposition, particularly collagen (Davoine and Lacy, 
2014). This was a feature that was also observed in the lesions in this study. In the 
present analysis, TGF-β was constitutively expressed by many cell types within the 
lesions.  It was, again, not possible to attribute a specific role in either entity to this 
mediator.  
RANTES/CCL5 has been described by, amongst others, Levy, (2009), and Appay 
and Rowland-Jones, (2001), as a highly pleiotropic chemokine that can be produced 
by many cell types (including T cells, macrophages, eosinophils and mast cells) 
with the potential to recruit a variety of leukocytes (including the same cells 
responsible for their production). In this study, RANTES was expressed by 
lymphocytes and some palisading macrophages in EGC, and at higher amounts in 
EG (Category I) compared to MCT (Categories III and IV), where only some 
scattered cells compatible with lymphocytes showed RANTES expression. This 
observation may partially contribute to the recruitment of different leukocytes in 
EG. However, the higher number of RANTES+ lymphocytes in EG may be 
explained by the higher number of T lymphocytes (CD3-positive) observed in this 
group and the fact that RANTES+ cells apparently account for a smaller 
subpopulation of the whole T cell repertoire (see Figure 3.51) . 
Eotaxin-1/CCL11 can also be secreted by many cell types, including fibroblasts, 
certain epithelial cells, and leukocytes like macrophages, T cells, and mast cells 
(Rankin et al., 2000). However, eotaxin is very well known as a potent and specific 
stimulator of eosinophil chemotaxis (Rankin et al., 2000, Weston et al., 2006). EG 
generally expressed a relatively abundant signal for eotaxin in cells compatible with 
Chapter 4: Discussion  
151  
  
macrophages, fibroblasts and lymphocytes (with the exception of two of the five 
EG lesions that were tested, which were basically negative). Very rare or no 
eotaxin-positive cells were detected in the MCT, with the exception of some 
ulcerated MCT which showed the presence of neutrophil infiltrates. These MCT 
showed abundant roundish eotaxin-positive cells but also an important component 
of eotaxin-positive fibroblastoid cells (granulation tissue). There is some 
controversy regarding the effect of eotaxin on neutrophil recruitment, although 
there are some authors who suggest that eotaxin has an effect on neutrophil 
chemotaxis (Huaux et al., 2005, Menzies-Gow et al., 2002), whilst other reports 
have documented that there is no effect (Cheng et al., 2002, Garcia-Zepeda et al., 
1996). This controversy led to the idea that it is not eotaxin that recruits those 
neutrophils and that there may be bacteria (as a result of the ulceration) that directly 
attract neutrophils, and indirectly recruit eosinophils possibly via eotaxin and IL-5 
induction in nearby cells (Ravin and Loy, 2016).  
MIP1α is the third chemokine included in this study that was expressed by scattered 
lymphocytes and macrophages. MIP1α was slightly more abundantly expressed in 
EG compared to MCT. However, the level of expression was generally very low 
and suggests that this chemokine is not a main ruler in either pathological condition.  
Th2 lymphocytes are known to generate the cytokines IL-4, IL-5 and IL13, which 
play important roles in regulating eosinophil recruitment (Rankin et al., 2000). 
Despite the potential role of IL-4 in eosinophil biology (Shakoory et al., 2004, 
Rankin et al., 2000) and the observation of some correlations with other mediators 
and cells in the statistical analysis, the extremely low number of cells expressing 
IL-4 mRNA in this study suggests that this cytokine is also not a main ruler.  
IL-5 is the most specific cytokine regulating eosinophil development, playing a 
crucial role in driving committed eosinophil progenitor-cell proliferation, terminal 
differentiation and activation (Sanderson, 1990). In this study, IL-5 was expressed 
in numerous lymphocytes and mast cells in MCT, compared with the scattered 
positive lymphocytes observed in EG. While IL-5 does not appear to be nearly as 
important as chemokines for eosinophil recruitment, locally produced IL-5 does 
have an important function in increasing the survival of eosinophils once they have 
reached tissue (Park and Bochner, 2010, see also Chapter 4.9), suggesting an 
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explanation as to why we observed a certain association between the density of 
viable eosinophils within the MCA and IL-5 production (Figure 60).  
Like IL-4, IL-13 is a Th2 cytokine with relevant roles in eosinophil biology, 
inducing transendothelial eosinophil migration, direct eosinophil activation and 
attraction, and triggering production of eosinophil-active mediators (Shakoory et 
al., 2004). In the present study, IL-13 was found to be highly expressed in EG and 
to a lesser extent in MCT. This suggests a major contribution not only in EG 
pathogenesis but also in MCT development. This finding supports the fact that IL-
13 was mainly detected in T cells and that T cells (CD3-positive) are more abundant 
in EG whilst also being present in MCT. This in turn suggests that IL13-secreting 
T cells are involved in the crosstalk in both lesions, potentially playing a major role 
in EG. According to these findings, it could be hypothesised that IL-5 has a major 
role in maintaining viable eosinophils in MCT, and that there is a partial 
contribution by IL-13. However, in EG eotaxin may have a greater role in 
recruiting, whilst the scarcity of IL-5 expressing cells explains the lower viability 
of eosinophils. One possible mechanism in EG development includes an IL13-
eotaxin-RANTES axis with the following interactions: (1) IL-13 stimulates 
VCAM-1 induction (Bochner et al., 1995) and selective endothelial transmigration 
of eosinophils (Jia et al., 1999), (2) IL-13 induces eosinophil active chemokines 
(i.e. eotaxin, RANTES) (Li et al., 1999), recruiting eosinophils, T lymphocytes and 
macrophages, (3) IL13 directs activation, chemoattraction and survival of 
eosinophils (Horie et al., 1997), and (4) IL-13 stimulates growth and differentiation 
of B cell aggregates (Murphy, 2012) which are frequently found in EG.  
It is well described that eosinophils can secrete several of the molecules included 
in this study (Rothenberg and Hogan, 2006, Davoine and Lacy, 2014). However, 
we did not detect expression of any of our markers in eosinophils. Moreover, 
eosinophils also lacked signals even with housekeeping gene control probes such 
as PPIB and UBC. This observation may be attributable to the high density of 
eosinophil granules in the cells which might obstruct the binding of the probes to 
target mRNA.  
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4.5. Conclusion  
This study attempted to classify EG and MCT with a rigorous approach based on 
the relative amount of EGC and MCA within lesions. Pure EG lacked any area of 
MCA, while MCT variably presented EGC. EG and MCT differed for several 
morphological characteristics and when comparing the two lesions the main 
features found were as follows:  
• EG were present in large numbers t in the most superficial areas of the dermis 
and often associated with hair follicles while MCT were not.  
• EGC areas within EG were characterised by collagen fragments and 
mineralisation. This feature was not prominent in MCT.  
• Lymphocyte aggregates were often localised within or in close proximity to 
the lesions in EG. They were not a feature of MCT.  
• Macrophages, despite increased in EG, represented the predominant 
inflammatory cells in both EG and MCT. 
• Macrophages were observed engulfing eosinophils in MCT, but not in EG. 
• T cells were more represented in EG compared to MCT. However, it should 
also be noted that they were present in large numbers in MCT.  
• B cells were scarce; they were evident only in EG.  
• In EG eosinophils recruitment seems to be driven by different immune cells 
(lymphocytes and macrophages) secreting predominantly Rantes, IL13 and 
Eotaxin. MCT mast cells and potentially lymphocytes seem to possibly 
recruit eosinophils via secretion of IL-5 which also increases the survival of 
these cells.  
These morphological and biological features differentiate EG from MCT and 
demonstrates that pure EG differs substantially from MCT. This supports the 
hypothesis that EG and MCT are two different entities with different pathogenesis.  
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APPENDIX I: METHODS  
Histology standard operating procedure  
 General PPE requirements  
• Howie Style Lab Coat  
• Bodyguards nitrile gloves to BS EN455:2000 and BS EN374:2003  
• Safety glasses BS EN166  
• Eye protection: Face Shield BS EN 166-3B or F  
• Respirator mask EN149:2001 & A1:2009 FFP3 NR  
Reagents  
• Formalin: Buffered Formalin Concentrate (Atom Scientific, RRFF5000-G). 
Contains Formaldehyde <50% (19-20% v/v), Mixed Phosphates. Add 100ml 
Buffered Formalin Concentrate to 400ml tap water to make working solution 
of 10% Formalin (1 in 5 dilution)  
• 4% Paraformaldehyde (PFA): Due to toxic fumes make this solution up in a 
fume hood-dissolve 10g paraformaldehyde in 200ml PBS at 600C on stirrer 
(do not increase temperature over 700C as solution will precipitate). Adjust 
pH to 7.24-7.4. Add PBS to 250ml. Store for maximum of 1 month  
• Ultraplast Polyisobutylene Histological Wax (Solmedia WAX060)  
• Mayers Haematoxylin: 1g Haematoxylin 95% Monohydrate (Atom 
Scientific, cat no: RRBD61-X), 0.2g sodium iodate, 50g potassium or 
ammonium alum, 20ml glacial acetic acid, 1 litre distilled water. Dissolve 
haematoxylin in the water using gentle heat. Add potassium alum and 
dissolve using gentle heat. Cool and add sodium iodate. Mix and filter the 
solution. Add 20ml glacial acetic acid.  
• Eosin Y stain: 50ml 1% Eosin Y (TCS Biosciences Ltd, cat no HS250-1L), 
390ml ethanol, 2ml glacial acetic acid  
• DPX mounting medium (Thermo Scientific, ref LAMB/DPX)  
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Method - Tissue handling  
1. Fix tissue by immersion in 10% Neutral Buffered Formalin (or 4% PFA*) for 
24 hours in a sealed pot (*better for immunohistochemistry procedures)  
2. In a well ventilated room, remove tissue from fixative and cut to appropriate 
size/orientation & place within labelled plastic cassettes. Snap cassette closed 
using cassette lid. Very small tissue pieces may be held within a cassette by 
placing the tissue between two pieces of embedding sponge within the plastic 
cassette.  
3. Process tissue within plastic cassettes on tissue processor overnight  
Method – Tissue processing using TISSUE-TEK©VIP, Miles Scientific  
Tissue processor removes water from tissue & replaces it with paraffin wax which 
penetrates and solidifies tissue and enables it to be cut. Consists of:  
1. Tissue dehydration through immersion in increasing concentrations of 
ethanol  
2. Immersion in xylene (removes ethanol)  
3. Tissue infiltration with molten paraffin wax (replaces xylene)  
 Method – Tissue embedding and cutting sections  
1. Place tissue in metal moulds containing molten paraffin wax. Gently press 
labelled plastic cassette on top of mould, and place on cold platform to 
solidify the wax block.  
2. Remove tissue block from mould and trim off excess wax from sides of 
cassette. Place block in microtome and trim face of block until the full tissue 
section is being cut. Remove the block from microtome and place on ice for 
30 minutes to cool before cutting.  
3. Cut 4 micron sections on microtome, float sections in 450C water bath and 
collect onto glass slides.  
4. Dry the cut sections at 370C for 30 minutes to allow adherence to slide before 
staining.  
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Method – Tissue staining  
H&E for basic histological analysis as follows (carry out in fume hood):  
1. Dewax sections in xylene 5 minutes  
2. Transfer sections to another xylene and take sections down through 
descending grades of alcohol (100%, 96%, 85%, 70%) to distilled water  
3. Stain sections in Mayers haematoxylin 5 minutes  
4. “Blue” sections in running water 6 minutes  
5. Stain sections in Eosin for 2 minutes  
6. Take sections through 3x 96% alcohol for 1 minute each (dipping sections up 
and down to remove excess stain)  
7. Take sections through 3x 100% alcohol  
8. Take sections through 2x xylene  
9. Mount sections in DPX mounting medium and place glass coverslip over top. 
Press out air bubbles using mounted needle by gently pressing on top of 
coverslip. Allow mounted sections to dry in fume cabinet.  
Toluidine Blue Reagent  
1% Toluidine Blue in distilled water (made in house from Toluidine Blue, 
9756880F, BDH Chemicals Ltd, Poole, UK)  
0.2% Acetic Acid in distilled water (made in house from Glacial Acetic Acid, 
A/0360/PB17, Fisher Scientific UK, Loughborough, UK)  
Lendrum’s method for eosinophils solutions  
Carbol Chromatrope  
Ready to use Lendrum’s Chromotrope (641550, Clin-Tech Limited, Guildford, 
UK) 
Mayers Haematoxylin 
1g Haematoxylin 95% Monohydrate (RRBD61-X, Atom Scientific, Manchester, 
UK) 
0.2g Sodium iodate (201761000, Acros Organics, New Jersey, USA)  
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Aluminium Potassium Sulphate (217485000, Acros Organics, New Jersey, 
USA)  
1000mls distilled water  
20mls glacial acetic acid (A/0360/PB17, Fisher Scientific UK, Loughborough, 
UK)  
Masson Trichrome Solutions (all made in house)  
Celestine Blue Solution   
2.5g Celestine Blue (206342, Sigma-Aldrich, St Louis, USA)       
25g Ferric Ammonium Sulphate (271644, BDH, Pool, UK)  
70ml Glycerol (24388.295, VWR International, Fontenaysous- Bois)  
500ml distilled water  
Cytoplasmic Stain     
Mix together:  
2 parts 1% Ponceau de Xylidine (HD1800, HD Supplies, Aylesbury, UK)  
1 part 1% acid fuchin (RRBD93/X, Biostain ready reagents, Manchester, UK) in 
1% acetic acid (made in house from Glacial Acetic Acid, A/0360/PB17, Fisher 
Scientific UK, Loughborough, UK)  
1% Phosphomolybidic acid  
(206381000, Acros Organics, New Jersey, USA) made in house  
2% Light Green 
(HD1535, HD Supplies, Aylesbury, UK) made in house 
Mayers Haematoxylin 
1g Haematoxylin 95% Monohydrate (RRBD61-X, Atom Scientific, Manchester, 
UK) 
0.2g Sodium iodate (201761000, Acros Organics, New Jersey, USA)  
Aluminium Potassium Sulphate (217485000, Acros Organics, New Jersey, USA)  
1000mls distilled water  
20mls glacial acetic acid (A/0360/PB17, Fisher Scientific UK,  
Loughborough, UK) 
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A modification of Von Kossa’s method for calcium solutions  
5% silver nitrate in distilled water (made in house from Silver Nitrate, S/1280/46, 
Fisher Scientific UK, Loughborough, UK)  
1% Neutral Red in 1% Acetic Acid (RRSP160-F, Atom Scientific, Manchester, 
UK)  
Perls’ Prussian Blue solutions  
2% Potassium ferrocyanide in distilled water (102054F, VWR International Ltd, 
Poole, UK)  
2% Hydrochloric acid in distilled water (H/1200/PB17, Fisher Scientific UK, 
Loughborough, UK)  
1% Neutral Red in 1% Acetic Acid (RRSP160-F, Atom Scientific, Manchester, 
UK)  
TBST buffer  
10x TBS STOCK  
 66.57g Tris-(hyroxymethyl) aminomethane (28811.295, VWR International, 
Leuven, Belgium)  
610ml distilled water  
390ml 1N Hydrochloric Acid (made in house from H/1200/PB17, Fisher 
Scientific UK, Loughborough, UK) pH 7.6  
TBST working solution  
7.2g NaCl  (59888, Sigma Aldrich, Steinheim, Germany)  
100ml 10x TBS Stock  
900ml distilled water  
500µl Tween (P1379, Sigma Aldrich, Steinheim, Germany)  
EDTA solution for pressure cooker 10x solution (1L)  
Dissolve in 900ml (warm at 60ºC)  
12gr Tris Base (Roche, 10708976001)  
3.7gr EDTA (Ethylene diamine-tetra acetic acid) (Fluka, 03610)  
Adjust with NaOH 1N at pH 9  
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Complete up to 1000ml  
Dilute 1:10 before use  
Immunohistochemistry protocol  
CD3 protocol on Autostainer Link 48  
Polyclonal Rabbit anti Human CD3 (Dako A0452)  
PT Link  
Deparaffinisation, rehydration and epitope retrieval using:  
EnVisionTM FLEX Target Retrieval Solution (TRS) High pH (Citrate buffer, pH 
9.0, K8004)  
Dako Autostainer Link 48  
Step Reagent Volume Time 
Rinse Buffer1   
Endogenous Enzyme Block FLEX Peroxidase Block2 150µl 5 min 
Rinse Buffer1   
Primary Antibody   CD3 1:500 in diluent3    150µl 20 min 
Rinse Buffer1   
Labelled Polymer FLEX/HRP8 150µl 20 min 
Rinse Buffer1   
Rinse Buffer1   
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Rinse Buffer1   
Counterstain    FLEX Hematoxylin7 150µl 5 min 
Rinse DI Water   
Rinse Buffer1   
Rinse DI Water   
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Autostainer set up to deliver 2x reagent drops of 150µl to upper and lower zones on 
the slide (position of reagent drops can be maximum of 3x zones per slide).  
Following end of protocol remove slides to staining racks and dehydrate (1minute 
96% ethanol, 2x 3minutes 100% ethanol), coverslip and mount in DPX.  
Dako/AgilentReagents  
1. EnVisionTM FLEX Wash Buffer (K8007)  
2. EnVisionTM FLEX Peroxidase-Blocking Reagent (SM801)  
3. EnVisionTM FLEX Antibody Diluent (K8006)  
4. EnvisionTM+System-HRP Labelled Polymer α Rabbit (K4003)  
5. EnVisionTM FLEX DAB+ Chromogen (DM827)  
6. EnVisionTM FLEX Substrate Buffer (SM802)  
7. EnVisionTM FLEX Hematoxylin (K8008)  
8. EnVisionTM FLEX/HRP (SM802)  
CD79a protocol on Autostainer Link 48  
Monoclonal mouse anti-human CD79a (AbDserotec,MCA2538H )  
PT Link  
Deparaffinisation, rehydration and epitope retrieval using:  
EnVisionTM FLEX Target Retrieval Solution (TRS) Low pH (Citrate buffer, pH 
6.1, K8005)  
Dako Autostainer Link 48  
Step Reagent Volume Time 
Rinse Buffer1   
Endogenous Enzyme Block FLEX Peroxidase Block2 150µl 5 min 
Rinse Buffer1   
Primary Antibody   CD79a 1:300 in diluent3    150µl 20 min 
Rinse Buffer1   
Labelled Polymer FLEX/HRP8 150µl 20 min 
Rinse Buffer1   
Rinse Buffer1   
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
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Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Rinse Buffer1   
Counterstain    FLEX Hematoxylin7 150µl 5 min 
Rinse DI Water   
Rinse Buffer1   
Rinse DI Water   
 
 
Autostainer set up to deliver 2x reagent drops of 150µl to upper and lower zones on 
the slide (position of reagent drops can be maximum of 3x zones per slide).  
Following end of protocol remove slides to staining racks and dehydrate (1minute 
96% ethanol, 2x 3minutes 100% ethanol), coverslip and mount in DPX.  
Dako/AgilentReagents  
1.        EnVisionTM FLEX Wash Buffer (K8007)  
2.        EnVisionTM FLEX Peroxidase-Blocking Reagent (SM801)  
3.        EnVisionTM FLEX Antibody Diluent (K8006)  
4.        EnvisionTM+System-HRP Labelled Polymer α Rabbit (K4003)  
5.        EnVisionTM FLEX DAB+ Chromogen (DM827)  
6.        EnVisionTM FLEX Substrate Buffer (SM802)  
7.        EnVisionTM FLEX Hematoxylin (K8008)  
8.        EnVisionTM FLEX/HRP (SM802)  
 
 C-Kit protocol on Autostainer Link 48  
Polyclonal mouse anti-human CD117 (Dako,A4502 )  
PT Link  
Deparaffinisation, rehydration and epitope retrieval using:  
EnVisionTM FLEX Target Retrieval Solution (TRS) High pH (Citrate buffer, pH 
9.0, K8004)  
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Dako Autostainer Link 48  
Step Reagent Volume Time 
Rinse Buffer1   
Endogenous Enzyme Block FLEX Peroxidase Block2 150µl 5 min 
Rinse Buffer1   
Primary Antibody   C-kit 1:500 in diluent3    150µl 20 min 
Rinse Buffer1   
Labelled Polymer FLEX/HRP8 150µl 20 min 
Rinse Buffer1   
Rinse Buffer1   
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Rinse Buffer1   
Counterstain    FLEX Hematoxylin7 150µl 5 min 
Rinse DI Water   
Rinse Buffer1   
Rinse DI Water   
 
 
Autostainer set up to deliver 2x reagent drops of 150µl to upper and lower zones on 
the slide (position of reagent drops can be maximum of 3x zones per slide).  
Following end of protocol remove slides to staining racks and dehydrate (1minute 
96% ethanol, 2x 3minutes 100% ethanol), coverslip and mount in DPX.  
Dako/AgilentReagents  
1.        EnVisionTM FLEX Wash Buffer (K8007)  
2.        EnVisionTM FLEX Peroxidase-Blocking Reagent (SM801)  
3.        EnVisionTM FLEX Antibody Diluent (K8006)  
4.        EnvisionTM+System-HRP Labelled Polymer α Rabbit (K4003)  
5.        EnVisionTM FLEX DAB+ Chromogen (DM827)  
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6.        EnVisionTM FLEX Substrate Buffer (SM802)  
7.        EnVisionTM FLEX Hematoxylin (K8008)  
8.        EnVisionTM FLEX/HRP (SM802)  
 
C-Kit protocol on Autostainer Link 48  
Polyclonal mouse anti-human CD117 (Dako,A4502 )  
PT Link  
Deparaffinisation, rehydration and epitope retrieval using:  
EnVisionTM FLEX Target Retrieval Solution (TRS) High pH (Citrate buffer, pH 
9.0, K8004)  
Dako Autostainer Link 48  
Step Reagent Volume Time 
Rinse Buffer1   
Endogenous Enzyme Block FLEX Peroxidase Block2 150µl 5 min 
Rinse Buffer1   
Primary Antibody   Iba1 1:500 in diluent3    150µl 20 min 
Rinse Buffer1   
Secondary Reagent  anti-goat IgG9 150µl 20 min 
Rinse Buffer1   
Rinse Buffer1   
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Rinse Buffer1   
Counterstain    FLEX Hematoxylin7 150µl 5 min 
Rinse DI Water   
Rinse Buffer1   
Rinse DI Water   
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Autostainer set up to deliver 2x reagent drops of 150µl to upper and lower zones on 
the slide (position of reagent drops can be maximum of 3x zones per slide).  
Following end of protocol remove slides to staining racks and dehydrate (1minute 
96% ethanol, 2x 3minutes 100% ethanol), coverslip and mount in DPX.  
Dako/AgilentReagents  
1.        EnVisionTM FLEX Wash Buffer (K8007)  
2.        EnVisionTM FLEX Peroxidase-Blocking Reagent (SM801)  
3.        EnVisionTM FLEX Antibody Diluent (K8006)  
4.        EnvisionTM+System-HRP Labelled Polymer α Rabbit (K4003)  
5.        EnVisionTM FLEX DAB+ Chromogen (DM827)  
6.        EnVisionTM FLEX Substrate Buffer (SM802)  
7.        EnVisionTM FLEX Hematoxylin (K8008)  
8.        EnVisionTM FLEX/HRP (SM802)  
9.        ImmPRESSTM HRP Reagent Kit Peroxidase anti-Goat IgG (MP-7405) 
MCT protocol on Autostainer Link 48  
Monoclonal mouse anti-human Mast Cell Tryptes (Dako,M7052 )  
PT Link  
Deparaffinisation, rehydration and epitope retrieval using:  
EnVisionTM FLEX Target Retrieval Solution (TRS) Low pH (Citrate buffer, pH 
6.1, K8005)  
Dako Autostainer Link 48  
Step Reagent Volume Time 
Rinse Buffer1   
Endogenous Enzyme Block FLEX Peroxidase Block2 150µl 5 min 
Rinse Buffer1   
Primary Antibody   MCT 1:500 in diluent3    150µl 20 min 
Rinse Buffer1   
Labelled Polymer FLEX/HRP8 150µl 20 min 
Rinse Buffer1   
Rinse Buffer1   
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Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Rinse Buffer1   
Counterstain    FLEX Hematoxylin7 150µl 5 min 
Rinse DI Water   
Rinse Buffer1   
Rinse DI Water   
 
 
Autostainer set up to deliver 2x reagent drops of 150µl to upper and lower zones on 
the slide (position of reagent drops can be maximum of 3x zones per slide).  
Following end of protocol remove slides to staining racks and dehydrate (1minute 
96% ethanol, 2x 3minutes 100% ethanol), coverslip and mount in DPX.  
Dako/AgilentReagents  
1.        EnVisionTM FLEX Wash Buffer (K8007)  
2.        EnVisionTM FLEX Peroxidase-Blocking Reagent (SM801)  
3.        EnVisionTM FLEX Antibody Diluent (K8006)  
4.        EnvisionTM+System-HRP Labelled Polymer α Rabbit (K4003)  
5.        EnVisionTM FLEX DAB+ Chromogen (DM827)  
6.        EnVisionTM FLEX Substrate Buffer (SM802)  
7.        EnVisionTM FLEX Hematoxylin (K8008)  
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Lysozyme protocol on Autostainer Link 48  
Poloclonal Rabbit anti-human Lysozyme (Dako,A0009 )  
PT Link  
Deparaffinisation, rehydration and epitope retrieval using:  
EnVisionTM FLEX Target Retrieval Solution (TRS) Low pH (Citrate buffer, pH 
6.1, K8005)  
Dako Autostainer Link 48  
Step Reagent Volume Time 
Rinse Buffer1   
Endogenous Enzyme Block FLEX Peroxidase Block2 150µl 5 min 
Rinse Buffer1   
Primary Antibody   Lysozyme 1:2500 in diluent3    150µl 20 min 
Rinse Buffer1   
Labelled Polymer FLEX/HRP8 150µl 20 min 
Rinse Buffer1   
Rinse Buffer1   
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Substrate-Chromogen FLEX DAB+ Sub-Chromo5+6 150µl 5 min 
Rinse Buffer1   
Counterstain    FLEX Hematoxylin7 150µl 5 min 
Rinse DI Water   
Rinse Buffer1   
Rinse DI Water   
 
 
Autostainer set up to deliver 2x reagent drops of 150µl to upper and lower zones on 
the slide (position of reagent drops can be maximum of 3x zones per slide).  
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Following end of protocol remove slides to staining racks and dehydrate (1minute 
96% ethanol, 2x 3minutes 100% ethanol), coverslip and mount in DPX.  
Dako/AgilentReagents  
1.        EnVisionTM FLEX Wash Buffer (K8007)  
2.        EnVisionTM FLEX Peroxidase-Blocking Reagent (SM801)  
3.        EnVisionTM FLEX Antibody Diluent (K8006)  
4.        EnvisionTM+System-HRP Labelled Polymer α Rabbit (K4003)  
5.        EnVisionTM FLEX DAB+ Chromogen (DM827)  
6.        EnVisionTM FLEX Substrate Buffer (SM802)  
7.        EnVisionTM FLEX Hematoxylin (K8008)  
8.        EnVisionTM FLEX/HRP (SM802)  
PCNA Envision IHC Method  
Steps of Envision (use separate rack)  
 Xylene 2x 5minutess  
100% ethanol 2x 2minutes  
96% ethanol 1x 2minutess  
80% ethanol 1x 2minutess  
70% ethanol 1x 2minutes  
Leave in dH20  
 Pre-treatments (Antigen Retrieval) Citrate 4  
Rack up slides in sequenza clips using TBST (TBS Buffer + 0.05% Tween 20)  
 3x 2minute TBST wash  
 Peroxidase Block ~100µl DAKO REAL™ Peroxidase Blocking Solution S2023 
(250ml) 10mins  
 3x 2minute TBST wash  
 
~100µl Primary Antibody (PCNA, Dako, M0879) dilute 1:100 in TBST  
4°C overnight  
 3x 2minute TBST wash  
 Apply 3 drops of Dako Envision+ System-HRP α mouse (K4001, 110ml) 
30mins, room temp  
 3x2min TBST wash  
 Remove from sequenza clips to dH20  
DAB 10mins  
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0.2g Diaminobenzidine in 400mls Imidazole Buffer:  
(280ml 0.1M Imidazole/120ml 0.42MHCl pH 7.2), filtered, activate with 140µl 
30% Hydrogen Peroxide H202 (Fisher Scientific BP2633-500)  
 3x 5minute washes dH20  
 Counterstain with Papanicolaou’s 1b Hematoxylin Solution (Merck 1.09254.0500) 
20mls in 400mls dH20 stain 1minute.  
“blue” running tap water 5 minutes  
 Dehydrate, Clear & Mount:  
96% ethanol 1 minute  
100% ethanol 2 minutes  
100% ethanol 3 minutes  
Xylene 2 minutes  
Xylene 3 minutes 
 Xylene 3 minutes  
Coverslip with DPX  
The mRNA sequences of the selected chemokines/cytokines form NCBI  
Equus caballus peptidylprolyl isomerase B (PPIB), mRNA  
NCBI Reference Sequence: NM_001099761.1  






















Equus caballus chemokine (C-C motif) ligand 3 (CCL3), mRNA  
NCBI Reference Sequence: NM_001114941.1  










 Equus caballus chemokine (C-C motif) ligand 11 (CCL11), mRNA  
NCBI Reference Sequence: NM_001081871.1  












AAAAATAC ATATATTGCAAAAAAAAAAAAAAA  
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Equus caballus KIT ligand (KITLG), mRNA  
NCBI Reference Sequence: NM_001163962.1  
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Equus caballus interleukin 5 (IL5), mRNA  
NCBI Reference Sequence: NM_001082499.1  










Equus caballus interleukin 4 (IL4), mRNA  
NCBI Reference Sequence: NM_001082519.1  










Equus caballus transforming growth factor beta 1 (TGFB1), mRNA  
NCBI Reference Sequence: NM_001081849.1  






























Equus caballus interleukin 13 (IL13), mRNA  
NCBI Reference Sequence: NM_001143791.1  
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APPENDIX II SECTION A:  
Additional tables and figures / Section B: Published papers 
Section A: Additional tables and figures 
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Section A, Table A1:  
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Section A, Table A2:  
Summary table of the cases analysed for cytokine/chemokine interaction with raw 
results.  
  Ref.  Categ.  RANTES  Eotaxin  MIPα  IL4  IL5  IL13  
1  06L-1257  IV  5(5)  0  7  0  340  46  
2  11L-4484A  IV  7(3)  0 (161*)  2  0  472  88  
3  11L-4484B  IV  10(4)  0 (94*)  NA  NA  303  39  
4  11L-4696  III  3(2)  0  7  0  31  5  
5  15L-1571a  III  8(10)  25  1  NA  85  239  
6  09L-3297  I  23(16)  4  10  18  28  777  
7  11L-2439  I  15(9)  2049  10  28  53  362  
8  11L-3991  I  11(9)  0  29  0  3  431  
9  13L-4160a  I  14(9)  872  147  21  82  207  
10  15L-4903  I  7(4)  654  15  0  9  213  
Rantes (IHC): mean no cells/40x field (SD).  NA (Not analysed),  0,  1-10, 
 11-20,  21-40,  41-50 cells/40x field. Rest (ISH): total no of positive 
cells/cm2.  NA (Not analysed),  0-10,  11-100,  100-500,  500-1000,  
1000-3500 cells/cm2. 
  
• TGF-β: Not quantified (constitutively expressed by many cell types in all 
cases).  
• SCF/cKIT-L: Not quantified (constitutively expressed in all cases by 
endothelial cells and some vascular smooth muscle cells).  
• *Very Focal Eotaxin expression (not evenly distributed in the lesion). 
Associated with the presence of focal infiltrates of neutrophils. Considered 
negative in the whole mass (-), except for those focal areas  
  
  
 x x 
x x x 
 x x x x x 
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Section B: Published papers  
Section B: Printout from the publication describing 4 atypical mast cell tumours 
(Elbahi A, Kipar A, Ressel L. J Comp Pathol. 2018 July; 162:14-17. doi: 
10.1016/j.jcpa.2018.05.003. Epub 2018 June 30)   
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[continued] Printout from the publication describing 4 atypical mast cell tumours (Elbahi A, 
Kipar A, Ressel L. J Comp Pathol. 2018 July; 162:14-17. doi: 10.1016/j.jcpa.2018.05.003. 
Epub 2018 June 30)  
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A, Ressel  
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30)  
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